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Introduction and outline of the thesis

INTRODUCTION
Narcolepsy is a p r im a iry  sleep disorder, classified in the  category o f  hypersomnias 
o f  centra l or igin (ICSD-2, 2005) [1]. Narcolepsy is characterized by tw o  main 
symptoms: excessive day t im e sleepiness (EDS) and cataplexy. However, a ra ther 
broad spectrum  o f  o th e r  sym ptom s is o f ten  present, includ ing hypnagogic and 
hypnopom p ic  hallucinations, sleep paralysis, nocturna l sleep d isruption, as well 
as non-sleep symptoms such as obesity  [2]. Disease onset varies f rom  early 
ch i ldhood into the  f i f th  decade o f  life, w i th  a b imodal d is tr ibu t ion  w i th  a large 
peak around 15 years o f  age and a small peak around 36 years [3]. The estimated 
prevalence in the weste rn  w o r ld  (Europe and U.S.) is 0.02% to  0.07% [4,5] which 
wou ld  am oun t to  3500 -  10.000 pat ien ts in the  Netherlands. In recent years, it 
was discovered tha t  narcolepsy is caused by a de f ic iency in hypotha lamic 
hypocre tin  (orexin) neurotransmission, wh ich is re f lec ted in a de f iency o f  the 
hypocre tin  neuropep t ide  in the  cerebrospinal f lu id  [6].
SEMIOLOGY
Excessive Daytim e Sleepiness
Excessive day t im e sleepiness (EDS) is usually the  f i rs t  sym ptom  to  appear and 
o f ten  the  most disabling. The urge to  fal l asleep can be im perat ive  and results in 
lapses into sleep at unusual t imes and occasions dur ing the  day. Naps typ ica lly  
have a refreshing effect,  wh ich is short  lived however. A lthough patients can 
sometimes fall  asleep dur ing  activ it ies, sleep 'at tacks ' are m ost likely to  occur 
dur ing s ituations such as watch ing  TV or s i t t ing  in the  passenger seat o f  a car, 
when active pa r t ic ipa t ion  is no t required. W hen unmedicated the need to  sleep is ¡£
_C
very hard to  resist, and m ostly  uncon tro l lab le  [7]; moving around can on some ~
occasions ward o f f  a sleep attack. M a in ta in ing  day t im e alertness is a major issue ~
fo r  patients, ever th rea ten ing  the ir  level o f  function ing . Patients can even become £C
preoccupied w i th  losing con tro l o f  the ir  alertness and fa l l ing asleep in public. izDO
~o
Cataplexy ™
Cataplexy, the  second ch ie f  sym ptom  o f  narcolepsy, is v i r tua l ly  pa thognom on ic  °
fo r  the  disease. It is characterized by a sudden bila teral loss o f  muscle tone -^o
provoked by s trong emotions, usually o f  the  posit ive varie ty :  laughter, start le, 2
pride, e lat ion, surprise and exc i tem ent in meeting  someone [8]. Cataplexy can be ~
generalized or partia l,  a f fec t ing  the  neck, m ou th  or limbs selectively. A head
drop, facial sagging, slurred speech, buckling o f  the  knees are all expressions o f  
partia l cataplexy. Cataplexy not only varies highly in d is tr ibu t ion  bu t also in
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frequency. The dura t ion  o f  a catap lectic  a ttack ranges f rom  seconds to  a few 
minutes at most. During cataplexy consciousness is mainta ined: pat ien ts hear 
and rem em ber all w h a t  happens around them. A  m in o r i ty  o f  pat ien ts reports  
mult isensory  hallucinations dur ing cataplexy [8].
H ypnagogic hallucinations
Hypnagogic hallucinations occur at sleep- wake transit ions, com m only  
experienced at sleep onset bu t inc identa l ly  dur ing  catap lectic  attacks and sleep 
paralysis as well .  They are called hypnopom p ic  when occurr ing dur ing w ak ing up. 
These halluc inations can be ex trem e ly  fr igh ten ing  and very  realistic. They are 
c laimed no t to  be un ique fo r  narcolepsy, occurr ing in o ther  sleep disorders and in 
the  general popu la t ion  as well  [4,9]. This has been a reason fo r  some authors  to 
t r iv ia lize these symptoms, wh ich is un founded. Patients are o f ten  re luc tan t  to 
rep o r t  these hallucinations because o f  the  fear o f  being v iewed as m enta l ly  ill 
[10]. Indeed, hypnagogic ha lluc inations are sometimes mistaken fo r  psychosis by 
psychia tr ists [11-14] and can create mis leading in te rp re ta t ions  in the  legal sphere 
[15]. Patients rep o r t  an impressive loss o f  qua l i ty  o f  life due to  these sensory 
perceptions [10].
Sleep paralysis
Sleep paralysis occurs on sleep- wake t rans i t ions as well :  patients wake up but 
cannot move or speak dur ing a few  minutes. Even l i f t ing  a f inger is not possible at 
these periods. External s t imuli such as noises or the  touch o f  the  bedpartne r  can 
sometimes end this  state. This f r igh ten ing  experience is o f ten  accompanied by 
hypnagogic or hypnopom p ic  hallucinations, wh ich can push up the anxie ty to  an 
even higher level.
Disturbed nocturnal sleep
The sleep dysregulation in narcolepsy is also apparent in nocturna l sleep, wh ich is 
o f ten  highly f ragm ented . Nocturna l sleep f ragm en ta t ion  is a com m on compla int, 
and o f ten  very t roub lesom e to  patients. The n igh tt im e  sleep d isrup tion  is no t the 
cause o f  the  day t im e sleepiness however: t rea t ing  nocturna l sleep f ragm enta t ion  
does no t am e lio ra te  the  day t im e sleepiness.. Over 24 hours pat ien ts do no t sleep 
more than healthy contro ls  [16].
Autom atic behavior
Narcoleptic  pat ien ts can show autom atic beh avior: inadequate behavior, most 
likely dur ing periods w i th  a decreased vigilance. A com m on example is during 
w r i t ing ,  when pat ien ts notice tha t  they have w r i t te n  nonsense sentences, or 
illegible text. These automatisms are sometimes mistaken for dissociative behaviors.
Obesity
Narcolepsy patients have o f ten  been repor ted  to  be obese [17,18], w i th  an an 
increased wa is t c ircumference as well , po in t ing  to  abdominal fa t  depos it ion [19]. 
The increased BMI can be a major psychological burden fo r  patients, likely to 
con tr ibu te  to  the  low self  esteem tha t  patients may rep o r t  [10,20,21]. The 
increased BMI was classically a t t r ib u te d  to  a l i festy le o f  inac t iv i ty  inherent to  the 
tendency to  fal l asleep. However, nowadays m etabo l ic  changes, most probably 
due to  the  reduct ion  in hypocre tin  signaling, are believed to  be responsible for 
the increase in body w e igh t  [6,22].
DIAGNOSTIC CLASSIFICATION
The diagnosis o f  narcolepsy is based on a com b ina t ion  o f  repor ted  symptoms, 
fo rm al sleep recordings, and - i n  selected cases- m easurem ent o f  hypocre tin  in 
the cerebrospinal f lu id .  The curren t  diagnostic c lassif ication fo l lows the 
In ternat ional Classif ication o f  Sleep Disorders (ICSD-2), ed ited by the  American 
Academy o f  Sleep Med ic ine (AASM), and these criter ia are listed in Box 1 [1]. The 
DSM IV has a c lassif ication fo r  narcolepsy as well [23]. These cr iter ia are however 
less than satis factory, leading to  a clear overinclusion o f  narcolepsy patients. In 
the fo r thco m ing  DSM-V, new criter ia are proposed tha t  closely fo l low  the  ICSD-2.
NARCOLEPSY AND PSYCHIATRY
N arcolepsy m isdiagnosed as psych iatric disease
Narcolepsy has been frequ en t ly  misdiagnosed -  especially by psychia tr ists - as a ¡£
_C
psychia tr ic disorder. Psychiatrists have recognized a pa t te rn  o f  bo rder l ine  ~
persona l i ty  disorder, psychosis, and do worse than o ther  medical specialists in ~
diagnosing narcolepsy [24]. This has lead to  admissions o f  pat ien ts to  psychia tr ic £C
wards w i th  diagnoses o f  schizophrenia or b ipo lar d isorder [11,25]. W hat did iz 
deceive psychiatr ists? The most conspicuous po in t o f  confusion are the
hypnagogic hallucinations. These halluc inations can occur dur ing day t im e too, ro
dur ing m om ents  tha t  pat ien ts doze o f f  to  sleep. Psychiatrists may in te rp re t  this  °
as a sym ptom  of  a psychotic  disorder. Narcolepsy pat ien ts may su ffe r  f rom  mood ^
swings, w i th  i r r i ta ted  mood or even ou tburs ts  o f  anger when waking up, wh ich 2
may remind o f  m ood swings in Borderl ine Personali ty Disorder. The d is tant ~  
impression tha t  some pat ien ts make, and a certa in  ind if fe rence can rem ind of
o ther  persona l i ty  d isorders as well . Depression is diagnosed f requen t ly :  d is turbed 1 3
sleep can be a po in t o f  confusion here, as are loss o f  concen tra tion , fat igue, loss 1
BOX 1 Diagnostic criteria for narcolepsy with cataplexy
A. The patient has a compla int o f  excessive daytime sleepiness occurring almost 
daily for  at least three months.
B. A defin ite history o f  cataplexy defined as sudden and transient episodes o f  loss 
o f  muscle tone triggered by emotions, is present.
Note: To be labeled as cataplexy, these episodes must be triggered by strong 
emotions -  most reliably laughing or joking -  and must be generally bilateral and 
brief (less than 2 minutes). Consciousness is preserved, at least at the beginning 
o f  the episode. Observed cataplexy w ith  transient reversible loss o f  deep tendon 
reflexes is a very strong, but rare, diagnostic finding.
C. The diagnosis o f  narcolepsy w ith  cataplexy should, whenever possible, be 
confirmed by nocturnal polysomnography fol lowed by an MSLT; the mean sleep 
latency on MSLT is less than or equal to eight minutes and tow  or more SOREMP's 
are observed fo l lowing suffic ient nocturnal sleep (min imum six hours) during the 
night prior to the test. Alternatively, hypocretin 1 levels (less than or equal to 110 
pg/mL or one third o f  mean normal control values.
Note: The presence o f  tw o  or more SOREMP's during the MSLT is a very specific 
find ing whereas a sleep latency o f  less than eight minutes can be found in up to 
30% of the normal population. Low CSF hypocretin-1 levels (less than or equal to 
110 pg/mL or one third o f  normal control values) are found in more than 90% of 
patients w ith  narcolepsy w ith  cataplexy and almost never in controls or in other 
patients w ith  o ther pathologies.
D. The hypersomnia is not bette r explained by another sleep disorder, medical or 
neurological disorder, medication use o f  substance use disorder.
o f  l ib ido and the tendency to  w i thd raw .  Conversion d isorder is ano the r  pitfa ll , 
and this  diagnosis has been made frequ en t ly  in the  h is to ry  o f  narcolepsy: sleep, 
cataplexy were  seen as defense mechanisms, supposedly  enabling pat ien ts to 
cover up more serious f laws in the ir  personali ty.
The reasons f o r  psych iatric m isclassification
The in tr iguing question can be posed w he the r  psychiatrists were jus t mistaken in 
diagnosing psychiatric disorders instead o f  narcolepsy, or tha t narcolepsy patients 
really do show psychia tr ic signs and symptoms, e ither  secondary to  narcolepsy 
symptoms or as a d irec t  expression o f  the  pathophysio logica l process. A lthough
the l i te ra tu re  on narcolepsy is p len t i fu l ly  f i l led  w i th  references to  psychiatr ic 
com orb id ity ,  data as to  prevalence or incidence o f  psychia tr ic d isorders or 
f requency  o f  sym ptom s are inconclusive. M os t  data come f rom  case series, 
w here  psychia tr ic sym ptom s are o f ten  more i l lustra t ive than in formative . 
Furtherm ore, most data come f rom  se l f- repo r t  ins trum ents  such as the  Beck 
Depression Inventory  (BDI) as opposed to  con tro l led  studies w i th  formal 
d iagnostic  instruments.
The psych iatric ph enotype in narcolepsy is not well described  
Currently , too  few  studies have t r ied  to  pe r fo rm  a deta iled psychia tr ic assessment 
o f  narcolepsy patients, and the psychia tr ic phenotype  o f  narcolepsy is only 
vaguely described. I sorely missed such psychia tr ic data as a reference, when I 
f i rs t  encountered a narcolept ic  pa tient, w ho  is described in Box 2.
BOX 2 case vignette
Patient 1 is a 20-year-old physics student, who received the diagnosis of narcolepsy 
with cataplexy at age 14. Around the time he turned 18, hypnagogic hallucinations 
started to play an important role in his daily life. In a hypnagogic 'state' he sensed 
the presence of invisible beings which he called 'synteufles' that came from another 
'dimension'. These 'synteufles' tried to possess him, throwing a yellow powder in his 
nose to bring him under their influence. They wanted to eat his brains, and kill him. 
After waking up, the reality of these hallucinatory world still existed. The patient 
developed the habit to 'wash them off', taking showers that sometimes took a whole 
night. In his dreams these beings could take the form of chewing gum. The dreams 
were threatening him, and he started feeling depressed. He began to eat more. At one 
point, he was not able to separate the 'dream world ' from daytime reality for several 
weeks. He developed a way to 'defend' himself against the 'synteufli', fighting them by 
developing a glass plate in the frontal plane before him, that represented his mind. He 
always wanted to wipe this plate clean, for which he even created an extra extremity.
His neurologist prescribed antipsychotics which did not influence the symptoms. To 
get back to reality, it helped to start talking to someone or turning on the radio. He 
became obsessed with having fresh drinking water which he needed in his battle with 
the synteufles.
Only two years later, he gradually became able to put these experiences into 
perspective. Afterwards he started doing well in his studies, was able to get his MSc 
and now has a job as an information technology expert.
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AIMS OF THIS THESIS
The main goal o f  this  thesis is to  investigate the psychia tr ic p ro f i le  o f  narcolepsy 
in depth. We s ta r t  f rom  a systematic search o f  the  o lder l i te rature , looking for 
'unexpurga ted ' psychia tr ic aspects in original descrip tions o f  narcolepsy. 
Subsequently, the  results o f  a deta iled s tudy are described in wh ich the  psychiatr ic 
symptoms o f  a large and w e ll-de f ined  cohort  o f  narcolepsy pat ien ts is compared 
to  popu la t ion  contro ls, mainly using a we ll-va lidated sem i-s truc tu red diagnostic  
ins trum ent,  the  Schedules fo r  Assessment in Neuropsychiatry  (SCAN) version 2.1 
[26-29].
Chapter 2 contains a deta iled historical analysis o f  p r im ary  papers on narcolepsy, 
w i th  an emphasis on psychia tr ic features and invo lvem ent o f  psychia tr ists work ing 
f rom  d i f fe re n t  angles. A lthough a psychia tr ic approach was jus t i f ied  in many 
instances because o f  the  psychological suffer ing, this all too  o f ten  lead to 
st igmatizat ion o f  patients, adding to  a bad repu ta t ion  tha t  pat ien ts already had. 
Over the  years, a reappraisal o f  psychia tr ic com o rb id i ty  took  place, leading to  a 
new synthesis o f  'organic '  and 'psychiatr ic '  features o f  narcolepsy.
Chapter 3 focuses on psychotic  sym ptom s in narcolepsy, because o f  the  enduring 
discussion in the  l i te ra tu re  on the  d i f fe ren t ia l  diagnosis o f  narcolepsy and 
schizophrenia. We s tud ied psychotic  sym ptom s in th ree  groups: pat ien ts w ith  
narcolepsy, schizophrenic patients and a group o f  matched popu la t ion  controls. 
A deta iled analysis o f  the  pa t te rn  o f  hallucinations o f  narcolepsy pat ien ts and 
schizophrenic pat ien ts is given, to  enable a clear d i f fe ren t ia t ion  be tween the tw o . 
Furtherm ore, we describe the actual experiences o f  hypnagogic ha lluc inations in 
detail, as repo r ted  by the  narcolepsy patients.
Chapter 4 deals w i th  symptoms o f  depression as well as anxie ty in narcolepsy. 
Depression has received a lo t o f  a t ten t ion  in the  l i te rature , which contrasts w ith  
the  scarcity o f  in fo rm a t ion  regarding anxie ty symptoms. Many authors  have 
suggested an ove rrep resen ta t ion  o f  major depression, bu t  few  systematic  
diagnostic studies have been performed. Using the SCAN, symptom frequencies on 
depression and anxiety were assessed and compared w ith  controls. A discussion is 
added on the  signif icance o f  these symptoms; are they  a pr im ary  disease 
expression, or secondary to  the chronic sym ptom s o f  narcolepsy.
Chapter 5 describes the  results o f  a s tudy in to  eating disorders in narcolepsy, 
wh ich was tr iggered by the  ove rwe igh t  and obesity  wh ich are no tor ious associated 
features. A case- contro l study was perfo rm ed , com paring  sym ptom s o f  eating
disorders in pat ien ts w i th  narcolepsy versus popu la t ion  contro ls. In addit ion, 
symptoms w ere compared to  a separate con tro l group wh ich was matched for 
BMI as well.
In Chapter 6, a clinically relevant, but d i f f icu l t  top ic  is studied, namely the 
prevalence o f  fa t igue in narcolepsy, and its d i f fe re n t ia t ion  f rom  sleepiness. This 
subject has been neglected in the  l i te ra tu re  so far. To this  end, a fo rm al ins trum ent 
to  assess fat igue - t h e  Checklist Indiv idual Strength- was applied in a large cohort 
o f  narcolepsy patients. Dete rm inants  fo r  the  presence o f  severe fa t igue were 
assessed, and clinical d i f ferences described be tween narcolepsy pat ien ts w ith  
and w i th o u t  fat igue.
Chapters 7 and 8 contain a sum m ary o f  our results and a discussion o f  the ir  
relevance respectively. We e laborate on possible neurobio logica l mechanisms, 
but also on the  pa t ien t 's  perspective and t re a tm e n t  options.
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an evolving association
Based on:
H.A. D roo gleever Fortuyn, P.C. M ulders, W.O. Renier, J.K. Buitelaar, S. Overeem. 
N arcolepsy and psychiatry: an evolving association o f increasing interest.
Sleep M ed (2011 ), doi: 10 .1016/ j.s le e p .2 0 11 .01.013
ABSTRACT
Gélineau orig inal ly  described narcolepsy as a disease w i th  an organic cause. 
However, the  d isorder had undeniable em otiona l t r iggers and psychia tr ic-l ike 
expressions, and soon a psychia tr ic e t io logy  o f  narcolepsy became a seriously 
considered op t ion . In fact, the  psychia tr ic v iew dom inated sc ientif ic  th ink ing  for 
a long t im e, not necessarily to  the  bene fi t  o f  patients. W hen hypocre tin  (orexin) 
defects w ere  proven to  be the cause o f  narcolepsy Gélineau's original disease 
model was shown to  be r ight. However, the  psychia tr ic sym ptom s o f  the  disease 
were no t fo rgo t te n  a f te rwards,  bu t gained a d i f fe re n t  signif icance: as psychiatr ic 
expressions o f  a brain disease. These symptoms, such as anxiety and eating 
disorders, can be highly deb i l i ta t ing  and w a rran t  clinical a t ten t ion .  Here, we 
describe the  role o f  psychiatry in the history o f  narcolepsy, showing the ir evolving 
association.
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INTRODUCTION
Ever since its f i rs t  descrip t ion, narcolepsy has been associated w i th  psychiatry in 
various ways (see Figure 1). W hile  neurolog ica l exp lanations fo r  narcolepsy 
prevailed at f irs t ,  various a l te rna tive  theor ies  soon gained fo l lowers, suggesting 
under ly ing psychia tr ic disturbances as a cause o f  the  disease (for an overview, 
see [1]). Psychosomatic mechanisms w ere pressed by psychia tr ists trea t ing  
narcolepsy patients, fo r  example suggesting sexual devia tions and psychopathic 
persona li ty  s truc tures as under ly ing fac tors  [2,3]. These views persisted fo r  a 
long t ime, even far  into the  20th cen tu ry  [4]. W hen defects in hypotha lamic 
hypocre tin  (orexin) neuro transmiss ion were p inpo in ted as the  pr im ary  cu lp r i t  at 
the end o f  the 1990s, narcolepsy was f ina lly  established as an organic brain 
disease [5]. Perhaps surprisingly, this  paved the  way fo r  a tho rough descrip tion 
and apprecia t ion o f  the  psychia tr ic com o rb id i ty  which affec ts  many narcoleptic 
patients [6-14]. In this  rev iew we describe the  role o f  psychiatry in the  h is tory  of 
narcolepsy, showing the  evolv ing association be tween the  tw o  (Figure 1).
A DISEASE, A SYMPTOM OR A SYNDROME?
Narcolepsy was described and named in the  second ha lf  o f  the 19th century, by
Westphal and Gélineau respective ly [15-17]. Gélineau called narcolepsy a 'névrose
rare', a rare fo rm  o f  neurosis, wh ich te rm  at tha t  t im e  was not solely used fo r  o
psychia tr ic bu t also fo r  neurological d isorders [16,17]. This im p lica ted tha t
Gélineau regarded narcolepsy as a 'm orbus su i g en e ris ' ( 'disease o f  its own kind'),  $TO
and a l though he did no t use this  te rm  himself,  the  expression has been a t t r ib u te d  m
to  him ever since. The te rm  'disease' refers to  a cond it ion  w i th  a specif ic  cause, _g
and if  possible a un ifo rm  trea tm e n t .  But, a lthough Gélineau suggested tha t  S
narcolepsy was a d isorder o f  the  'p ro tuberance annulaire ' (pons) he ne ithe r knew ™
the cause o f  the  disease nor had a t rea tm e n t .  t
2JZ(J
Gélineau's publication did not go unnoticed: he received reactions and case reports £
from  many colleagues f rom  France and abroad. However, many o f  these cases were TO
patients w i th  an underly ing disease w ho merely  had narcolepsy-like clinical >■
symptoms. As a result, Gélineau described a 'narcolepsie secon d a ire ' due to various _üO
causes next to the original 'morbus sui generis ' ('n a rco lep sie essentielle') in his 1881 ^
monograph [18]. In other words, narcolepsy was split up in a primary disease and a z
secondary syndrome due to hysteria, diabetes, heart disease and so on. Gélineau 
also proposed to f i t  narcolepsy due to  hysteria in Charcot's classification of 2 3
hysterical stages, even adding a subtype: 'état n arcoleptique' (Figure 2) [16].
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Figure 2 Gelineau's proposal to f i t  narcolepsy secondary to hysteria into Charcot's 
classification o f  hysterical stages
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The subdiv is ion in to  essential and secondary types did not convince all however: 
the French neuro log is t  Ballet stated in 1882: 'N arcolepsie  n 'est pas une affection  
définie, encore m oins une m aladie: c'est, nous le répétons, un sym ptôm e qu i a , 
nous le voulons bien, ces caractères propres, sa physionom ie s p e c ia l' [19] .
Parmentie r (1891), a pupil o f  Charcot, advocated a s lightly  d i f fe re n t  classif ication, 
emphasiz ing tha t  the  'hysterical pa t ien t '  m ight m im ic narcolepsy. He preferred: 
'La fo rm e  n arcoleptique de l'a tta q u e  de som m eil hysterique: pseu d o -n a rcolepsie  
h y ste riq u e' [20].
In France, Lherm it te  (1910) w ro te  an art ic le  called 'les narcolepsies' in wh ich he 
strong ly posit ioned narcolepsy as a syndrome, w i th  m u l t ip le  etio logies, and not 
as a disease [21]. In contrast, the  idea o f  narcolepsy as a disease remained still 
very much alive in Germany in the  same period [22-25].
The controversies surround ing the  quest ion w h e the r  or no t to  consider narcolepsy 
as a pr im ary  disease, w ere  pa rt ly  fue lled by the  fac t  tha t  cataplexy was no t yet 
sharply de f ined and was no requis ite fo r  the  diagnosis.
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CATAPLEXY, INCLUDED OR NOT?
In 1902, the  German au tho r  Loewenfeld po in ted to  an im p o r ta n t  omission in the 
narcolepsy l i te ra tu re  so far [22]. He discovered tha t  Gélineau described 'astasia' 
as an im p o r ta n t  sym ptom  tha t  could be separated f rom  the excessive dayt ime 
sleepiness in narcolepsy. He st ipu la ted tha t  these tw o  symptoms -sleepiness and 
muscle weakness ('kataleptisch eS tarre ') t r iggered by laughing and o ther  emotions
- were  the  ch ie f compla in ts in narcolepsy.
A lthough the te rm  'catap lexy ' was in troduced 14 years la ter by Henneberg, [26] 
Loewenfeld already emphasized tha t  narcolepsy was an 'e ig en a rtig e  Krankheits­
zustan d' characterized no t jus t  by sleep episodes bu t also by attacks o f  m o to r  
inhib it ion. The discussion 'disease or syndrome' was now extended to  the question: 
'is cataplexy a requisite cr iter ion to make a narcolepsy diagnosis or not? 'Many 
authors in Germany and Austria answered this question aff irmative, imply ing a 
'restr ic ted de f in i t ion '  w i th  exclusion o f  hysterical cases and the like [23-25,27-31]. 
In France, England and the  USA most physicians defined narcolepsy in a much 
broader sense: by excessive daytime sleepiness and sleep attacks [21,32-35].
The 'syndrome versus disease' discussion, and the  unce r ta in ty  abou t diagnostic  
criteria, al lowed the emergence o f  a l te rna tive  theor ies  fo r  the  under ly ing cause 
o f  narcolepsy, and psychia tr ic explanations soon gained much more prominence.
INFLUENCE OF THE PSYCHO-ANALYTIC MOVEMENT
Start ing around 1885, Freud started  to  s tudy the dynamics o f  unconscious 
processes and the ir  expression in psychological sym ptom s and behavioral 
changes. He published his opus 'Traum deutung ' ('on the  in te rp re ta t ion  of 
dreams') in 1900, in wh ich he constructed his own model o f  sleep and dreaming 
[36]. He stated tha t  dur ing sleep neurons at the m o to r  end w ere blocked and the 
mental processes were directed to the sensory end. In this regressive process, an 
in tens i f icat ion o f  in terna l percep tion took  place wh ile  the  ego was shut o f f  f rom  
access to  ou tw a rd  m o to r  innervat ions (Figure 3). Freud a t t r ibu ted  various 
' func t ions '  to  sleep. In the  f i rs t  place, sleep provided a means to  dream: 
ha lluc ina tory  g ra ti f ica t ion .  Freud hypothesized tha t  in dreams people wou ld  
fu lf i l l  wishes -conscious as well as unconscious- tha t  had arisen dur ing  dayt im e 
but were  le ft  unsatis fied. But second, Freud stated tha t  sleep attacks could be a 
defense mechanism against sexual or aggressive impulses, at the same t im e 
shield ing them  f rom  consciousness and g ra t i fy ing  them  dur ing sleep.
Figure 3 Freud's ^  - model o f  the mental 'apparatus' : impulses to  action at the 
m otor  end at the right (M) are blocked during sleep, and redirected to 
the  sensory end (left) . This leads to  in tens if icat ion o f  the  in ternal 
perception: dreams. The preconscious (Vbw) disguises the  'dream 
material' in order not to disturb internal perception as well as sleep.
In this way, 'hallucinatory wish fu lf i l lm ent '  is reached during the dream.
Ubw = unconscious, Er = memory.
As psychoanalysis gained ground as a modern sc ientif ic  view, publ icat ions s tarted  -2
to  appear suggesting a re la t ion be tween these unconscious processes and sleep STO
attacks. One o f  the f i rs t  exponents o f  th is  line o f  th ink ing  was O be rn do r f  (1916), m
a psychoanalyst f rom  New York, w ho  w ro te :  J2
>CD
uncontrollable  attacks o f drow siness w ere in terpreted  as an escape fro m  intense  ™
sham e attendant upon a m asturbation co n flict in which fa n tasies o f in cest with ^TO
the m other played an im po rta n t role. The drow sy spells at the sam e tim e p rovid ed  j=
a substitute f o r  the autoerotic a ctiv ity ' [37]. £
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The f irs t  psychoanalytical ly oriented publication on narcolepsy came from the >
British army psychologist Myers (1920) [38,39]. He reacted on a description o f  a O
placebo trea tm ent o f  a narcoleptic patient tha t appeared in the Lancet: a piece of ^
bone was removed from  the skull o f  a narcoleptic patient and attached to  a necklace z
for him to  wear, turn ing out to be a cure [40,41]. Outraged about this ' indefensible 
treatment',  Myers described his own ' trea tm ent by exploration ' fo r  narcolepsy: 27
'Repression and dissociation are at the root o f the disorder and reintegration alone
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can effect a true cure'. Worster-Drought (1923) a neurologist at the Queen's Square 
National Hospital in London, cited Myers and advised the fo l lowing strategy for  the 
treatm ent o f  narcolepsy in cases w i thou t  evidence o f  organic disease:
'I believe  the m ost satisfactory  o f the s h o rte r m ethods o f treatm ent to be (1) a 
p relim in a ry  m o d ified  'psychoanalysis' with a detailed investigation into the h istory  
o f the onset o f the attacks, and o f the individual, fo llo w e d  by (2) reco nstru ction  of 
the orig in  o f n arcolepsy o r the em otional experience giving rise  to the condition, 
under lig h t h ypnosis' [33] .
Variat ions on this them e cont inued to  appear in the  l i te ra ture . W il ley  (1924) 
described the  escape mechanism th a t  narcolepsy provided as 'tem porary  su ic id e ' 
[42 ]. Missriegler (1924) portrayed narcolepsy as a way o f  g ra t i fy ing  murderous 
and sexual impulses dur ing sleep: 'A crim inal com ponent will p ro b a b ly  b e  fo u n d  to 
exist in n a rco lep sy ' [43]. Furtherm ore, he described successful t re a tm e n t  o f  a 
pa t ien t  w i th  psychoanalysis.
Not on ly  sleep attacks, bu t o ther  symptoms o f  narcolepsy could be expla ined as 
neuro tic  sym ptom s as well .  Coodley (1948) suggested fo r  example tha t  cataplexy 
m ight represent 'se lf castration, in which the entire  bod y -  equated with the penis
-  goes lim p ' [4 4 ].
However, no t  all con tem po ra ry  authors m entioned the  publ icat ions on 
psychoanalysis in narcolepsy. For example, Adie (1926) in his famous thesis on 
narcolepsy did no t cite one psychoanalyst. Ne ither did Redlich, the  Austrian 
a u th o r i ty  on narcolepsy, except in his very last paper in wh ich he stated th a t  he 
was not convinced o f  e i the r  the  psychogenic causation o f  narcolepsy or an 
essential psychological in f luence on the  disease:
'Ich selbst h abe mich, (...), von eine Psychogenese d er N arkolepsie o d er auch nur 
von e in er w esentlichen psychologischen B eeinflussung d er N arkolepsie  nicht 
überzeugen können, ich kann also auch nichts von e in er P sychotherapie b erich ten .' 
[25,27-29,45,46].
INFLUENCE OF PAVLOV'S INHIBITION THEORY
A second approach to  psychogenic mechanisms in narcolepsy was based on the 
w o rk  o f  Pavlov, one o f  the  godfathers  o f  behavior ism w ho received the Nobel 
Prize fo r  his w o rk  on classic cond it ion ing  in 1904. Later on, Pavlov developed his 
own the o ry  o f  sleep: the  inh ib it ion  theory , based on exper iments  w i th  dogs
[47,48]. He observed tha t  dogs w ou ld  fal l asleep a f te r  w i th ho ld ing  o f  a reward 
they were cond it ioned to. He reasoned tha t  sleep was no th ing  but internal 
inh ib it ion  rad ia t ing over the  cortex and involv ing lower bra in centers as well. 
Brailovsky [49] and Adie [45]. applied this  the o ry  to  narcolepsy, Adie using it to 
explain both sleep attacks and cataplexy:
'It seem s then as i f  narcolepsy is an expression o f fa tig u e  in individuals with a kind  
o f nervous activity that fa vo rs  the spread o f  in h ib itions and allow s excessive  
em otional responses; furth er, that the local response to inhibitions, w herever they  
arise, is abnorm al, and that the sym ptom s are due to a general alteration of 
nervous activity ra th er than to abnorm al stim u li which affect norm al structures at 
a distance'.
Levin, w ho  started  ou t  as a neuro log is t  in the  mil i tary,  extended this  tra in of 
though t  and suggested tha t  narcolepsy was caused by a wave o f  inh ib it ion , ju s t  as 
epilepsy was caused by a wave o f  exc ita t ion: 'the narcoleptic patient possesses a 
brain  in which in h ib ition  occurs with undue ease'. Levin believed tha t  the 
deve lopm ent o f  the  'machine age' caused the ' recent increase' in the  incidence of 
narcolepsy: having to  suppress reactions to  st imuli,  fo r  instance when dr iv ing a 
car, w ou ld  lead to  inh ib it ion  and consequently  to  narcolepsy symptoms [50]. In 
his la ter w o rk  , he stressed the im portance  o f  gu i l t  in cataplexy [51]. For example, 
h i t t in g  an adu lt  in anger wou ld  no t lead to  cataplexy, wh i le  h i t t in g  one's own child 
would . Levin expla ined this by Pavlov's physio logical concept o f  tra ined inh ib it ion . o
’ (J
'The classic exam ple is the angry fa th e r who raises his hand to punish his ch ild  and  «TO
is at that m om ent stricken with w eakness o f the upraised arm. The weakness m ay  m
spread to o ther lim bs as well. This event m ust b e  view ed fro m  two standpoints -  JE
the psych ological and the physiological. Psychologically, the fa th e r is torn by a 5
conflict; his aggressive im pulse tow ard his ch ild  m akes him  fe e l guilty. ™
Physiologically, he is the victim  o f what Pavlov called co n dition ed inhibition'. t
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Levin published on the subject repeatedly in h igh-ranking journa ls  such as the  £
American Journal o f  Psychiatry; his last publ icat ion (1961) fel l in the  same t im e TO
f ram e as the last publ icat ions o f  psychoanalysts on narcolepsy [52]. However, in >■
the 1950s, crit ical com m ents  started  to  appear, fo r  example f rom  the British O
neurophysio log is t  Pond (1952): 'such term s have a deceptive sim p licity  and an ^
appearance o f explaining everything, but as Pavlov's la ter w ork shows, m ore and z
m ore ad hoc hypotheses have to be invented to co ver the facts. Little is gained  
fro m  his term inology, which does not com pletely b rid g e  the gap betw een
psych ology and n e u ro lo g y ' [53].
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A FURTHER BOOST FOR THE PSYCHODYNAMIC APPROACH
The psychoanalyt ic v iew  on narcolepsy was strong ly s t im ulated by the  art ic le  in 
Brain by the  fam ous British neuro log is t  Kinnier Wilson in 1928 [34]. When 
analyzing the  e t io logy o f  the narco lept ic  syndrome, Wilson opened the  door 
w ide ly  to  psychiatry  and psychoanalysis. Quoting  art ic les o f  Carlill, Myers, 
W ors te r-D rough t and the psychoanalyst Missriegler,  he remarked about 
psychopatholog ica l causes; in a list o f  eight causal categories he placed ' the 
psychopatholog ica l g roup ' second a f te r  the ' t ra um a t ic  group ' and before 
endocrinology, epilepsy and encephalitis. The consequence o f  Wilson's reasoning 
was th a t  patients fo rm e r ly  cal led 'hyster ica l '  could now fu l ly  be classified as 
having narcolepsy. Wilson's v iew meant recogn it ion and a fo rm idab le  
breakthrough fo r  psychia tr ists w i th  psychoanalyt ic o r ien ta tion , and the  paper 
was f requ en t ly  cited in the  la ter psychoanalyt ic l i te ra tu re  on narcolepsy. 
W inneco t (1930), Jones (1935), Simmel (1942) and Schulte (1942) all reported  
the ir  psychoanalyt ical w o rk  w i th  narco lept ic  patients, po in t ing  to  ' th rea ten ing  
sexual fantasies', 'escape f rom  reali ty ',  ' re l iv ing the death o f  a fa the r  in o rder to 
be w i th  him', and 'homosexual inversion' as causing narcolepsy [54-57]. The 
psychodynamic descrip tions o f  narcoleptic  patients almost showed contempt, as 
the  next c i ta t ion  f rom  Langworthy and Betz (1944) shows:
'N arcoleptic and cataplectic reaction: a b rillian tly  selected sou rce  o f relief. A non 
verbal adm ission o f  inadequacy, not in com patible  with self- respect. (...) This 
condition is a p erso n a lity  reaction to em otional issues ra th er than an organic  
disease as has fo rm e rly  been assumed. The sym ptom s o f excessive diurnal sleep, 
cataplexy, sleep paralysis, som nam bulism , [and] nocturnal h allucinations appear 
to b e  neuro tic defenses with sym bolic s ig n ifica n ce against p rim a ry  anxieties  
associated with d ifficu lties in realistic adjustm ents in perso n al relationships with 
others. The n arcoleptic syndrom e as a n eurotic reaction  seem s s im ila r in m any 
respects to the hysterical reaction. They fe e l caugh t in a life-pattern  to which they 
are expected to conform , bu t which they deeply re se n t' [58].
THERAPEUTIC CONSEQUENCES OF THE PSYCHODYNAMIC 
APPROACH
There was 'good news' fo r  narcolept ic  pat ien ts though: the  psychodynamic 
approach provided a the rapeu t ic  opt ion, namely psychoanalysis. Langworthy and 
Betz described six patients, tw o  o f  w hom  proved responsive to  the ir  
psychoanalyt ical approach w i th  an am elio ra t ion  o f  the  narco lept ic  symptoms.
Figure 4  I llustration f rom  Barker's artic le on EEG registrations during a sodium
amytal in terv iew w ith  a narcolepsy patient [60]. See main text for  details.
The authors  state tha t  psychoanalyt ic psychotherapy provided 'a fundam ental 
approach to th eir d ifficulty'. Spiegel and O be rn do r f  (1944) described the  contents 
o f  such a t rea tm en t :  the  b reakthrough in the rapy  was a 'confessional catharsis', 
encouraged by the the rap is t  [59]. In the ir  case, a long s tanding sexual conf l ic t  
supposedly was closely related to  the  pa t ien t 's  states o f  sleepiness and other 
physical symptoms. A f te r  an unsuspected e lem ent o f  her sexual li fe had been 
discussed w i th  the  therapist,  she had few e r attacks o f  narcolepsy and her 
nocturna l insomnia dimin ished.
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Barker (1948), a psychoanalyst f rom  New York, used repeated in terv iews, free 
association, and  in travenous sodium amytal in the  search fo r  in fo rm at ion  [60]. 
In an am bit ion  to  'prove ' the  psychoanalyt ic approach, he recorded the  EEG of 
tw o  patients dur ing such a sodium amytal in te rv iew  (Figure 4). In the  observations 
section o f  his paper, a candid descrip t ion o f  the  session was provided:
Three m inutes a f te r  the  pa t ien t had been given 0.3 grams o f  sodium amytal, the 
discussion which had dealt w i th  early aggressive urges and his m ethods of 
handling them, proceeded as follows:
(...) d id  you ever have a f ig h t  with y ou r fa th e r /  No /  W hat kind o f a m an was 
h e ? /  He was a g oo d  guy /  Is he liv in g ? /  Yes /  A re  you r parents living together? (...) 
The pa t ien t did not respond to  the  quest ion bu t tu rned  his head to  the  r ight and 
w e n t  to  sleep. The in te rv iew  cont inued a f te rw ards  and Barkers final conclusion 
was:
'when the discussion was turned to incidents in which his aggressive urges 
co nflicted with his g u ilt o r  fe a r  o f punishm ents, the patient w ent to sleep instead  
o f discussing them and the EEG show ed patterns as those o f Fig. 1 B and D [i.e. 
norm al sleep]'.
THE TRIUMPH: FINAL 'PROOF' OF THE PSYCHOANALYTICAL 
VIEWS
In the  post-war period, the  psychoanalysts reached the  peak o f  the ir  in f luence on 
narcolepsy, much to  the  ir r i ta t ion  o f  more  biological th ink ing  neuro log ists such as 
Daniels. In a le t te r  to  Kle itman, dated July 21, 1948, Daniels w ro te :  'I (..) have 
been decidedly annoyed by recen t attem pts o f the psychosom aticists to revive the 
old idea that narcolepsy is sim ply a fo rm  o f esca p e' [61].
However, psychoanalysis had a final w o rd  to  say. In 1960, Vogel phrased the 
analytical v iews in the  fo l low ing  hypothesis:
'N orm al subjects dream  to prese rve  sleep, narcoleptics sleep to dream. The 
narcoleptic attack provides h allu cinatory  g ratifica tion  o f fo rb id d en  fa ntasies by  
the sp ecific  m echanism  o f wish fu lfillm e n t through dream ing. In that case, the 
p u rpose  o f the path olo gical sleep is not only to defend, but also to provid e  the ego  
regression  n ecessary f o r  h allucinatory  wish fu lfillm e n t through d re a m in g ' [62].
Based on the  recent discovery o f  REM sleep [63] and the f ind ing  tha t  dreaming
mostly  occurred during this sleep stage [64], Vogel w en t on to  test his hypothesis by 
perfo rm ing EEG recordings in a narcoleptic  patient in the afte rnoon in the sleep lab
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[62]. He observed tha t  his pat ient fall asleep only one m inute a fte r  the s tart o f  the 
experimental procedure. Moreover, REM sleep recorded occurred w i th in  three 
minutes a fte r sleep onset, much faster than normal. Vogel took these f indings as 
p roof  o f  his theory : 'the purpose o f som e narcoleptic sleep is to obtain through a 
dream  the hallucinatory gratification o f an unacceptable fantasy'.
Paradoxical ly, Vogel 's f ind ings marked the  end o f  the  psychoanalyt ic views on the 
pa thophys io logy o f  narcolepsy. He discovered Sleep Onset REM Periods 
(SOREMPs), wh ich tu rned  ou t  to  be a d iagnostic  ha llmark o f  the  d isorder th a t  is 
still in clinical use today. The occurrence o f  SOREMPs also fo rm ed  a suppo rt  for 
the sleep dissocia t ion th e o ry  tha t  was f i rs t  suggested by Bonhoeffe r  in 1928 [65] 
and ob ta ined neurobio logica l ground in 2001 [66]. Nevertheless, in those same 
1970s, psychoanalysis fo r  the t re a tm e n t  o f  narcolepsy was st ill advocated in the 
l i te ra tu re  [4].
ALTERNATIVE VIEWS
In 1934 Daniels, neuro log is t at the  Mayo clinic, w ro te  his landmark monograph in 
which he m eticu lous ly  described 146 patients w i th  narcolepsy [67]. As m entioned 
earlier, Daniels did no t believe in a psychogenic origin  o f  narcolepsy, and he 
addressed several psychoanalyt ical v iews directly. For example, Daniels made 
clear tha t  even if  M issriegler's reasoning th a t  the  l ib ido may f ind  expression in a
the dreams o f  some narcoleptics, th is  wou ld  no t at all w a rran t  general conclusions -2
on the  etio lo gy  o f  the  syndrome. He also fe l t  tha t  narcoleptics did not have an $
altered personali ty, describ ing pat ien ts as stable, aside f rom  a certa in  degree o f  m
i r r i tab i l i ty ,  'likely to b e  m anifested by any drow sy person '. _|
Interestingly, exactly these possible personali ty changes were used as f i t t in g  w i th  ev
an organic cause by several authors. Thiele and Bernard (1933) were convinced tha t  ™
narcolepsy was a 'complex', localized in the brain, and pointed to  the sleep center ^TO
proposed by von Economo, ten ta t ive ly  including the hypothalamus [68,69]. Next to j=
the sleep symptoms they also described psychological disturbances to  be present £
in the  'genuine narcolepsy' cases. Terms like 'phlegmatic, slo w ' were used, but also 1TO
'Pom adigkeit' [indifferent, blasé] and 'D ickfelligkeit' [thick skinned]. Important ly ,  >
a
personali ty symptoms were described to be 'organic' in nature and comparable to  el O
personali ty changes in post-encephali tis patients. M ost patients were treated w i th  ^
medication (thyroxin in combinat ion w i th  caffeine or ephedrine). N
The Swiss Benedett i  (1953) fo l lowed Thie le and Bernard's line o f  reasoning and 33
described the  psychopatho logy o f  eight narcolepsy pat ien ts [70]. He regarded
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narcolepsy as a focal brain and endocr ine syndrome. A f te r  describ ing personali ty  
changes in the sense o f  apathy, lack o f  in terest, ind if fe rence and mood labil ity, he 
linked these t ra its  to  endocr ine dysfunct ion.
It is s tr ik ing tha t  Thiele, Bernard and Benedett i ,  being psychiatr ists, to ta l ly  
disregarded all con tem pora ry  psychoanaly t ical publ ications, as the ir  references 
show. In turn, psychoanalysts neglected the more 'organic' studies. This constituted 
a clear separation between 'organic' or 'phenomenological ' psychiatrists -at that 
t ime considered as more traditional, and 'psychogenic/ psychoanalytical ' thinking 
psychiatrists, as the modern and revolu tionary movement at tha t time.
THE NEUROBIOLOGICAL CAUSE OF NARCOLEPSY
In 1957, Yoss and Daly published a study o f  241 pat ien ts they examined at the 
Mayo Clinic [71]. Based on these series, the  fo rm u la ted  fo rm al d iagnostic  criteria, 
and the classic ' te t ra d '  o f  narcolepsy was born: the  com b ina t ion  o f  excessive 
day t im e sleepiness, cataplexy, sleep paralysis and hypnagogic hallucinations. 
A lthough recent insights show tha t  the  la t te r  tw o  are not t rue  'core ' symptoms, 
Yoss and Daly's criter ia cons t i tu ted  an im p o r ta n t  landmark, not on ly  clinically, but 
also scientif ica lly: the  diagnostic  criter ia were pivotal fo r  the  systematic studies 
in the  next decades.
The search fo r  the  neurobio logica l cause o f  narcolepsy was also st imulated 
tremendously,  w hen in 1973 the canine m odel was described [72]. The narcoleptic 
dogs fo rm ed  a pe r fec t  animal model fo r  such a complex disease as narcolepsy, 
especially because the  cataplexy pheno type  was s tr ik ing ly  sim ilar to  cataplexy in 
humans. Research was fu r th e r  s t im ulated when it became clear tha t  in a few 
breeds, narcolepsy was t ransm it te d  as a m onogenetic  t ra i t  in an autosomal 
dom inan t fashion [73]. The hunt fo r  the  narcolepsy gene had begun, coming to  an 
end when it was iden t i f ied  in 1999: m uta t ions  in one o f  the  receptors fo r  the 
hypotha lam ic  neu ropep t ide  hypocre tin  (also known as orexin) were  responsible 
fo r  famil ia l narcolepsy in bo th Dobermans and Labradors [5].
In an unusually fast str ing o f  discoveries, the  hypocre tin  system was also 
p inpo in ted as the  pr im ary  cu lp r i t  in human narcolepsy. In early  2000 it was shown 
tha t  the  m a jo r i ty  o f  patients w i th  narcolepsy lack the  hypocre tin  pept ides in the ir  
cerebrospinal f lu id  [74]. W ith  these discoveries, narcolepsy was f ina l ly  and 
ind isputab ly  shown to  be a pr im ary neurological disorder.
The hypocre tin  system was found to  have s trong connections no t on ly  w ith  
s leep-wake systems in the  b ra in ,  b u t  also w i th  a range o f  o th e r  bra in regions, 
includ ing the limbic system [75-77]. This no t ion  opened up the  way to  address the 
psychia tr ic part  o f  narcolepsy in a fundam enta l new way: as an essential part  of 
the phenotype , and a d irec t  consequence o f  the  under ly ing pathophysio logica l 
mechanisms.
AN OPEN VIEW TOWARDS PSYCHIATRIC COMORBIDITY
In several case studies in the  second ha lf  o f  the  20th century, several psychiatr ic 
symptoms were  repor ted  to  be present in narcolepsy [78-83]. Depressive mood 
was most o f ten  described, next to  personali ty  and sexual disorders. In addition, 
the re lat ion be tween narcolepsy and schizophrenia was discussed in several 
papers. Only recently, con tro l led  studies in to the  psychia tr ic com o rb id i ty  of 
narcolepsy have been pe r fo rm ed  however.
In several con tro l led  studies, a h igher f requency  o f  depressive symptoms was 
described in narcolepsy, using questionnaires such as the  Beck Depression 
Inventory. However, the  tw o  studies which used a fo rm al diagnostic ins trum en t 
showed tha t  the  f requency  o f  m ajor depression or o th e r  a f fec t ive  d isorders is not 
increased [6,11]. Anx ie ty  disorders were recent ly  shown to  be o f  importance, 
w i th  a high level o f  anxie ty symptoms in m ore  than ha lf  o f  the  patients, and an 
increased prevalence o f  social phobia and panic attacks [11].
Daniels already showed th a t  narcolepsy pat ien ts are o f ten  overwe igh t,  and 
popu la t ion  studies have now con f irm ed this  v iew  [67]. It remains unclear w h e the r  
this overwe igh t  is related to  the  'carbo craving' tha t  patients o f ten  repor t .  Indeed, 
eating disorders sym ptom s are f requ en t ly  present in narcolepsy [8,13], although 
a h igher presence o f  fo rm al eating d isorder diagnoses has been disputed [9].
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CONCLUSIONS
The association be tween psychiatry  and narcolepsy has shown many d i f fe ren t  
faces in the  past (Figure 1). O ften, the  psychia tr ic views on narcolepsy ref lected 
the  con tem po ra ry  way o f  medical th ink ing. Un fo rtuna te ly ,  some views were not 
favorable fo r  the  pat ien ts involved. Now tha t  narcolepsy is f i rm ly  established as 
brain disorder, the  t im e has come to  carefu lly  describe and understand the 
spectrum o f  psychia tr ic com o rb id i ty  in narcolepsy. Given tha t  the  psychiatr ic 
symptoms clearly  a f fec t  qua l i ty  o f  life in a negative way, it is o f  param ount 
im portance  tha t  they  are addressed in the  clinical care. In addit ion, narcolepsy is 
an excellent 'm ode l '  to  study the  large num ber o f  d i f fe re n t  func t ions  tha t  the 
hypocre tin  system per fo rm s in the  brain, and hope fu l ly  these insights w i l l  lead to 
new t re a tm e n t  op t ions in the  fu ture .
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Psychotic symptoms in narcolepsy
Phenomenology and a comparison with schizophrenia
H.A. D roo gleever Fortuyn, G.A. Lappenschaar, F.J. N ienhuis, J.W. Furer, 
P.P. Hodiam ont, C.A. Rijnders, G.J. Lammers, W.O. Renier, J.K. Buitelaar, 
S. Overeem. Psychotic sym ptom s in narcolepsy: ph enom enology and a 
com parison with schizophrenia.
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ABSTRACT
Objective: Patients w i th  narcolepsy o f ten  experience pervasive hypnagogic 
hallucinations, som etim es even leading to  confusion w i th  schizophrenia. We 
aimed to  prov ide a deta iled qua l i ta t ive  descrip t ion o f  hypnagogic hallucinations 
and o ther  "psycho tic" sym ptom s in pat ien ts w i th  narcolepsy and contrast these 
w i th  schizophrenia patients and healthy contro ls. We also compared the 
prevalence o f  fo rm al psychotic  disorders be tween narcolepsy pat ien ts and 
contro ls.
Methods: We used SCAN 2.1 in te rv iews to  compare psychotic  sym ptom s be tween 
60 pat ien ts w i th  narcolepsy, 102 w i th  schizophrenia, and 120 matched popu lat ion 
contro ls. In addit ion, qua l i ta t ive  data was col lected to  enable a detailed 
descrip t ion o f  hypnagogic ha lluc inations in narcolepsy.
Results: There w ere clear d iffe rences in the  pa t te rn  o f  ha lluc inatory  experiences 
in narcolepsy versus schizophrenia patients. Narcoleptics repor ted  mult isensory 
"ho l is t ic "  hallucinations ra the r  than the  p redom inan t ly  verbal- aud i to ry  sensory 
mode o f  schizophrenia patients. O ther  psychotic  sym ptom s such as delusions 
were not m ore  f requ en t  in narcolepsy compared to  popu la t ion  contro ls. In 
addit ion, the  prevalence o f  fo rm al psychotic  d isorders was no t increased in 
patients w i th  narcolepsy. A lm ost ha lf  o f  narcoleptics repor ted  modera te  
in te rfe rence w i th  func t ion ing  due to  hallucinations, m ost ly  due to  related anxiety.
Conclusions: Hypnagogic hallucinations in narcolepsy can be d i f fe ren t ia ted  on a 
phenomenolog ica l basis f rom  hallucinations in schizophrenia wh ich is useful in 
d if fe ren t ia l  d iagnostic  dilemmas.
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INTRODUCTION
Narcolepsy is a centra l nervous system d isorder w i th  excessive dayt im e 
sleepiness, f ragm ented  n igh tt im e  sleep and cataplexy as the  core symptoms. In 
addit ion, pat ien ts o f ten  experience hypnagogic ha llucinations, wh ich are vivid 
hallucinations occurr ing when fa l l ing asleep. W hen hallucinations occur at 
awakening, they are called hypnopom p ic  Overeem Narcolepsy is caused by a 
def ic iency in hypotha lam ic  hypocre tin  (orexin) signaling [1]. The hypocre tin  
neurons are exclusively located in the lateral and periforn ical hypothalamus, but 
p ro jec t  extensive ly th rough  the rest o f  the  brain, includ ing the  limbic system. 
Interestingly, recent data po in t to  a possible role o f  the  hypocre tin  system in 
psychiatric disorders, such as addiction [2,3] and schizophrenia [4]. These data in 
tu rn  focus (renewed) a t ten t ion  to  possible psychia tr ic sym ptom s in narcolepsy.
Hypnagogic hallucinations in narcolepsy patients can be very  pervasive. In 
isolated cases this has been repo r ted  to  create diagnostic confusion in physicians 
not fam il ia r  w i th  narcolepsy [5-8] Narcolepsy patients have even been mistaken 
fo r  having schizophrenia
[9-12] On the o th e r  hand, hypnagogic hallucinations have been repor ted  to  occur 
in the general popu la t ion  as well , wh ich may quest ion the ir  pathological 
signif icance [13,14].
In the  present study, we provide a deta iled phenomenolog ica l s tudy o f  "psychotic 
sym ptom s" such as (hypnagogic) ha llucinations, o ther  perceptual experiences as 
well  as delusions in pat ien ts w i th  narcolepsy, using the Schedules fo r  Clinical 
Assessment in Neuropsychiatry  (SCAN) [15] The f ind ings are contrasted w i th  a 
cohort  o f  schizophrenia pat ien ts and compared w i th  a contro l group o f  matched 
popu la t ion  subjects. Furtherm ore, we assess d iffe rences be tween the  prevalence 
o f  DSM /^-d iagnosed psychotic  disorders in narcolepsy pat ien ts and populations 
contro ls . Finally, we prov ide a qual i ta t ive  descr ip t ion o f  the  con ten t  o f  hypnagogic 
hallucinations in narcolepsy.
METHODS
We pe rfo rm ed  a cross-sectional study, com paring  psychotic  symptoms 
(hallucinations, o ther  perceptual experiences and delusions) in th ree  groups: 60 
patients w i th  narcolepsy-cataplexy, 102 pat ien ts w i th  schizophrenia and 120 
popu la t ion  contro ls. 43
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Participants
Narcolepsy pat ien ts (n=60, group I), w ere  recru ited f rom  the  o u tpa t ie n t  clinics of 
the  Center fo r  Sleep-Wake Disorders "Kempenhaeghe" (Heeze, The Netherlands) 
and the  de pa r tm e n t  o f  Neurology, Leiden Un ivers ity  Medical Center (Leiden, The 
Netherlands). All patients fu l f i l led  the  ICSD-2 diagnostic criter ia o f  narcolepsy 
w i th  cataplexy [16]. In accordance, the  M u l t ip le  Sleep Latency Test showed a 
mean sleep la tency o f  less than 8 m inutes as well as tw o  or more sleep-onset REM 
periods. O ther  sleep disturbances, such as s leep-re la ted breath ing disorders, 
were excluded as a cause fo r  the excessive day t im e sleepiness.
Schizophrenia pat ien ts (n = 102, group II) were selected f rom  the "MESIFOS" 
study which was designed to  recru it  pat ien ts w i th  a f i rs t  psychotic  episode 
[17,18] We selected those subjects w ho  fu lf i l led  the DSM-IV A-c r i te r ion  for 
schizophrenia. The m a jo r i ty  (75%) had schizophrenia, 22% had schizophren iform  
and 3% schizoaffective disorder. Because o f  the  pr im ary  aim o f  the  MESIFOS 
study, the  average age o f  the  subjects was s ignif icantly  lower compared to  the 
narcolepsy coh o r t  (see Table 1).
Table 1 Demographic and clinical variables
Narcolepsy Schizophrenia Controls
N 60 102 120
Male 28 (47%) 68 (75%)a 56 (47%)
Age (years) 43 ± 16 26 ± 6b 43 ± 15
Symptom duration (years) 
Medication
24 ± 16 1.1 ± 2.5 -
Stimulants 28 (47%) - -
Antidepressants 26 (43%) - 5 (4%)
Sodium oxybate 7 (12%) - -
Antipsychotics 2 (2%) 83 (81%) -
a: p < 0.001 schizophrenia versus either narcolepsy or controls 
b: p < 0.001 schizophrenia versus either narcolepsy or controls
Control subjects (n = 120, group III) were random ly  selected f rom  the cross­
sectional popu lat ion-based Nijmegen-Health-Area-2 study, in wh ich psychiatr ic 
symptoms were assessed in 368 people f rom  the Dutch population [19]. Controls 
44  were matched w i th  the narcolepsy pat ien ts fo r  age, gender and urban
env ironm ent.
SCAN sem i-structured interview
Symptoms o f  psychosis were assessed using the Schedules fo r  Clinical Assessment 
in Neuropsychiatry  (SCAN) version 2.1 [20]. All in te rv iews were  admin is tered by 
tra ined and ce r t i f ied  SCAN in te rv iewers. The SCAN is a sem i-s truc tu red in te rv iew  
tha t  incorporates the  Present State Examination, version 10 [21]. It is a valid and 
rel iable diagnostic ins trum en t tha t  is w ide ly  endorsed [15,20,22]. DSM-IV 
diagnostic  classif ications w ere  derived f rom  the computer ized version o f  the 
SCAN (Ishell, version 1.0.4.6). In add it ion  to  the  fo rm al SCAN analysis, qual ita t ive 
descrip tions o f  SCAN items re ferr ing  to  hallucinations were col lected and 
described.
The SCAN chapters analyzed in this study cover "ha l luc ina t ions" (chapter 17), j=
"experiences o f  tho ugh t  d isorder and rep lacem ent o f  w i l l "  (chapter 18) and 
"delus ions" (chapter 19). A lthough no t used in the  MESIFOS study, SCAN chapter 8
16 ("perceptual disorders o ther  than ha lluc inat ions") was also com ple ted by the  hcs
narcolepsy pat ien ts and the  con tro l subjects. £
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Clinical ju dg m en t  regarding the presence and the  qua l i ty  o f  the  assessed sir
symptoms was scored using ra t ing scales w i th  the  fo l low ing  basic fo rm a t :  0: a |
posit ive ra t ing o f  absence; 1: sym ptom  de f in i te ly  occurred bu t uncom m on or g
trans i to ry ;  2: sym ptom  was de f in i te ly  present, on m u l t ip le  occasions or fo r  part 
o f  the  t im e; 3: sym ptom  was present m ore  or less continuously. Accord ing to  the ™
SCAN criteria, a sym ptom  is 'p resent '  when scored as 2 or 3. _o
OCCD
In the  SCAN, it is a fo rm al p rerequis i te  to  score ha lluc inations in a state o f  clear mo
consciousness. It may be tha t  the  hallucinations in narcolepsy, wh ich are o f  neh
hypnagogic or hypnopom p ic  nature, occur in a state o f  lowered consciousness. p:y
Patients o f ten  describe hypnagogic hallucinations however as lively and clear, spe
sometimes experienced in "w ide  awake cond i t ion "  [23]. To make a systematic °
descrip t ion possible o f  the  m od ality (visual, auditory, olfactory, tactile), and fo rm  ™
(i.e. verbal, non- verbal, internal, external) o f  the  hallucinations, we scored the ~
items fo r  all ha lluc ination types includ ing the  fo rm al i tem o f  hypnagogic or mo
hypnopom p ic  character. It should fu r th e r  be noted tha t  hypnagogic hallucinations !|
in narcolepsy, a l though being described here as psychotic  symptoms, are by itse l f  y  s
no diagnostic c r i te r ion  o f  a psychotic  disorder.  £
_Cu
Statistics CL
Demographics are presented as f requency  or as mean ± S.D. For each SCAN item, 
f requencies were  de te rm ined  by considering the  f i rs t  tw o  categories as being a 45
negative score and the o ther  categories a posit ive score. Frequencies were
<U■Ha
compared be tween the  narcolepsy and schizophrenia group and be tween the 
narcolepsy and con tro l group, using Fisher's tes t  w i th  a signif icance level of 
p=0.01. Fisher's exact test was also used to  de te rm ine  if  the re  was any in fluence 
o f  m ed ication and gender. Inf luence o f  age and du ra t ion  o f  illness was tes ted by 
Spearman's rank correlation coefficient. These statistical analyses were performed 
using the SPSS package, version 14.0. In addit ion, the Mplus program was used to 
perform a latent class analysis, to test fo r  the presence o f  patient subgroups that 
score high on a specific pattern o f  hallucinations. The Bayesian Information Criteria 
(BIC) and Lo-Mendell-Rubin (LMR) test were used as f i t  indexes [24].
RESULTS
Dem ographics and clinical variables
Dem ograph ic  character istics and m edica tion use are listed in Table 1. Narcolepsy 
patients and popu la t ion  contro ls  were  well matched fo r  gender, age and urban 
env ironm ent.  A bo u t  half  o f  the narcolepsy pat ien ts used s t im u lan t  med ica tion  to 
suppress sleepiness; less than ha lf  used ant idepressant m edica tion fo r  cataplexy 
or sodium oxybate (Table 1). O f the  schizophrenia patients, a m a jo r i ty  used 
ant ipsychot ic  medica tion. Four percent o f  the  contro ls  used antidepressant 
medication.
H allucinations
In Table 2, characteristics o f  the  hallucinations in the  th ree  groups are summarized 
(SCAN chapter 17). M ore  than 80% o f  narcolepsy pat ien ts experienced 
hallucinations ever in life compared to  70% o f schizophrenia pat ien ts and 2% of 
popu lat ions contro ls. In present state, 65% o f  narcolepsy pat ien ts reported  
hypnagogic or hypnopom p ic  ha llucinations. This contrasted str ik ingly w i th  the 
schizophrenia group, w ho  only reported hypnagogic/hypnopompic hallucinations 
in 4% o f  cases. None of the  population contro ls scored 2 or higher on this type of 
ha llucination, a lthough sporadic  hypnagogic hallucinations may thus be 
sometimes reported .  In the narcolepsy patients, hypnagogic ha llucinations 
occurred not only when going to  sleep at night or waking up in the  morn ing, but 
also in the  con tex t  o f  day t im e sleep episodes.
M odality and form
The analysis on m oda l i ty  and fo rm  was pe r fo rm ed  on all types of hallucinations, 
includ ing hypnagogic or hypnopom p ic  ones. Verbal aud ito ry  hallucinations were 
more p ro m ine n t ly  present in the  schizophrenia patients than in the  narcoleptics, 
w i th  long dura t ion , th ird  person qual it ies and com m ent ing  voices as p rom inen t
Table 2 Hallucinations
Narcolepsy Schizophrenia Controls pa Pb
Hallucinations ever present in life 48 (83%) 70 (70%) 2 (2%) 0.089 0.000 **
Hypnagogic and hypnopompic hallucinations 39 (65%) 4 (4%) 0 (0%) 0.000 ** 0.000 **
Auditory hallucinations non-verbal 28 (47%) 15 (15%) 0 (0%) 0.000 ** 0.000 **
Auditory hallucinations verbal
Weekly or more often 24 (40%) 59 (59%) 0 (0%) 0.023 0.000 **
Long or continous auditory hallucinations 17 (28%) 49 (49%) 1 (1%) 0.012 0.000 **
Internal hallucinations 25 (42%) 34 (33%) 1 (1%) 0.313 0.000 **
External hallucinations 13 (22%) 41 (40%) 0 (0%) 0.017 0.000 **
Second person 21 (35%) 40 (45%) 1 (1%) 0.248 0.000 **
Third person 6 (10%) 19 (20%) 0 (0%) 0.179 0.001*
Voices commenting or discussing. 10 (17%) 41 (42%) 0 (0%) 0.001 * 0.000 **
Auditory hallucinations without insight or delusional 13 (22%) 47 (48%) 1 (1%) 0.001 * 0.000 **
Visual hallucinations
Unformed 9 (15%) 13 (13%) 0 (0%) 0.813 0.000 **
Formed, not whole scenes 23 (38%) 13 (13%) 1 (1%) 0.000 ** 0.000 **
Scenic visual hallucination 4 (7%) 8 (8%) 0 (0%) 1.000 0.012
Dissociative hallucinations 8 (13%) 2 (2%) 0 (0%) 0.006 * 0.000 **
O lfactory hallucinations
Present 17 (28%) 9 (9%) 0 (0%) 0.002 * 0.000 **
Sexual hallucinations
Present 10 (17%) 4 (4%) 1 (1%) 0.008 * 0.000 **
Hallucinations of other senses
Temperature, pain, floating or like a crawling sensation 29(48 %) 18 (18%) 1 (1%) 0.000 ** 0.000 **
underthe skin
a: narcolepsy versus schizophrenia; b: narcolepsy versus controls; *: p < 0.01; ** : p<0.001
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Figure 1 Patterns o f  hallucinations based on latent class analysis for  schizophrenic 
patients, narcolepsy patients and healthy controls.
features (Table 2). A ud ito ry  hallucinations in narcoleptics were  more o f ten  o f  a 
non-verbal quality, examples includ ing foo tsteps, music, doors open ing or animal 
noises. Scenic and un form ed visual hallucinations were equally present in both 
patients w i th  narcolepsy and schizophrenia. A lm ost 40% o f  narcolepsy patients 
repor ted  f ragm en ta ry  fo rm ed  visual hallucinations compared to  only  13% of 
schizophrenia patients. In addit ion , o th e r  ha l luc ina tory  modalit ies, such as 
o l fac to ry  or tac t i le  experiences were more o f ten  repo r ted  by the  narcolepsy 
patients. Combin ing the above characteristics, 85% o f  the narcolepsy patients 
w i th  hallucinations repor ted  a com b ina t ion  of visual, aud i to ry  and tac t i le  
modalit ies, fo rm in g  a m ult im oda l,  'ho l is t ic '  experience. This pa t te rn  of 
hallucinations is i l lustra ted in Fig. 1. It d i f fe red f rom  the  schizophrenia patients,
as la tent class analysis showed tha t  a th ree  group divis ion (schizophrenia, 
narcolepsy and contro ls) is op t im al (BIC=4390, p-value LMR = 0.01). O ther 
solutions, e i ther  w i th  more (e.g. d i f fe re n t  severit ies) or less (e.g., combin ing 
schizophrenia and narcolepsy) groups, had worse f i t  indexes.
Interference
About 40% o f  narcoleptics repor ted  m odera te  in te rfe rence w i th  func t ion ing  due 
to  ha llucinations, most ly  due to  related anxiety. However, severe in terference 
was s ignif icantly  more o f ten  repo r ted  in the  schizophrenia group (46% vs. 13%).
Experiences o f disorder of thought and replacem ent o f will
Experiences o f  d isorder o f  tho ugh t  or rep lacem ent o f  w i l l  was hardly ever 
experienced by narcolepsy patients, and the f requency  o f  occurrence 
consequently  did not d i f fe r  f rom  popu la t ion  contro ls  (Table 3). These experiences 
were much m ore prevalent in the  schizophrenia patients. Three narcolepsy 
patients described a fear o f  being taken over by an external force (i.e., the devil), 
but they did no t keep this sym ptom  wh ile  clearly  awake.
D elusions
Only th ree  (5%) o f  60 narcolepsy patients repo r ted  delusions, y ie ld ing no 
diffe rences w i th  the  popu la t ion  contro ls  (Table 4). Again, these fo rm  a clear 
con trast w i th  schizophrenia patients, w here  delusions were f requ en t ly  present. 
However, narcolepsy pat ien ts w ere  sometimes in doub t abou t the  level o f  reali ty 
o f  experiences dur ing ha llucinations. A lthough this  doub t at t imes persisted, 
narcolepsy pat ien ts kept enough insight to  be ra t iona lly  convinced tha t  the 
experiences w ere  no t real. This was ref lected in the  fac t  tha t  pat ien ts were o ften 
able to  exp lic i t ly  "check" the  rea lity  o f  the  experiences.
Perceptual sym ptom s other than hallucinations
In te rv iew  o f  this  chapter was not adm in is tered in the  group o f  schizophrenia 
patients. As shown in Table 5 changed perception o f  t ime, déjà vu and jamais 
vu experiences were repor ted  more f requ en t ly  by the  narcolepsy patients 
(25%) than by the  popu la t ion  contro ls  (1%). Feelings o f  derealization and de­
personalization also were repor ted  s ignif icantly  m ore  o f ten  in the narcolepsy 
group. M odera te  in te rfe rence o f  activ i t ies due to  these perceptual d isorders 
was considerable in the  narcolepsy group (45%) compared to  the  popu la t ion  
contro ls  (1%).
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Table 3 Experiences of disorder of thought and replacement of will
Narcolepsy Schizophrenia Controls pa Pb
Loud thoughts 1 (2%) 20 (20%) 0 (0%) 0.000 ** 0.333
Thought echo 1 (2%) 13 (13%) 0 (0%) 0.010 0.333
Thought insertion 1 (2%) 28 (28%) 1 (1%) 0.000 ** 0.557
Thought broadcast 0 (0%) 18 (18%) 0 (0%) 0.000 ** -
Thought block 2 (3%) 25 (25%) 0 (0%) 0.000 ** 0.110
Thought withdrawal 1 (3%) 5 (5%) 0 (0%) 0.261 0.333
Other subjective disorder of thought 1 (3%) 5 (5%) 0 (0%) 0.269 0.333
Replacement of will by external force 0 (0%) 14 (14%) 0 (0%) 0.001 * -
Replaced control of voice 1 (2%) 8 (8%) 0 (0%) 0.075 0.333
Replaced control of handwriting 1 (2%) 6 (6%) 0 (0%) 0.181 0.333
Replaced control of actions 1 (2%) 9 (9%) 0 (0%) 0.056 0.333
Replaced control of affect 0 (0%) 9 (9%) 0 (0%) 0.012 -
Other experiences of replaced control 0 (0%) 1 (1%) 0 (0%) 0.618 -
a : narcolepsy versus schizophrenia 
b : narcolepsy versus controls 
*: p < 0.01 ** : p<0.001
Table 4 Delusions
Narcolepsy Schizophrenia Controls pa Pb
Delusions of being spied upon 1 (3%) 68 (67%) 0 (0%) 0.000 ** 0.110
Delusions of reference 1 (2%) 54 (55%) 0 (0%) 0.000 ** 0.333
Delusional misinterpretation 1 (2%) 21 (21%) 0 (0%) 0 .0 00 ** 0.333
Quotations of ideas 1 (2%) 23 (23%) 1 (1%) 0 .0 00 ** 0.557
Delusional misidentification 0 (0%) 16 (16%) 0 (0%) 0.000 ** -
Delusional perception 1 (2%) 24 (25%) 1 (1%) 0.000 ** 0.557
Delusions of persecution 1 (2%) 68 (67%) 0 (0%) 0.000 ** 0.333
Delusions of conspiracy 0 (0%) 58 (57%) 0 (0%) 0.000 ** -
Delusional memories and fantastic delusions 3 (5%) 9 (9%) 0 (0%) 0.279 0.036
Delusional paranormal explanations 1(2%) 23 (23%) 0 (0%) 0.000 ** 0.333
Delusions of grandiose abilities 1 (2%) 15 (15%) 0 (0%) 0.004 * 0.333
Monothematic delusions 0 (0%) 26 (26%) 1 (1%) 0.000 ** 0.667
Systematization of delusions 0 (0%) 68 (67%) 1 (1%) 0.000 ** 0.667
Prominence of delusions 0 (0%) 65 (64%) 0 (0%) 0.000 ** -
Conviction about delusions or hallucinations 1 (2%) 67 (66%) 1 (1%) 0.000 ** 0.557
Actions based on delusions or hallucinations 0 (0%) 36 (36%) 0 (0%) 0.000 ** -
Bizarreness of delusions 0 (0%) 45 (44%) 0 (0%) 0.000 ** -
a : narcolepsy versus schizophrenia 
b : narcolepsy versus controls 
*: p < 0.01 ** : p<0.001
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Table 5 Perceptual symptoms o ther than hallucinations
Narcolepsy Controls pa
Unusual sensations 21 (35%) 1 (1%) 0.000 **
Changed perceptions 7 (12%) 1 (1%) 0.002 *
Dulled perceptions 2 (3%) 0 (0%) 0.110
Heightened perception 6 (10%) 0 (0%) 0.001 *
Changed perception of time, deja vu, jamais vue 15 (25%) 1 (1%) 0.000 **
Derealization (things) 8 (13%) 0 (0%) 0.000 **
Derealization (people) 9 (15%) 0 (0%) 0.000 **
Depersonalization 8 (13%) 1 (1%) 0.001 *
Depersonalized perception of self 4 (7%) 0 (0%) 0.012
Unfamiliarity (self) 4 (7%) 1 (1%) 0.043
Changed personal apprearance (dysmorphophobia) 0 (0%) 0 (0%) -
Delusions concerning appearance 0 (0%) 0 (0%) -
Delusion of depersonalization or derealization 1 (2%) 0 (0%) 0.333
Other perceptual abnormalities 9 (15%) 0 (0%) 0.000 **
a : narcolepsy versus controls 
*: p < 0.01 ** : p<0.001
A dditional qualitative description of reported hypnagogic hallucinations
In the  39 patients repo r t ing  to  have had hypnagogic ha lluc inations in the  recent 
past, we col lected descrip tions o f  the  con ten t  o f  the  experiences. Patients 
described the m u lt im oda l ha lluc inations to  be very hard to  distinguish f rom  real 
experiences. During the  ha llucination, typ ica l ly  a com b ina t ion  was present o f  the 
actual env ironm en t o f  the pa t ien t  (such as the  bedroom ) superimposed w i th  the 
hallucinated perceptions, fo r  example a fam ily  m em ber en ter ing the  room, while 
not actually  being in the house. Tactile sensations (touching, pain) con tr ibu ted  to 
the impression o f  reali ty. The hallucinations, rem em bered  in detail ,  w ere  o ften 
very th rea ten ing  and sometimes fo rm ed  an im ped im en t to  go to  bed. The content 
o f  the  hallucinations had a typica l pa t te rn  in wh ich animals such as cats, dogs, 
mice, snakes, a l ligators or ants f requen t ly  played a role (n=17). The animals were
CD
often physically fe l t  as if  touch ing or craw ling over the  skin, in some cases J=
strangulat ing the  neck, st inging or biting. A pa t ien t  described a hole in his 8
bedroom  f rom  which a wave o f  mice poured ou t  and ran over his body. "Real is t ic" "5
hallucinations were repor ted  such as foo ts teps  on the  stairs or on the roo f  (n=8), ~
burglars in the  house (n=7) or songs and music (n=5). One pa t ien t  f requ en t ly  |
O
heard her bedroom  door open ing in the  night. She developed the habit o f  locking .a
her door  dur ing the  night to  be sure tha t  nobody could en ter her room. One |-
pa t ien t noticed the  co lor o f  her lamp had changed dur ing the  hypnagogic 3 
ha lluc ination (dyschromatopsia). There w ere  more extravagant ones as well :
fee ling the  presence o f  unseen, unheard v is i tors (n=10), touch ing o f  hands tha t  ™
strangulated, to re  hair or ex trac ted tee th  (n=10). Contacts were repo r ted  w i th  _o
deceased fam ily  members, strangers or spir its f rom  the dead (n=8). Patients |
fu r th e r  repo r ted  miscellaneous paranormal experiences (n=7) in wh ich predic t ions |
such as fu tu re  accidents or fata l illnesses were received. Contact w i th  persons or J
messages f rom  specif ic  h istor ic episodes (i.e., m idd le ages) were repor ted  as well  ^
(n=5). In 17 cases " f ly in g "  was repor ted  as f requen t  hypnagogic phenom enon, a.
o f ten  fe l t  as a pleasant experience. This type  o f  ha lluc inat ion has been cal led °
"k ine t ic  ha l luc ina t ion" [25]. In o rde r  to  check the  rea lity  level o f  the  f ly ing  ™ 
experience, one pa t ien t pu t a baseball cap on top  o f  the  bedroom  cupboard:
when he " f l ie d "  in the bedroom  the missing cap on the cupboard wou ld  prove to  |  
him tha t  the f ly ing  was no t real. In 11 cases ou t-o f-body  experiences were
reported . Sometimes the re  was a fear o f  no t being able to  re turn  to  the  body. «
Three pat ien ts described w itnessing a so called parallel universe. One o f  them  -g
_C
could sur f  f rom  one universe to  another. A no the r  had a small tunnel in the £
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bedroom  th rough  wh ich he could reach a "paralle l w o r ld " .  O lfac to ry  ha lluc inations ^
(n=17) w ere  m ost ly  o f  bad odors as stool, burn ing material,  and spoiled material.
Ten pat ien ts repo r ted  sexual hallucinations tha t  m ost o f ten  were unpleasant and 53
threaten ing, such as being abused or raped.
<D■M
a
Influencing factors
Gender, age and dura t ion  o f  illness did not show any e f fec t  on the  f requency  of 
the  various SCAN items in e ithe r  subject group. Furtherm ore, the re  were no 
d ifferences be tween the  f requency  o f  i tems in narcolepsy pat ien ts w i th o u t  
m edica tion or using e i the r  s t imulants, antidepressants or sodium oxybate.
Diagnosis according to DSM IV Classification
In the narcolepsy group, tw o  pat ien ts reached the  diagnostic criter ia fo r  a 
psychotic  d isorder according to  DSM IV-TR. The th ird  narco lept ic  pa t ien t  repor t ing  
delusions did not fu lf i l l  these cr iter ia, because the delusions w ere not associated 
w i th  distress or disabil i ty . One pa t ien t fu l f i l led  the  cr iter ia o f  bo th "delusional 
disorder, persecu to ry  ty p e "  and "psychotic  d isorder w i th  delusions due to 
narcolepsy". The second pa t ien t received only the la t te r  diagnosis. The f irs t  
pa t ien t  repor ted  hypnagogic hallucinations in wh ich demons played a dom ina t ing  
role: apart  f rom  this, she had the delusion o f  being watched by cameras. This 
delusion was not based on hypnagogic hallucinations or dreams and exclusively 
played a role in dayt ime, when awake. The second pa t ien t was bull ied at night by 
spir its o f  deceased people tha t  w anted  to  chase her ou t  o f  her house. In dayt ime 
she believed these spir its were  real. For this reason she eventua lly  decided to 
move. Contact w i th  spir its was no t consonant w i th  her social or cultural 
background. Two subjects f rom  the popu la t ion  contro ls  fu lf i l led  the  cr iter ia for 
schizophrenia: one schizophrenia-paranoid type, and one schizophrenia- 
und i f fe ren t ia ted  type. The prevalence o f  a diagnosed psychotic  d isorder did not 
d i f fe r  be tween the  narcolepsy pat ien ts and the  popu la t ion  contro ls.
DISCUSSION
This study examined the  prevalence and qua l i ty  o f  hypnagogic ha lluc inations and 
o ther  psychotic  sym ptom s in pat ien ts w i th  narcolepsy and addressed the  question 
w h e the r  psychotic  symptoms o f  narcolepsy can be distinguished f rom  those of 
schizophrenia. We found, apart  f rom  the ir  re lat ion to  sleep, tw o  main dif ferences: 
a qual i ta t ive  d i f fe rence in sensory modalit ies o f  hallucinations and a quan t i ta t ive  
d if fe rence in the  presence o f  concurrent delusions. In the  narcolepsy group, 
the re  was no increased prevalence o f  fo rm al psychotic  d isorders compared to  the 
popu la t ion  contro ls.
Sensory m odalities and concurrent delusions
54 Hallucinations o f  the  visual m oda l i ty  w ere  -  in agreement w i th  the  l i te ra tu re
[23,25] - much more f requ en t  in narcolepsy pat ien ts than in schizophrenia, where
ve rba l-aud ito ry  was the most f requ en t  sensory mode. Our data fu r th e r  showed 
tha t  the  hallucinations in narcolepsy are typ ica l ly  m ult im oda l,  com bin ing visual, 
aud i to ry  (non-verbal and verbal) and tac t i le  ha llucinations. This "ho l is t ic "  
character o f  ha lluc inations in narcolepsy strong ly con tr ibu ted  to  a deceiving 
sense o f  rea lity  o f  the  experience. Patients could actually feel snakes crawling 
over the ir  skin or b lood d r ipp ing f rom  a fresh wound. However, these "ho l is t ic "  
hallucinations hardly in fluenced rea lity  testing: on ly  th ree  pat ien ts (5%) reported  
delusions, most ly  based on hypnagogic experiences. Just one type  o f  delusion 
was repor ted  more f requ en t ly  than in the  popu la t ion  contro ls: delusional 
m em or ies /  fan tastic  delusions, vary ing f rom  memories o f  f r igh ten ing  encounters 
w i th  ghosts to  insistence on qu ite  pleasurable f ly ing expedit ions. This scarcity of 
delusions is str ik ing, given the  high f requency  and the  realistic  nature o f  the
CD
hallucinations, and points to  relatively healthy insight in patients w ith  narcolepsy. J=
This com binat ion  o f  hallucinations w i th  a low frequency  o f  ha l luc inat ion- 8
congruent delusions is the  second dis tinguish ing fea tu re  be tween patients w i th  "5
narcolepsy and schizophrenia. Hallucinations can, however, in fluence in ter- ~
pre ta t ion  o f  reali ty, creating confusion abou t the quest ion w h e the r  an event |
O
really happened. Some pat ien ts claim to  be c la irvoyant on basis o f  ha llucinated or .a
dream t messages. In o ther  patients. the  f requ en t  déjà vue experiences help to  |-
create a m ult i layered sense o f  rea l i ty  tha t  even predisposes fo r  paranormal 3 
in te rpre ta t ions .  Psychiatr ic c lassif ication is complica ted in these cases because o f
overlap w i th  beliefs tha t  are sanctioned in certa in cultural and rel ig ious ™
backgrounds. _o
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Diagnostic classification |
Although hypnagogic ha lluc inations are pervasive and in fluence daily func t ion ing ,  J
they do not lead to  a separate psychia tr ic c lassif ication in DSM IV. DSM IV  places ^
these perceptual symptoms w i th in  the  range o f  normal experiences and includes a.
them  in the  classif ication o f  narcolepsy. This is in keeping w i th  our f ind ing  tha t  °
the prevalence o f  a psychotic  d isorder according to  D SM -IV  in the narcolepsy ™
group was very low and no t d i f fe re n t  f rom  the  popu la t ion  contro ls. ■­
EO
Several au thors  discuss d i f fe ren t ia t ion  o f  psychotic  disorders in narcolepsy 
-exceptional as they may be- in th ree  possible subtypes: (a) as a psychotic  fo rm  o f  «
narcolepsy, (b) as a chance coincidence w i th  schizophrenia or (c) as s t im ulan t  £
_C
induced psychosis [5,10,23,26,27]. In our s tudy 2 pat ien ts were classified as ü
lA
having a psychotic  disorder. One pa t ien t fel l in to  Category (a): in this  case, the  ^
delusions were com p le te ly  consistent w i th  the  con ten t  o f  the  hypnagogic 
hallucinations. The o ther  pa t ien t f i t te d  in to Category (b): paranoid delusions 5 5
were independent o f  con ten t  o f  hypnagogic ha llucinations, and, clinically, the re
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was a m ix tu re  o f  the  tw o  disorders. Ne ither pa t ien t was using st imulants. In fact, 
we did no t f ind any evidence fo r  s t im ulan t- induced psychotic  sym ptom s in our 
study.
D ifferential diagnosis
W hile  hypnagogic hallucinations in narcolepsy can usually be d i f fe ren t ia ted  f rom  
schizophrenia, the re  remain a num ber o f  o ther  d i f fe ren t ia l  d iagnostic possibili ties. 
Hallucinations in de l ir ium  are also accompanied by sleep disturbances. They are 
p redom inan t ly  visual ra the r  than aud i to ry  [28], o f ten  fea tu r ing  animals, and are 
frequ en t ly  accompanied by delusions [29]. In cocaine and am phe tam ine  induced 
psychosis, hallucinations are more o f  the  aud i to ry  sensory type  and accompanied 
by tho ugh t  disorders and delusions [30,31]. In Parkinson's disease, hallucinations 
o f ten  occur in com b inat ion  w i th  sleep disturbances, and are comparable to  those 
in narcolepsy in having a visual and tac t i le  character [32-34]. Hallucinations in 
Parkinson's disease are m ore f requ en t ly  accompanied by delusions however.  In 
focal epilepsy, hallucinations are br ie f  and s tereo typed . Symptoms are dependent 
o f  the  localization o f  the  ep ilep t ic  focus and are associated w i th  o ther  ep ileptic 
m anifestat ions [35].
Peduncular hallucinosis seems to  be most sim ilar to  hypnagogic hallucinations 
[36]. Peduncular hallucinosis typ ica l ly  occurs in the evening, w i th  an altered sleep 
pa tte rn , and is seldom accompanied by delusions or paranoia [37]. The durat ion 
o f  episodes seems longer than hypnagogic hallucinations, however. The f irs t  
descrip t ion by Lherm it te  in 1922 describes a pa t ien t th a t  suffered f rom  visual and 
tac t i le  hallucinations [38]. In his sum m ary he stated tha t  peduncu lar hallucinations 
should be considered as expressions o f  sleep dysfunct ion  and can be regarded as 
an equiva lent o f  narcolepsy. Later reports  described the  visual, tac t i le  and 
aud ito ry  m odalit ies  as well , a lthough these modalit ies are less o f ten  occurr ing at 
the  same t im e  [36]. In this  cond it ion  abnorm ally  viv id dreams can occur too, and 
animals play a comparable role in the  ha llucinations. Usually, healthy insight in to 
the  nature o f  the  hallucinations is preserved. Interestingly, lesions o f  pons and 
midbra in  can cause both sym ptom at ic  narcolepsy and peduncular hallucinosis 
[39]. Lesions are o f ten  vascular [36] and may also occur as a com plica t ion  of, e.g., 
neuroradio log ica l in te rventions.
Previous studies
Goswami [40] stud ied hypnagogic hallucinations in 129 narcolepsy patients. In 
79.4% o f  the patients hypnagogic hallucinations w ere  present. Patients described 
visual, audito ry, vestibular, somatic, o l fac to ry  and tac t i le  hallucinations but 
frequencies o f  these sensory modalit ies were not given. Vourdas et al. [23] found
tha t  11 (24%) o f  45 narcolepsy pat ien ts experienced hypnagogic hallucinations 
ever in the ir  l i fe t im e, according to  the  Present State Exam ina tion. Sensory 
modalit ies were no t specif ied. Four pat ien ts (9%) m et cr iter ia fo r  am phetam ine- 
induced psychotic  disorder. The d i ffe rence in f requency  o f  hypnagogic 
hallucinations compared to  our results (65%, present state) is str ik ing, and also 
much lower than in o ther  studies. Dahmen et al. [25] compared hallucinations of 
148 patients w i th  narcolepsy to  those o f  pat ien ts w i th  schizophrenia and normal 
contro ls , using a te lephone  quest ionnaire . The percentage o f  hypnagogic 
hallucinations was 79.7%, using the  Stanford Center fo r  Narcolepsy Sleep 
Inventory. U n fo r tuna te ly ,  no fo rm al psychiatr ic d iagnostic  ins trum en t was used. 
Add it iona l analyses w ere  carried ou t  in a subgroup o f  31 narcolepsy patients, 
showing th a t  ha llucinations were o f  the  visual mode in 83%, k inetic  in 71% and 
aud i to ry  in 45%. In the  rare contro l subjects w i th  ha lluc ina tory  experiences, the 
kinetic  m oda l i ty  clearly  dom inated (53%, versus 19% visual and 9% auditory). This 
conf irms a qua l i ta t ive  d i f fe rence be tween narcoleptics and normal contro ls, as is 
also apparent in our data. The absence o f  fo rm al hypnagogic ha llucinations in our 
con tro l subjects contrasts w i th  o ther  studies tha t  found these present to  some 
ex ten t  [13]. This d i f fe rence may be expla ined by the  ra ther s tr ingen t SCAN 
criteria, in wh ich a phenom enon must be present on m u l t ip le  occasions and not 
jus t  incidentally .
Conclusion
In summary, this  study adds to  a more re f ined descr ip t ion o f  the  psychopathological 
phenotype  o f  narcolepsy. Hypnagogic ha lluc inations in narcolepsy can be 
d i f fe ren t ia ted  on a phenomenolog ica l basis f rom  hallucinations in schizophrenia 
which is useful in d i f fe ren t ia l  diagnostic  d i lemmas. The im pact of hypnagogic 
ha llucinations and the ir  considerable in te rfe rence w i th  func t ion ing  calls fo r  an 
active approach o f  patients inv it ing  them  to  discuss these symptoms and f ine 
tune t rea tm en t ,  in due balance w i th  the  o ther  core sym ptom s o f  narcolepsy.
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Anxiety and mood disorders in narcolepsy
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H.A. Droogleever Fortuyn, G.A. Lappenschaar, J.W. Furer, P.P. Hodiamont, 
C.A. Rijnders, W.O. Renier, J.K. Buitelaar, S. Overeem. Anxiety and mood 
disorders in narcolepsy: a case-control study.
General Hospital Psychiatry, 32 (2010) 49-56
ABSTRACT
Introduction
Narcolepsy is a primary sleeping disorder with excessive daytime sleepiness and 
cataplexy as core symptoms. There is increasing interest in the psychiatric 
phenotype of narcolepsy. Although many authors suggest an overrepresentation 
of mood disorders, few system atic studies have been performed, and conflicting 
results have been reported. Anxiety disorders in narcolepsy have only received 
little attention.
Methods
We performed a case-control study in 60 narcolepsy patients and 120 age- and 
sex-matched controls from a previous population study. The Schedules for Clinical 
Assessment in Neuropsychiatry were used to assess symptoms and diagnostic 
classifications of mood and anxiety disorders.
Results
Symptoms of mood disorders were reported by about one third of patients. 
However, the prevalence of formal mood disorder diagnoses -  including major 
depression -  was not increased. In contrast, more than half of the narcolepsy 
patients had anxiety or panic attacks. Thirty-five percent of patients could be 
diagnosed with anxiety disorder (odds ratio = 15.6), with social phobia being the 
most im portant diagnosis. There was no influence of age, sex, duration of illness 
or medication use on the prevalence of mood or anxiety symptoms and disorders.
Discussion
Anxiety disorders, especially panic attacks and social phobia's, often affect 
patients with narcolepsy. Although symptoms of mood disorders are present in 
many patients, the prevalence of major depression is not increased. Anxiety and 
mood symptoms could be secondary complications of the chronic symptoms of 
narcolepsy. Recent studies have shown that narcolepsy is caused by defective 
hypocretin signaling. As hypocretin neurotransmission is also involved in stress 
regulation and addiction, this raises the possibility that mood and anxiety 
symptoms are primary disease phenomena in narcolepsy.
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INTRODUCTION
Sleep and psychiatric disorders often co-occur and influence each other mutually 
[1-3]. A case in point is narcolepsy, a prototypical primary sleep disorder with 
excessive daytime sleepiness and cataplexy -sudden attacks of muscle weakness 
triggered by emotions- as core symptoms [4,5]. Many patients also have hypnagogic 
hallucinations, sleep paralysis and nocturnal sleep fragmentation. However, 
psychiatric symptoms and disorders, including eating disorders and psychotic 
symptoms, have frequently been reported to affect narcoleptic patients [6,7]. The 
discovery that narcolepsy is caused by deficiencies in hypothalamic hypocretin 
(orexin) neurotransmission, has sparked a new interest in the psychiatric phenotype 
of the disorder. For example, recent data implicate the hypocretin system in the 
mediation of the stress response [8] and in a rat model of depression [9,10].
Depressive symptoms and mood disorders have been studied many times in 
narcolepsy, most often using self-report questionnaires such as the Beck 
Depression Inventory (BDI). In a large cross-sectional study using the BDI, 
Dauvilliers et al. found that 29% of narcoleptic patients had moderate to severe 
depressive symptoms [11]. An overrepresentation of depression is suggested by 
most authors, although others have questioned this thesis. Vourdas et al. did not 
find an increase in depressive disorders using a 'life-tim e approach' with a 
structured psychiatric interview [12]. Anxiety disorders have been studied less 
often in narcolepsy, although neurotic disorder is among the most frequent (mis) 
diagnosis given to patients before the diagnosis of narcolepsy is made [13].
The present study was undertaken to accurately examine the presence and 
severity of mood and anxiety disorders in narcolepsy. We used the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) as a validated formal diagnostic 
instrument in a large cohort of narcolepsy patients. Data were compared with 
those of a matched control group from a population study. Finally, we explored 
the influence of age, disease duration and medication use on symptoms of anxiety 
and depression.
METHODS
We performed a case-control study in 60 patients with narcolepsy-cataplexy and 
120 matched population controls. Symptoms of depression and anxiety were 
assessed, as was the frequency of formal diagnoses of both anxiety and mood 
disorders, using a semistructured psychiatric interview .
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Participants
Narcolepsy patients (n=60) were recruited from outpatient clinic of the Center 
for Sleep Medicine 'Kempenhaeghe' (Heeze, The Netherlands), and the Leiden 
University Medical Center Department of Neurology (Leiden, the Netherlands). 
All patients fulfilled the ICSD-2 diagnostic criteria of narcolepsy with cataplexy
[14]. Sleep disordered breathing and other alternative causes for the excessive 
daytime sleepiness were excluded. Control subjects (n = 120) were selected from 
the cross-sectional population-based Nijmegen-Health-Area -2 study, in which 
psychiatric symptoms were assessed in 368 people from the Dutch population
[15]. Controls were matched for age, sex and urban environment (living in a 
community with more or less than 100.000 inhabitants).
SCAN sem i-structured interview
Symptoms of anxiety and depression were assessed using the Dutch edition of the 
SCAN, version 2.1 [16]. All interviews were performed by trained and certified 
SCAN interviewers. The SCAN consists of a semi-structured interview, developed 
from the Present State Examination, version 10 [17]. The SCAN is a reliable and valid 
diagnostic instrument that is widely endorsed [16,18,19]. DSM IV-TR diagnoses 
were generated with I-Shell, the analysis program developed for the SCAN.
For this study, we used SCAN chapters 3 (worrying and tension),Chaper 4 (panic, 
anxiety and phobias), Chapter 5 (obsessional symptoms),Chapter 6 (depressed 
mood and ideation) and Chapter 7 (thinking, concentration and energy) and 
Chapter 10 (expansive mood and ideation). We decided not to separately display 
individual symptom frequencies of Chapter 8 (bodily functions; e.g., sleep 
disturbances and weight changes) because of considerable overlap with the core 
symptoms of narcolepsy. However, bodily functions are included in the SCAN 
diagnostic algorithm. In this algorithm, weight loss and loss of concentration are 
taken into account, but sleep symptoms and fatigue are not, because these were 
typically scored as "due to an organic disorder" in narcolepsy.
Symptoms were recorded as "present state"(i.e ., during the last month). The 
presence and the quality of the assessed symptoms were scored using the SCAN 
rating form at: 0= a positive rating of absence; 1= symptom definitely present, but 
in a mild degree, considered below threshold for diagnosis; 2= symptom definitely 
present but of moderately severe intensity or, if severe, present for less than half 
of the tim e. 3= severe for more than half of the period. Ratings were then 
dichotomized as 'absent' (score 0 or 1) or 'present' (score 2 or 3). When patients 
spontaneously reported additional aspects of a certain symptom, these details 
were recorded and reported where appropriate.
Statistics
Demographics are presented as frequencies or as mean ± SD values. Assessed 
symptomps and diagnostic classifications are presented as the number of patients 
or controls who present the respective item. Patients and controls were then 
compared using logistic regression, showing odds ratios (ORs) together with 
95%-confidence intervals (CIs). In cases in which ORs could not be computed 
(e.g., when the frequency of an item was zero in one of the groups), frequencies 
were compared using Fisher's exact test, w ith a significance level set at P=.01. 
Influence of sex and that of medication use on symptom frequency was tested 
with Fisher's exact test. Influence of age and duration of illness was tested using 
Spearman's rank correlation coefficient. All statistical analyses were performed 
using the SPSS package for W indows, Version 16.0.
RESULTS
Dem ographics and clinical variables
Demographic characteristics and medication use are listed in Table 1. Narcolepsy 
patients and population controls were well matched for gender and age. About 
half of the narcolepsy patients used stimulant medication to suppress sleepiness; 
43% used antidepressant medication or sodium oxybate for cataplexy (Table 1). 
Less than one third of patients did not use medication. Average doses used for 
the most important medication classes are shown in Table 1.
Table 1 Demographic and clinical variables
Narcolepsy Controls
N 60 120
Male 28 (47%) 56 (47%)
Age (years) 43 ± 16 43 ± 15
Symptom duration (years) 24 ± 16 -
Medication
Stimulants 28 (47%) -
Antidepressants 26 (43%) 5 (4%)
Sodium oxybate 7 (12%) -
Antipsychotics 2 (2%) -
No medication 17(28%) 115 (96%)
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W orrying and tension
In Table 2, the symptoms assessed in SCAN chapter 3 (worrying and tension) are 
summarized. As a whole, these symptoms were present significantly more in the 
narcolepsy patients. Two thirds of the patient scored positive on 'fatiguability 
and exhaustion'. Furtherm ore, 'irritab ility ' was as a prominent symptom. A 
physical dimension of this category was reflected in 'localized tension pains' and 
'increased general muscle tension'. S ixty percent of patients reported interference 
with daily activities due to symptoms of worrying and tension.
Table 2 Worrying and tension (SCAN chapter 3)
Narcolepsy Controls Odds Ratio C.I. /  P*
Worrying 35 (58%) 11 (9%) 13.9 6.20- 31.03
Feeling of nervous tension 27 (45%) 10 (8%) 9.0 3 .96- 20.50
General muscular tension 18 (30%) 12 (10%) 3,8 1 .69- 8.62
Nervous in face of problems 14 (23%) 1 (1%) 35.3 4 .51- 276.25
Localized tension pains 22 (37%) 7 (6%) 9.18 3.63- 23.20
Subjectively described restlessness 22 (37%) 8 (7%) 8.1 3.33- 19.72
Fatiguability and exhaustion 39 (65%) 6 (5%) 35.3 13.28- 93.78
Sensitivity to noise 18 (30%) 2 (2%) 25.1 5.58- 112.68
Irritability 26 (43%) 3 (3%) 29.8 8.51- 104.58
Simple ideas of reference 10 (17%) 0 - <0.001
Suspiciousness 8 (13%) 2 (2%) 9.0 1 .85- 43.85
Depersonalization and derealization 14 (23%) 0 - <0.001
Non-delusional jealousy 4 (7%) 0 - <0.001
Interference 36 (60%) 14 (12%) 11.4 5 .31- 24.28
C.I. / P: This column shows the 95% confidence interval (C.I.) for the odds ratio comparing 
narcolepsy patients versus controls. When the odds ratio cannot be computed because the 
frequency of an item is zero in one of the groups, the P-value obtained by Fisher's exact test is 
given. All significant outcomes are printed in bold.
Panic, a n x ie ty  and phobias
Phobias and signs of panic and anxiety were often present in narcoleptic patients 
(Table 3). Anxiety or panic attacks were reported by 53% of patients. When the 
patients were questioned into more detail, panic attacks turned out to be 
frequently linked to frightening experiences during hypnagogic hallucinations, 
but could also be triggered in social situations, such as meeting strangers. The 
mean frequency of panic attacks was once a month. More than 25% of the 
patients reported considerable interference with activities due to panic attacks.
Phobias were often present in patients, w ith more than half of the patients 
describing some kind of phobia. Among the situational phobias, 'collapsing alone 
or with no help near' was the strongest (OR 23.8) and often related to a fear of 
getting a cataplexy attack. The most feared social situation was 'speaking in 
public to strangers' (OR= 51.0). Fear of heights was the most prevalent specific 
phobic symptom in patients. In some patients, phobic symptoms resulted from 
daytime associations with frightful previous experiences. For example, one 
patient answered to SCAN question 4 .040 ('are you afraid in enclosed spaces'): 
'yes, when I am lying in a coffin'. Only later did she realize that she had experienced 
this specific sensation in (recurring) hypnagogic hallucations; therefore, we 
scored this item negative.
Table 3  Panic, anxiety and phobias (SCAN chapter 4)
N arcolepsy Controls Odds Ratio C.I. /  P*
Anxiety or panic attacks present 32 (53%) 10 (8%) 12.6 5 .52- 28.61
Phobias present 33 (55%) 21 (18%) 5.8 2 .88- 11.52
Panic 15 (25%) 9 (8%) 4.1 1 .68- 10.07
Can't get breath 15 (25%) 9 (8%) 4.1 1 .68- 10.07
Heart pounding 24 (40%) 9 (8%) 3.5 1 .72- 7.15
Dizzy 21 (35%) 7 (6%) 8.6 3 .40 - 21.83
Tingling 8 (13%) 2 (2%) 9.1 1 .86- 44.22
Chest pain 12 (20%) 11 (9%) 2.5 1 .02- 6.01
Dry mouth 7 (12%) 12 (11%) 1.2 0.44- 3.16
Difficulty swallowing 5 (8%) 8 (7%) 1.2 0.40- 4.07
Sweating 28 (47%) 25 (21%) 3.3 1.70- 6.51
Trembling 8 (13%) 14 (12%) 1.15 0.46- 2.92
Hot or cold sweats 14 (23%) 8 (7%) 4.2 1 .66- 10.75
Unreality 12 (20%) 5 (4%) 5.75 1 .92- 17.21
Nausea 9 (15%) 9 (8%) 2.18 0.81- 5.81
Fear of dying 14 (23%) 3 (3%) 11.8 3 .26- 43 .24
Feeling of choking 14 (23%) 9 (8%) 3.75 1.52- 9.28
Fear of going crazy 17 (28%) 6 (5%) 7.5 2 .78- 20.31
Apprehension 25 (42%) 19 (16%) 3.8 1.87- 7.72
Other 8 (13%) 6 (5%) 2.9 0.96- 8.78
Panic attacks 15 (25%) 3 (3%) 10.2 2.76- 37.92
Afraid for another panic attack 8 (13%) 1 (1%) 18.0 2.19- 147.63
Action to prevent or end panic 
attack
12 (20%) 2 (2%) 14.5 3.12- 67.25
Free-floating anxiety 7 (12%) 6 (5%) 2.5 0.82- 7.99 67
<U
■Ma
Table 3 Continued
Anxious foreboding with autonomic 
symptoms
11 (19%) 3 (3%) 8.9 2.39- 33.46
Depersonalization /derealizaton  
with anxiety 
Situational phobias
7 (12%) 3 (3%) 5.15 1 .28- 20.70
Public place, open spaces 5 (8%) 2 (2%) 5.36 1 .0 1- 28.51
Crowds, shops, theaters 10 (17%) 2 (2%) 11.8 2 .50- 55.81
Going out or traveling alone 8 (13%) 2 (2%) 9.08 1 .86- 44.22
Traveling away from home 7 (12%) 1 (1%) 15.7 1 .89- 130.96
Collapsing alone or no help near 10 (17%) 1 (1%) 23.8 2 .97- 190.89
Being alone at home 
Social phobias
6 (10%) 1 (1%) 13.2 1.56- 112.53
Eating, drinking, etc. in public 5 (8%) 2 (2%) 5.36 1.01- 28.51
Blushing, shaking, fear of vomiting, 
micturition or defecation
2 (3%) 1 (1%) 4.1 0.37- 46.19
Speaking in a small known group 6 (10%) 1 (1%) 13.2 1.55- 112.53
Speaking in public to strangers 
Specific (simple) phobias
18 (30%) 1 (1%) 51.0 6.60- 393.86
Storms, thunder, lightning 5 (8%) 2 (2%) 5.36 1.01- 28.51
W ater -  pool, lake, sea... 8 (13%) 3 (3 %) 6.0 1.53- 23.53
Animals -  insects, birds, rats 13 (22%) 9 (8%) 3.4 1.37- 8.52
Enclosed spaces -  lifts, tunnels 9 (15%) 5 (4%) 4.06 9.39- 56.31
Flying 4 (7%) 1 (1%) 8.5 0.93- 77.81
Heights -  bridges, stairs 29 (48%) 7 (6%) 15.1 6.04- 37.74
Related to illness (hospitals, 
dentist, injections
9 (15%) 4 (3%) 5.12 1.51- 17.39
Fear of contracting illness (cancer, 
HIV)
8 (13%) 1 (1%) 18.3 2.23- 150.14
Other
Interference w ith activities
4 (7%) 2 (2%) 4.2 0.75- 23.70
Due to situational phobias 17 (28%) 0 - <0.001
Due to social phobias 17 (28%) 1 (1%) 45 5.82- 349.07
Due to specific phobias 8 (13%) 1 (1%) 18 2.23- 150.14
Due to panic and vegetative 
symptoms
16 (27%) 5 (4%) 8.4 2 .89- 24.20
C.I. / P: This column shows the 95% confidence interval (C.I.) for the odds ratio comparing
narcolepsy patients versus controls. When the odds ratio cannot be computed because the
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frequency of an item is zero in one of the groups, the P-value obtained by Fisher's exact test is 
given. All significant outcomes are printed in bold.
O bsessional sym ptom s
Patients reported the same frequency of symptoms related to obsession as did 
the population controls.
D epressed  m ood and ideation
A third of the patients reported a depressed mood (Table 4). The highest OR 
(21.5) among symptoms of depression was found for anhedonia. Loss of self 
esteem and self confidence was also reported significantly more in patients 
compared to controls. Interestingly, in contrast to depressive symptoms in other 
chronic diseases [20], pathological guilt (22%) and guilty ideas of reference (15%) 
were clearly part of the mood symptom profile in patients with narcolepsy. 
Suicidal thoughts or self harm were reported by 13% of the patients. Interference 
in daily activities by mood symptoms was present in 33% of patients.
Table 4  Depressed mood and ideation (SCAN chapter 6)
N arcolepsy Controls Odds Ratio C.I.
Depressed mood 18 (30%) 10 (8%) 4.71 2 .01- 11.04
Masked depression 5 (8%) 3 (3%) 3.52 0.81- 15.24
Tearfulness and crying 15 (25%) 3 (3%) 12.8 3.53- 46.26
Anhedonia 16 (27%) 2 (2%) 21.5 4.74- 97.14
Loss of hope for the future 12 (20%) 4 (4%) 7.1 2 .16 - 23.00
Feeling loss of feeling 9 (15%) 4 (4%) 5.0 1 .48- 17.09
Loss of reactivity 6 (10%) 7 (6%) 1.78 0.57- 5.55
Morning depression 3 (5%) 2 (2%) 3.08 0.50- 18.95
Preoccupation with death or 
catastrophe
3 (5%) 2 (2%) 3.05 0.50- 18.79
Suicide (thoughts) or selfharm 8 (13%) 2 (2%) 8.9 1.83- 4 3 .48
Tedium vitae 10 (17%) 2 (2%) 11.5 2.43- 5 4 .4 0
Pathological guilt 13 (22%) 2 (2%) 16.0 3.48- 73.85
Guilty ideas of reference 9 (15%) 1 (1%) 20.5 2.53- 165.84
Loss of self confidence 12 (20%) 3 (3%) 9.5 2.57- 35.18
Social withdrawal 13 (22%) 1 (1%) 22.1 4 .0 8 -  252.24
Loss of self esteem 8 (13%) 1 (1%) 18.0 2 .19- 147.63
Interference 20 (33%) 8 (7%) 6.87 2 .81- 16.85
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Thinking, concentration and energy
Patients scored higher on many items of this category (Table 5). However, some 
of these items may be d ifficult to interpret. For example, 'loss of concentration', 
reported by 80% of patients, is inherent to the state of drowsiness and lowered 
consciousness that accompanies excessive daytime sleepiness, the hallmark of 
narcolepsy. The same may hold true for symptoms such as 'loss of energy'. This 
symptom category resulted in the most striking interference with daily activities, 
as reported by 90% of patients (OR= 89.2).
Table 5 Thinking, concentration, energy (SCAN chapter 7)
Narcolepsy Controls Odds Ratio C.I.
Loss of positive cognitive functioning 47 (78%) 6 (5%) 68.7 24 .64- 191.50
Loss of concentration 48 (80%) 5 (4%) 91.2 30 .47- 273.00
Subjectively inefficient thinking 25 (42%) 4 (3%) 20.5 6.69- 63.02
Loss of interest 12 (20%) 2 (2%) 14.6 3 .15 - 67.82
Subjective feeling of retardation 18 (30%) 2 (2%) 25.1 5 .58- 112.68
Loss of energy (drive) 42 (72%) 5 (4%) 57.7 20 .04- 165.96
Feeling of being overwhelmed by 
everyday tasks
35 (58%) 5 (4%) 31.9 11.37- 89.61
Interference 54 (90%) 11 (9%) 89.2 31 .31- 254.04
Expansive m ood and ideation
The frequency of (hypo)manic symptoms was low in the patient group, never 
affecting more than 10% of the subjects. However, four patients described 
hypomanic episodes, one of whom with a rapid cycling pattern. Three of these 
patients had been admitted with a manic episode in the past. Many patients 
(30%) reported an irritable mood compared to only 3% of controls (OR 16.7). 
However, this irritab ility was often reported to occur during moments of 
sleepiness and may therefore not necessarily be a symptom of a mood disorder.
Influence o f  dem ographic  and clinical character istics  on sym p tom  frequency
Women tended to score higher on many anxiety items compared to men. 
However, this only reached significance for a m inority of symptoms, most notably 
phobic reactions to animals and avoidance of anxiety provoking social situations 
(both P <0.001). Age was unrelated to the symptom frequencies of any category. 
However, age was related to the degree of interference with activities in patients 
with depressive mood and ideation: higher age resulted in lower interference
(R2 = -0.33, P=0.011). Longer disease duration was even a better predictor for 
lower interference (R2= -0.37, p=0.004).
There were no differences in symptom frequency between patients with and 
those w ithout medication. Furtherm ore, type of medication did not influence 
symptom profiles.
When patients with and those w ithout medication were compared, there was no 
difference in (individual) symptoms frequencies. In addition, we performed 
comparisons between symptom frequencies and subgroups of medication. Only a 
few associations turned up in the analysis. Patients using SSRI's more often 
reported loss of libido (P=0.008). All three patients who were using venlafaxine 
described panic attacks (P=0.008 versus other patients). The items "depressed 
mood" and "tearfulness and crying" tended to occur more often in patients using 
methylphenidate (P=0.013 and P=.012, respectively).
Diagnostic Classification
Table 6 lists the frequency of DSM-IV diagnoses regarding mood disorders, panic 
attacks and anxiety disorders. Overall, there was no increase in the prevalence of 
mood disorders in narcolepsy patients. In contrast, anxiety disorders were 
strikingly more prevalent in narcolepsy patients (35%, OR= 15.6). The most 
important diagnosis in this category was social phobia, affecting 20% of patients 
(OR= 29.8). In addition, panic attacks were overrepresented in narcolepsy patients 
(22%, OR= 4.5).
DISCUSSION
Our study is the first one to show that anxiety - more than depression- dominates §TO
the psychiatric comorbidity of narcolepsy patients. We found an excess of panic |
attacks and social phobia in the patient group compared to the population ^
controls. Furtherm ore, the frequency of mood- related symptoms in narcolepsy -S
was significantly higher than that in controls. However, the prevalence of formal .§"O
mood disorders -  including major depression- was not increased. ^
O
E
The high prevalence of anxiety symptoms and that of formal anxiety disorders in 1TO
narcolepsy are striking. In the past, anxiety disorders have not received the same >■
amount of attention as mood disorders in narcolepsy. Older studies reported 
unspecified anxiety in 17% of patients [21] and 10% of narcoleptics having a history <
of anxiety disorder [22]. Personality studies reported higher levels of psychasthenia 
and hypochondria in patients with narcolepsy compared with patients with 71
idiopathic hypersomnia [23], which may be associated with the increase in anxiety.
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Table 6 Diagnostic classification according to the DSM-IV criteria
Narcolepsy Controls Odds Ratio C.I. /  P*
Mood disorders 9 (15%) 6 (5%) 3.35 1.13- 9.92
Major depressive episode 4 (7%) 3 (3%) 2.79 0.60- 12.87
Dysthymic disorder 0 (0%) 3 (3%) - 0.55
Bipolar I disorder 4 (7%) 0 - 0.012
Bipolar II disorder 1 (2%) 0 - 0.33
Anxiety disorders 21 (35%) 4 (3%) 15.62 5 .05- 48.30
Panic attacks 13 (22%) 7 (6%) 4.47 1 .68- 11.90
Panic disorder without 
agoraphobia
1 (2%) 1 (1%) 2.02 0.12- 32.82
Agoraphobia without panic 
disorder
1 (2%) 0 - 0.33
Specific phobia 1 (2%) 0 - 0.33
Social phobia 12 (20%) 1 (1%) 29.75 3.76- 235.14
Obsessive-compulsive disorder 0 (0%) 1 (1%) - 1.00
Generalized anxiety disorder 1 (2%) 1 (1%) 2.02 0.12- 32.82
Adjustment disorder 1 (2%) 0 - 0.33
Anxiety disorder NOS 4 (7%) 0 - 0.012
C.I. / P: This column shows the 95% confidence interval (C.I.) for the odds ratio comparing 
narcolepsy patients versus controls. When the odds ratio cannot be computed because the 
frequency of an item is zero in one of the groups, the P-value obtained by Fisher's exact test is 
given. All significant outcomes are printed in bold.
The explanation for the frequent occurrence of anxiety symptoms and disorders 
in patients with narcolepsy may be twofold. On the one hand, anxiety may be 
secondary to having narcolepsy and being chronically exposed to anxiety-inducing 
situations or experiences. This mechanism has been described in other disorders 
-  for example, M eniere's disease -  in which paroxysmal dizziness may lead to 
phobic anxiety [24]. On the other hand, there may be a direct link between the 
primary pathophysiology of narcolepsy and that of anxiety.
Sensitivity to stress may be enhanced by the lack of control that narcoleptic 
patients experience during irregular sleep- wake states, cataplexy attacks, 
unpredictable automatic behaviour or bulimic attacks. These symptoms could all 
'push up' the level of stress due to a more external locus of control. In addition,
social anxiety could be linked to shame from falling asleep or having cataplectic 
attacks in the company of others. The avoidance of social interaction can be seen 
as a strategy to gain control over these embarrassing situations. Specific phobias 
may also have a different source. Narcoleptic patients may have severe difficulty 
in discerning reality from experiences during hypnagogic hallucinations [7].
Associations between these 'two worlds' are frequently reported by patients, 
and frightening hallucinations can influence daytime reality. Specific phobic 
symptoms, such as a fear of certain animals or water, may well be related to 
frightful experiencies during hypnagogic hallucinations.
Regarding mood disorders, most previous studies in narcolepsy are case series 
that used self-report questionnaires such as the BDI, instead of formal diagnostic 
instruments. Many of these reported high frequencies of depression [11,21,25-27]. 
Quality-of-life instruments, such as the SF- 36, pointed to a high level of depressive 
symptoms in narcolepsy as well [28-30]. However, the controlled study by Vourdas 
et al [12], which used the Present State Exam ination, did not confirm an 
overrepresentation of depressive disorders in narcolepsy patients, which is 
comparable to our findings . One of the reasons for these discrepant results is the 
considerable overlap between the symptomatology of narcolepsy and the somatic 
features of depression, such as sleep disturbances, weight changes, and loss of 
concentration (see below). Using self- completed questionnaires with predefined 
cutoff scores may lead to high prevalence estimates.
Many individual mood symptoms, including depressed mood an anhedonia, were
reported more often by the narcolepsy group. The question on whether these >.lA
symptoms belong to the narcolepsy profile proper, reflect an adjustment reaction
to the narcolepsy or are indicative of an independent psychiatric disorder, §TO
remains. This diagnostic dilemma complicates the psychiatric classification of c
depression in many chronic somatic illnesses and currently has not been ^
adequately solved [31] . The cause of the dilemma lies in the "somatic symptoms -S
"that are included in the DSM-IV-TR diagnostic criteria for depression ( weight .§"O
changes, disturbed sleep, fatigue and loss of concentration). Several solutions ^
have been proposed, such as an "exclusive approach" in which symptoms |
overlapping with the somatic disorder are left out, and an "inclusive approach"in 1TO
which all somatic symptoms count fully [32]. In our study, we followed the SCAN >■
algorithm to obtain DSM - IV  diagnoses that can be described as "partially 
inclusive", including weight changes and loss of concentration, but excluding <
sleep symptoms and fatigue [16]. Given the significant impairments that 
depressive symptoms can pose on patients, it is still prudent to apply a rather 73
inclusive approach in clinical practice, in order not to withhold treatm ent.
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Recent data raise the interesting possiblity that anxiety and mood symptoms in 
narcolepsy may be a direct consequence of the neuropathophysiology of the 
disease. It is now firm ly established that narcolepsy is caused by deficiencies in 
hypothalamic hypocretin (orexin) signaling [4,5], with more than 90% of patients 
with clear-cut cataplexy being deficient in hypocretin. Studies suggest a role for 
the hypocretin system in the mediation of the stress response [8]. Changes in 
hypocretin levels have been reported in a rat model for depression [9,10]. Brundin et 
al. [33] reported significantly lower hypocretin concentrations in the cerebrospinal 
fluid (CSF) of patients with major depressive disorder who attempted suicide, 
compared to control suicide attem pters with dysthymia or adjustment disorder. 
In a follow-up sample of suicide attem pters with miscellaneous diagnoses, 
cerebrospinal hypocretin concentrations were negatively correlated with 
symptoms of lassitude and slowness of movement [33]. Hypocretin neurons are 
part of the central reward circuit- for example, by influencing dopaminergic 
neurons in the ventral tegmental area [34,35]. Animal data show that hypocretin 
defects indeed lead to abnormal reward processing [36]. Interestingly, changes in 
reward processing are also found in patients with social anxiety disorder, in whom 
positive and reinforcing aspects of social interactions are muted [37-39]. Although 
we do not have data on the hypocretin status of our patients, a direct connection 
between the hypocretin deficiency in narcolepsy and anxiety and mood disorders a 
likely possibility. Studies in hypocretin- deficient animal models for narcolepsy 
may shed further light on this mechanism.
Our findings have consequences for the care for patients with narcolepsy. Anxiety 
symptoms are often not spontaneously reported, and should be actively asked 
for. Recognition and discussion of these symptoms can provide important relief 
for patients. M any patients reported a clear impairment in daily functioning due 
to anxiety and mood problems. Interference with activities due to mood 
symptoms diminished with longer disease duration, indicating better adjustment 
in time possibly by acquiring effective coping strategies. However, by paying 
attention to these complaints, physicians can help patients become less isolated 
and gain more control over these symptoms. It is crucial for doctors to realize 
that patients with narcolepsy display a highly complex phenotype, that is not just 
limited to sleep symptoms.
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High prevalence of 
eating disorders in narcolepsy
Based on:
H.A. Droogleever Fortuyn, S. Swinkels, J.K. Buitelaar, W.O. Renier, J.W. Furer, 
C.A. Rijnders, P.P. Hodiamont, Sebastiaan Overeem. High prevalence of eating 
disorders in narcolepsy with cataplexy: a case-control study.
Sleep, 31;3 ( 2008) 335- 341
ABSTRACT
Objectives. To study the prevalence of (symptoms of) eating disorders in patients 
with narcolepsy.
Design. We performed a case-control study comparing symptoms of eating 
disorder in patients with narcolepsy versus healthy population controls, using the 
Schedules for Clinical Assessm ent in Neuropsychiatry (SCAN 2.1). To study 
whether an increased body mass index (BMI) could be responsible for symptoms 
of eating disorder, we also compared patients to BMI-matched controls, using the 
SCAN as well as the Eating Disorder Exam ination-Questionnaire.
Patients and participants. Patients with narcolepsy/cataplexy (n=60) were 
recruited from specialized sleep centers. Healthy controls (n=120) were drawn 
from a population study previously performed in the Netherlands. Separately, 32 
BMI-matched controls were recruited.
M easurem ents and Results. In total, 23.3% of the patients fulfilled the criteria 
for a clinical eating disorder, as opposed to none of the control subjects. Most of 
these were classified as Eating Disorder -  Not Otherwise Specified, with an 
incomplete form of binge eating disorder. On the symptom level, half of the 
patients reported a persisting craving for food, as well as binge eating. Twenty-five 
percent of patients even reported binging tw ice a week or more often. When 
compared to BMI-matched controls, the significant increases persisted in 
symptoms of eating disorders among patients with narcolepsy. Except for a higher 
level of interference in daily activities due to eating problems in patients using 
antidepressants, medication use did not influence our findings.
Conclusions. The majority of patients with narcolepsy experience a number 
symptoms of eating disorders, with an irresistib le craving for food and binge 
eating as the most prominent features. Eating disorder symptomatology 
interfered with daily activities. These findings justify  more attention for eating 
disorders in the treatm ent of patients with narcolepsy.
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INTRODUCTION
Narcolepsy is a clinically heterogeneous condition [1,2]. Next to the core features 
of excessive daytime sleepiness and cataplexy, there is a varying number of 
additional symptoms. Besides sleep related symptoms, such as sleep paralysis, 
hypnagogic hallucinations and fragmented nocturnal sleep, non-sleep symptoms 
are often encountered. One of the more prominent of those is the increase in 
body weight in many patients. Already in the 1930s, Daniels reported that 57% of 
his patients with narcolepsy were overweight or obese [3]. Recently, a number of 
epidemiological studies showed a clear increase in Body Mass Index (BMI) in 
narcoleptic patients compared to the general population[4-6], w ith a preferential 
storage of fat in the abdominal compartment. Several explanations for the weight 
gain have been put forward. Although the psychoanalytic theory of weight gain 
due to 'substitutive oral activ ity ' held for a while [7], recent discoveries into the 
biological basis of narcolepsy provided more founded mechanisms.
Most cases of narcolepsy with cataplexy are caused by a deficiency in hypocretin 
(orexin) neurotransmission [8,9]. The hypocretin neurons are located in the 
perifornical area of the lateral hypothalamus and are involved not only in the 
regulation of sleep, but in endocrine and autonomic regulation as well [10]. The 
weight gain in narcolepsy could be caused by changes in energy expenditure due 
to excessive sleepiness, changes in basal metabolic rate [11,12] or endocrine 
disturbances [13,14]. Excessive daytime sleepiness is not likely to be a major 
factor, as patients with narcolepsy have a significantly higher BMI than do patients 
with idiopathic hypersomnia [6]. Interestingly, recent studies showed that the 
hypocretin system may also be active in the psychiatric domain [15,16]. This, in 
combination with the known stimulatory effect of hypocretin on food intake [17] 
raises the possibility that eating disorders may be present in narcolepsy.
Although a controlled diary study showed no differences in total caloric intake 
between patients with narcolepsy and controls [18], there have been some 
reports on symptoms of eating disorders. Kotagal et al found a history of binge 
eating in 5 out of 31 children with narcolepsy [19]. Recently, Chabas et al reported 
a mild eating disorder, classified as Eating Disorder Not Otherwise Specified 
(EDNOS), in 6 patients with narcolepsy-cataplexy [12]. Besides this study, no 
system atic studies on the prevalence of (symptoms of) eating disorders have 
been carried out. Furtherm ore, the influence of an increased body weight per se 
on such symptoms remains unknown in narcolepsy.
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To determine w hether eating disorders (at the diagnostic as well as the symptom 
level) are indeed more prevalent in narcolepsy, we performed a large cross­
sectional case control study comparing 60 patients with narcolepsy-cataplexy 
with healthy controls from the general population. In addition, to study the 
influence of overweight, we performed a separate study in which 32 patients 
with narcolepsy were compared with 32 controls, who were also matched for 
BMI.
METHODS
General s tudy design
We conducted two separate cross-sectional case-control studies. In study I, we 
compared symptoms of eating disorder in 60 narcolepsy-cataplexy cases with 
120 age- and sex-matched controls taken from a large population based study. In 
study II, 32 patients with narcolepsy were compared (using an additional 
diagnostic instrument) with 32 specifically recruited controls, matched not only 
for age and sex, but also for BMI. This study was conducted according to the 
guidelines of the medical ethical committee of the Radboud University Nijmegen 
Medical Center. All subjects gave informed consent prior to entering the study.
Participants
Narcoleptic patients were recruited from the outpatient clinics of Sleep-Wake 
Center 'Kempenhaeghe' (Heeze, The Netherlands) and the departm ent of 
Neurology, Leiden University Medical Center (Leiden, The Netherlands). All 
patients fulfilled the ICSD-2 diagnostic criteria of narcolepsy with cataplexy [20]. 
All were HLA-DQB1*0602 positive, and Multiple Sleep Latency Testing showed a 
mean sleep latency of less than 8 minutes as well as 2 or more sleep-onset rapid 
eye movement periods. In only a m inority of patients, CSF hypocretin-1 
measurements were performed [9]. Other sleep disturbances, such as 
sleep-related breathing disorders were excluded as the cause for the excessive 
daytime sleepiness.
In study I, 60 narcoleptic patients were compared with 120 control subjects. 
Controls were randomly taken from the cross-sectional population-based 
Nijmegen-Health-Area-2 study, in which psychiatric symptoms were assessed in 
368 people from the Dutch population [21]. Controls were matched for age, sex 
and urban environment (living in residential area with less or more than 100.000 
inhabitants).
In study II, 32 narcoleptic patients were compared with 32 controls, recruited by 
advertisem ent in a local newspaper. Here, subjects were also matched for BMI, as 
BMI has been shown to influence eating attitudes and behavior [22-24].
M easu rem en ts
Symptoms of eating disorders were assessed using chapter 8 and 9 of the 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) version 2.1. The 
SCAN consists of a semi-structured interview that incorporates the Present State 
Examination, version 10 [25]. The SCAN is a validated diagnostic instrument that 
is w idely endorsed [25-28]. Both the patients and the population controls were 
interviewed by trained and certified SCAN investigators. From the SCAN data, 
symptoms of eating disorders can be assessed on the item level. In addition, it is 
possible to classify symptoms into the Diagnostic and Statistical Manual of Mental 
Disorders, 4th edition (DSM-IV) diagnostic classification for eating disorders: 
anorexia nervosa, bulimia nervosa, and EDNOS [29]. EDNOS contains incomplete 
forms of anorexia nervosa or bulimia nervosa, as well as Binge Eating Disorder. To 
enable classification as binge eating disorder with more certainty, we added 1 
question from the Structured Clinical Interview  for DSM-IV to our SCAN interview. 
Section 8 of the SCAN assesses physical functions such as changes in BMI over 
time. Section 9 assesses various symptoms of eating disorders, as well as the 
interference with daily activities due to these symptoms. We added section 6 and 
7 from the SCAN, which cover depressive symptomatology, in order to assess the 
influence of mood symptoms on eating behavior.
In study II, besides the SCAN, subjects completed the Eating Disorders Examination- 
Questionnaire (EDE-Q 4th edition) [30]. The EDE-Q is a self report version of the 
Eating Disorder Examination[31]. It is a 36-item scale that assesses features of 
eating disorders, generating 4 subscale scores: dietary restraint, eating concern, 
weight concern and shape concern. Respondents rate the items on a 7-points scale, 
indicating the number of days out of the previous 28 in which specific behaviors 
and attitudes occurred. The EDE-Q has received psychometric support, including 
adequate test- retest reliability[32,33] and a good convergence with the EDE- 
interview [30,34,35]. Disordered eating was defined when subjects scored 4 or 
greater on either the weight concern or the shape concern subscale, had a mean 
global score of 4 or greater, or had more than 1 episode of self-induced vomiting, 
binging with loss of control or diuretic or laxative use over the last 4 weeks [24,36].
Statistical analysis
All data are presented as mean ± standard deviation. Mean item scores and item 
frequencies were compared between groups using Students t-test and Fisher
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<u■Ha
exact test respectively. To obtain DSM IV diagnostic classifications from the SCAN 
interview , we used the softw are algorithm w ritten by C.R. in SAS version 8, in 
consultation with and after approval of the World Health Organization SCAN 
workgroup. All other statistical comparisons were done using SPSS version 14. 
Significance level was set at p= 0.05.
RESULTS
Demographic and clinical variables
In table 1, the demographic characteristics of the participants are listed. In both 
studies, patients and controls were well matched for sex and age. On average, 
patients had narcolepsy symptoms for around 20 years at the time of study. 
Fifty-two percent of patients used stimulant medication (modafinil or 
methylphenidate), 12% used sodium oxybate, and 43% antidepressants for 
cataplexy.
Table 1  Demographic and clinical characteristics
Study I
Patients Controls p
Study II
Patients Controls p
N 60 120 32 32
Age 43.5 ± 15.6 43.5 ± 15.4 0.97 40.4 ± 15.1 42.2 ± 11.7 0.079
M ales 28 (47%) 56 (47%) 1.00 11 (34%) 11 (34%) 1.00
BM I 27.8 ± 5.7 24.6 ± 3.3 0.001 27.6 ± 7.1 27.6 ± 5.0 0.43
Age at onset 20.1 ± 9.2 19.7 ± 7.6
Age at diagnosis 30.6 ± 11.6 28.2 ± 10.8
Duration o f symptoms 23.9 ± 15.8 20.4 ± 13.0
Duration since diagnosis 10.5 ± 11.0 11.10 ± 9.4
In study I we again confirmed that patients with narcolepsy are overweight: there 
was a significant difference in BMI between patients (27.8 ± 5.7) and controls 
(24.6 ± 3.3, p= 0.001). BMI was not influenced by sex. In study II, patients and 
controls were well matched for BMI.
Sym p to m s o f  eating disorders
The percentages of participants scoring positive on the various items of the SCAN 
are listed in table 2. In study I, patients with narcolepsy scored significantly higher 
on all items, except for 'actions to loose weight through purgation'. About half of
Table 2 SCAN Section 9 (item level symptoms of eating disorders)
Study 1
Patients Controls P
Study II
Patients Controls P
N 60 120 32 32
Dread o f becoming fa t 62% 8% <0.001 78% 31% <0.001
Earlier episode o f undereating 13% 5% 0.074 22% 16% 0.75
Irresistible and persistent craving fo r  food 67% 5% <0.001 66% 13% <0.001
Earlier episode o f overeating 42% 5% <0.001 50% 22% 0.036
S e lf perception o f fa tness w / intrusive dread o f becoming too fa t 33% 1% <0.001 38% 22% 0.274
Im poses low  weight threshold 5% 0% 0.036 13% 3% 0.355
Avoidance o f fa tten ing foods 45% 3 % <0.001 53% 34% 0.207
Actions to lose weight through se lf  restriction 42% 2% <0.001 43% 13% 0.011
Actions to lose weight through purgation 3% 1% 0.258 9% 0% 0.24
Binge eating w / sense o f lack o f control
None 45% 99% <0.001* 31% 78% 0.002*
Binges but retains control 12% 0% 13% 13%
Binges infrequently w / feeling o f loss o f control 18% 1% 28% 9%
Binges tw ice a week, w / a feeling o f lack o f control 20% 0% 16% 0%
Binges more frequently w / a feeling o f loss o f control 5% 0% 9% 0%
Dread o f getting too fa t  in sp ite o f craving 30% 0% <0.001 28% 0% 0.002
Actions to correct binging through purgation 7% 0% 0.012 6% 3% 1.000
Restrictive actions to correct binging 18% 0% <0.001 25% 0% 0.005
*: Chi-square test
Chapter 5 -j High p re v a le n ce  o f e a tin g  d iso rd e rs  in n a rc o le p sy
the patients reported a persisting craving for food, experienced an earlier episode 
of overeating, and experienced binge eating. Twenty-five percent of patients 
even reported binging tw ice a week or more. The m ajority of patients reported a 
dread of becoming fat, a self-perception of fatness or both. Patients also took 
more measures for weight control, such as the avoidance of fattening foods or 
trying to lose weight through self-restriction. No endocrine disturbances were 
reported, such as delayed onset of puberty or amenorrhea.
Female patients showed significantly higher scores than males on the following 
items: dread of becoming fat (78 vs 43%, P =0.001) and dread of getting too fat in 
spite of craving (44 vs 15%, P=0.02). Furtherm ore, women more often reported a 
certain level of interference of symptoms of eating disorder in daily life (72% vs 
43%, P=0.013).
In study II, BMI-matched controls also reported symptoms of eating disorders, 
such as a self-perception of fatness and measures for weight control (table 2). 
However, even when compared to BMI matched controls, patients with narcolepsy 
had a significantly increased frequency of episodes of overeating, binge eating 
and a persistent craving for food. Furtherm ore, w ithin the patient group, there 
was no difference in BMI between subjects who reported binge eating and those 
who did not. There were also no significant correlations between BMI and the 
EDE-Q subscales on objective and subjective bulimic episodes.
Symptoms of eating disorder posed a clear interference with daytime activities in 
patients. Over 30% of patients reported moderate to severe (and incapacitating) 
interference with activities, compared to 1% of controls in the general population 
and 6% in BMI-matched controls (P< 0.001).
DSM IV classification o f  eat ing  d isorders
Using the SCAN data, subjects were classified in the DSM-IV eating disorders 
diagnoses (table 3). In total, 23.3% of the patients fulfilled the criteria for a clinical 
eating disorder, against none of the control subjects. Only 1 patient was classified 
as having anorexia nervosa. Four patients (6.7%) fulfilled the criteria of bulimia 
nervosa. Nine patients (15%) were classified as EDNOS. Within this category, 2 
patients were subthreshold anorexia nervosa cases (having all criteria except 
amenorrhea), 1 patient subthreshold bulimia nervosa (having all criteria, but binge 
frequency was less than twice a week). Six patients met the criteria for binge eating 
disorder, 5 of whom were subthreshold because of missing the DSM IV criterion of 
'marked distress regarding binge eating'. In study II, the results regarding DSM-IV 
eating disorders diagnoses were essentially the same as in study I.
Table 3 DSM IV eating disorders classification
Study I
Patients Controls p
Study II
Patients Controls p
N 60 120 32 32
Anorexia 1 (1,7%) 0 (0%) 0.33 1 (3%) 0 (0%) 1.00
Bulimia 4 (6.7%) 0 (0%) 0.012 2 (6.3%) 0 (0%) 0.49
Eating Disorder NOS 9 (15%) 0 (0%) <0.001 8 (25%) 0 (0%) 0.005
At the time of study, 17 out of 60 patients (28.3%) did not receive treatm ent for 
their narcolepsy, with stim ulants, sodium oxybate, or antidepressants. Only 6 
control subjects (5%) used antidepressant drugs. We compared BMI, eating 
disorders diagnoses and the most salient eating disorders symptoms between 
treated and untreated patients and, separately, between patients with or without 
the use of antidepressants or stim ulants. The results are shown in table 4. 
Interestingly, medication use did not increase BMI. Treated patients even tended 
towards a lower BMI. Furtherm ore, medication use did not influence the 
prevalence of eating disorders symptoms and diagnoses, except for a trend 
towards more irresistib le craving in the patients using antidepressants. 
Furtherm ore, the patients who received treatm ent reported a significantly higher 
level of interference with activities due to eating problems.
Mood disorders may interact with the presence of eating disorders diagnoses and 
symptoms of eating disorders. The number of patients fulfilling the criteria for 
depression or bipolar disorder was too small to make any comparisons. We 
therefore compared patients with and w ithout the SCAN-symptom 'depressive 
mood' and 'anhedonia' on BMI, key symptoms of eating disorders and diagnoses 
of eating disorders. We found no effect of these mood symptoms, except for a 
higher prevalence of binge eating with lack of control (with depressed mood: 67% 
vs 33%, P=0.024, P= 0.024; with anhedonia 75% vs 7% P = 0.008) and a higher 
number of EDNOS diagnoses (39% vs. 5%, P=0.002). So, especially for the diagnosis 
EDNOS there seems to be a relation with the presence of depressed mood and 
anhedonia.
EDE-Q results
Results from the EDE-Q auto-questionnaire are presented in tables 5 and 6. 
Several measures of attitudes in eating behavior (d ietary restraint, eating and 
weight concern) were significantly higher in patients compared to BMI-matched 
controls. Objective bulimic episodes showed a trend to occur more often in
in
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Table 4  Influence of medication on BMI, key eating disorders symptoms and eating disorders diagnoses
Med No med P AD no AD P Stim No Stim P
43 17 26 34 28 32
BM I 26.8 30.2 0.09 26.9 28.4 0.31 26.6 28.8 0.13
Dread o f becoming fa t 61% 65% 1.0 62% 62% 1.0 61% 63% 1.0
Irresistible and persistent craving fo r  food 72% 53% 0.23 81% 56% 0.06 71% 63% 0.59
Earlier episode o f overeating 37% 53% 0.38 35% 47% 0.43 39% 44% 0.80
Actions to lose weight through purgation 2% 6% 0.49 4% 3% 1.0 0% 6% 0.49
Binge eating w / sense o f lack o f  control 40% 53% 0.40 42% 44% 1.0 39% 47% 0.61
Interference with activities due to eating problem s 33% 24% 0.55 46% 18% 0.02 29% 31% 1.0
Diagnosis Anorexia Nervosa 2% 0% 1.0 4% 0% 0.4 4% 0% .047
Diagnosis Bulimia Nervosa 7% 6% 1.0 4% 9% 0.63 7% 6% 1.0
Diagnosis EDNOS 9% 29% 0.1 12% 18% 0.72 11% 19% 0.48
Med: medication 
AD: antidepressants 
Stim: stimulants
Table 5 EDE-Q subscale scores in patients versus BMI-matched controls
Patients Controls p
N 32 32
Dietary Restraint 8.0 ± 7.3 2.6 ± 3.6 <0.001
Eating Concern 5.2 ± 7.8 1.1 ± 2.5 0.009
Weight Concern 9.3 ± 7.1 5.8 ± 5.6 0.031
Shape Concern 17.0 ± 13.1 11.1 ± 11.8 0.067
Objective Bulimic Episodes 2.0 ± 5.0 0.2 ± 0.8 0.057
Subjective Bulimic episodes 1.1 ± 4.5 0.4 ± 1.8 0.40
patients than in controls. However, the frequency of subjective bulimic episodes 
was not significantly higher.
Female patients scored significantly higher than males on the dietary restraint 
(9.5 ± 8.4 vs 5.2 ± 3.1, p = 0.046) and eating concern (7.3 ± 9.1 vs 1.5 ± 1.5, P = 
0.011) subscales. Weight and shape concern showed a trend towards a higher 
score in women (11.0 ± 7.4 vs 6.2 ± 5.5, P = 0.068 ; 20.1 ± 12.8 vs 11.1 ± 12.2, P = 
0 .064 respectively). There were no differences in the frequency of objective and 
subjective binges between men and women.
Disordered eating behavior can be assessed using cut-off criteria for the various 
EDE-Q subscales (table 6) [24,36]. Disordered eating is a measure of pathogenic 
eating behavior, at risk for developing an eating disorder. Our analysis yielded a 
high degree of disordered eating in narcoleptic patients, even when compared to 
BMI-matched controls, corroborating the results from the SCAN.
DISCUSSION
In this study, we showed that a considerable number of patients with narcolepsy- 
cataplexy display various symptoms of eating disorders, with an emphasis on a 
craving for food and binge eating behavior. In almost a quarter of patients, it was 
even possible to make a formal DSM-IV eating disorder classification. Many 
patients reported a dread of becoming fat, and the eating problems posed a clear 
interference with daily activities in more than one third of our cohort. Eating 
disorders seem to be an integral part of the narcolepsy phenotype and not only 
due to the increase in BMI, as narcoleptic patients scored significantly higher on
in
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Table 6 Disordered eating behaviors in patients versus BMI-matched controls
Patients Controls P
N 32 32
Score > 4 d ietary restraint 62.5% 21.9% 0.002
Score > 4 eating concern 29% 9.7% 0.11
Score > 4 weight concern 78.1% 51.6% 0.036
Score > 4 shape concern 90.6% 64.5% 0.016
M ean global score > 4 82.8% 50% 0.012
> 1 episode o f se lf induced vomiting 3.2% 0% 0.49
> 1 episode o f se lf induced binging with lack o f control 29% 6.3% 0.022
>1 episode o f diuretic use 0% 0% *
>1 episode o f laxative use 0% 0% *
* no statistics computed because both patients and controls = 0
various items of both the SCAN and EDE-Q when compared to BMI-matched 
healthy controls.
On the symptom level, narcoleptics reported irresistible and persistent craving 
for food, binge eating with lack of control, and restrictive actions to correct 
binging. However, there was no single specific eating disorder classification 
within the patient group: bulimia nervosa (4/60), anorexia nervosa (1/60) and 
EDNOS (9/60) were all present. Within the EDNOS group however, 6 out of 9 
patients could indeed be categorized into binge eating disorder, while the others 
had subthreshold bulimia or anorexia. These prevalence numbers are clearly 
higher than those in the overall population. In our control cohort, no formal 
eating disorders could be diagnosed, and this is in line with previous studies who 
found very low prevalences, even in selected populations that would be at higher 
risk, such as young fem ales (in the range of 0.7% for anorexia nervosa to 1-2% for 
bulimia nervosa) [37]. The prevalence for EDNOS has been established less 
extensively; a recent study of 2018 Portuguese young fem ales found a prevalence 
of not more than 2.4% [38].
Interestingly, the effect of the various medications used for narcolepsy had no 
clear influence on the prevalence of diagnoses and symptoms of eating disorders,
nor on BMI. In fact, medication use tended to be associated with a lower BMI. 
There was as slight trend towards more craving in patients using antidepressants,
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and these patients also report more interference in activities due to eating 
problems. Regarding the influence of symptoms of mood disorders, patients with 
depressive mood and/or anhedonia had a higher number of EDNOS diagnoses as 
well as binge eating with lack of control. However, in our cross-sectional study 
design, it is not possible to decipher the 'direction' of this correlation. Further 
(longitudinal) studies may shed light on this issue.
The few other reports on eating disorder symptomatology in narcolepsy also 
found an emphasis on binge eating [3,12]. Recently, Chabas et al. reported that 
half of 6 typical and 7 atypical patients with narcolepsy could be classified as 
EDNOS, with features of bulimia nervosa [12]. Diagnosis of EDNOS seems to have 
been made on a rough exclusion of anorexia and bulimia nervosa w ithout precise 
criteria however [12]. Because of the small sample size, the influence of sex on 
eating behavior could not be assessed. In our study, we did not find a difference 
in binging behavior between men and women. However, women more often 
reported a dread of becoming fat and a higher level of interference activities. So, 
despite binging to the same extent, women are more worried about their eating 
behavior.
Previous studies into Binge Eating Disorder have shown a positive correlation 
between binge eating and obesity [39]. Chabas et al also showed a trend towards 
more pronounced symptoms in the narcoleptics who were overweight compared 
to those with a normal BMI [12]. However, in our study, we could not establish a 
relation between BMI and binge eating. In fact, the relationship between 
symptoms of eating disorder and BMI may be the other way: a higher BMI has 
been shown to influence eating attitudes and behaviors [22,23]. The controls 
subjects in study II (matched with the patients for BMI) indeed showed an increase 
in symptoms, compared with the general population controls in study I. However, 
even when compared to BMI-matched controls, patients had significantly more 
eating disorder symptomatology. This suggests that the eating disorder is an 
integral part of the narcolepsy phenotype and not a pure consequence of the 
obesity per se. We propose that the eating disorder could be a direct consequence 
of the hypocretin deficiency. This is not in contradiction with the fact that Chabas 
et al found that both 'typ ical' and 'atypical' patients displayed symptoms of 
eating disorders; in that study hypocretin levels were not measured, and even in 
patients with normal hypocretin levels, it remains possible that the hypocretin 
system is dysfunctional, for example through postsynaptic mechanisms. in
Although the hypocretin system was initially proposed to be mainly stimulating 91
feeding [40], it is now clear that it subserves a broad range of functions, including
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metabolic and endocrine regulation [10,41]. One tantalizing link between 
hypocretin defects and binge eating forms the melanocortin system . Binge eating 
has been reported as a major phenotype of mutations in the melanocortin-4 
receptor (MC4-R) [42]. The hypocretin system has connections with cells in the 
arcuate nucleus that produce pro-opiomelanocortin (POMC), the precursor of 
melanocortin [43]. So, hypocretin deficiency may directly influence melanocortin 
signaling, which in turn may cause eating disorders.
The increased scores on weight and eating concern in the EDE-Q data reflect the 
impact that the symptoms of eating disorder have on the lives of patients. This 
was fu rther corroborated with the high levels of interference with activities as 
assessed in the SCAN. Clearly, symptoms of eating disorder pose a great burden 
on the patients. Now that obesity has become a social and even political issue, 
the pressure to correct the increase in body weight may even add to the suffering 
and concern of patients. It is not improbable that shame around this theme 
suppresses communication, partly explaining that eating disorders in narcolepsy 
are a relatively unknown issue to physicians. It is im portant that doctors treating 
patients with narcolepsy discuss these symptoms, and give proper information 
and guidance. In patients with prominent symptoms of eating disorders, referral 
to a specialized psychiatrist may be indicated. Cognitive behavior therapy can be 
useful in certain eating disorders, such as bulimia, binge eating disorder, and 
other EDNOS subtypes [44]. Guided weight-reduction programs may also be used. 
Although we did not have information on formal diagnoses of the metabolic 
syndrome in our cohort, patients with a BMI greater tan 30 more often used 
cardiovascular and antidiabetic medication than did those with a BMI less than 30 
(6/7 vs 4/43, P = 0.004). An increased BMI is thus suggested to predispose 
narcoleptic patients to complications such as the metabolic syndrome, which 
warrants medical intervention.
This is the first epidemiological study assessing eating disorder symptomatology 
in narcolepsy with cataplexy, using a cross-sectional case-control design in a 
large number of subjects. Furtherm ore, we not only used auto-questionnaires, 
but also a semi-structured interview to assess symptoms. We used both a general 
population control group, as well as controls matched for BMI. All patients 
fulfilled the ICSD-2 criteria[20] for narcolepsy with cataplexy. Hypocretin-1 levels 
were known in only a small number of patients, so we were not able to assess the 
influence of hypocretin-deficiency. However, it is known that in patients with 
sporadic and clear-cut cataplexy, over 90% of subjects is hypocretin-1 deficient
[9]. Although we used validated instruments to assess symptoms, we did not 
system atically collect data to measure the timing of binges and craving for food.
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We were thus unable to assess the presence of the night eating syndrome. Six out 
of 32 patients in study II spontaneously mentioned binging at night; other patients 
reported that, with a build-up of sleep pressure throughout the day, the resistance 
against binging diminished. Future studies should include a formal assessment of 
the night eating syndrome and address circadian, sleep homeostatic and mood 
influences on the frequency and severity of binging. Furtherm ore, the prevalence 
of the metabolic syndrome and other (cardio)vascular and endocrine complications 
should be assessed in narcolepsy.
in
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Severe fatigue in narcolepsy
Based on:
H.A. Droogleever Fortuyn, R. Fronczek, M. Smitshoek, S. Overeem,
G.A. Lappenschaar, J.S. Kalkmak, W.O. Renier, J.K. Buitelaar, G.J. Lammers, 
G. Bleijenberg. Severe fatigue in narcolepsy with cataplexy.
J Sleep Res (pending minor revisions)
ABSTRACT
Excessive daytime sleepiness (EDS) is the core symptom of narcolepsy. However, 
there have been indications that fatigue -that should be separated from EDS- is a 
frequent complaint as w ell. We determined the prevalence of severe fatigue in a 
group of narcolepsy patients, and its relation with excessive daytime sleepiness, 
psychological distress, functional impairment and quality of life. We included 80 
patients fulfilling the ICSD-2 diagnostic criteria of narcolepsy with cataplexy. 
Fatigue was measured using the Checklist Individual Strength (CIS). In addition 
psychological distress, including symptoms of depression, functional impairment 
and quality of life were assessed. Comparisons were made between patients with 
(CIS-fatigue score 35) and w ithout severe experienced fatigue. Fifty patients 
(62.5%) reported severe fatigue. There were no sex or age differences between 
patients with and w ithout severe fatigue. Both fatigued and non-fatigued patients 
had the same amount of daytime sleepiness (Epworth Sleepiness Score 14.3 ± 4.2 
vs. 13.1 ± 4.4, p=0.22), confirming the separation between sleepiness and fatigue. 
Interestingly, fatigued patients more often used stimulant medication (64% vs. 
40%, p=0.02). Severe fatigue was associated with a significantly increased 
functional impairment, increased depressive symptoms, and a lowered general 
quality of life. In conclusion, a m ajority of patients with narcolepsy suffer from 
severe fatigue, which can be distinguished from daytime sleepiness, and results 
in severe functional impairment.
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INTRODUCTION
Excessive daytime sleepiness and cataplexy form the core symptoms of narcolepsy, 
a primary sleep disorder with a prevalence of about 5-6 per 10,000 [1]. Fragmented 
nighttime sleep, hypnagogic hallucinations and sleep paralysis are frequently 
reported additional symptoms. Many patients also complain about fatigue, a 
finding that was already reported in the older narcolepsy literature [2]. In a strict 
sense, fatigue should be defined as a subjective experience of mental or physical 
exhaustion that does not disappear after a period of sleep [3]. In contrast, daytime 
sleepiness is defined as the inability to stay awake and alert during the major 
waking episodes of the day, resulting in unintended lapses into drowsiness and/or 
sleep. Patients however may have trouble distinguishing between daytime 
sleepiness with sleep attacks and the physical feeling of fatigue. Medical doctors 
have difficulty to differentiate between sleepiness and fatigue as well, often 
tending to equate them [4]. In some languages, for example Finnish, sleepiness and 
exhaustion are even synonymous. However, although excessive daytime sleepiness 
and fatigue may have overlapping features, they are distinct symptoms that have 
been shown to co-occur independently in sleep-disordered patients [4].
Severe fatigue has been found in high percentages of patients with chronic 
neurological conditions such as Parkinson's disease [5], multiple sclerosis [6] and 
neuromuscular disorders [7]. In these diseases, it was shown that severe fatigue 
has important clinical consequences, such as increased functional lim itations and 
lowered general health status [8]. Finally, there have been reports of patients 
diagnosed with chronic fatigue syndrome, who later turned out to have narcolepsy 
[9]. The exact prevalence and the functional consequences of fatigue in narcolepsy 
remain unknown. Therefore, we performed a detailed questionnaire study on the 
presence, severity and consequences of fatigue in narcolepsy.
METHODS §TOc
c
Patients nD
Patients were recruited from the outpatient clinic of the departm ent of Neurology, ■“TO
Leiden University Medical Center (Leiden, The Netherlands). The local medical ^
ethical committee approved the study. >CDCO
A total of 127 patients under active treatm ent were approached by mail to 
participate. We did not approach patients with comorbid sleep apnea (defined by 99
an apnea-hypopnea index of more than 15 per hour on the original diagnostic
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polysomnography) and those not proficient in Dutch. All patients were clinically 
assessed by GJL and fulfilled the ICSD-2 clinical diagnostic criteria of narcolepsy 
with cataplexy [10]. A total of 80 (63%) patients returned a completed 
questionnaire. CSF hypocretin-1 measurements were performed in 25 of these 
patients: hypocretin-1 was undetectable in 23, and within normal limits in two 
patients. Diagnostic polysomnographic and Multiple Sleep Latency Test 
registrations were performed on average more than six years before data 
collection, so these data were not used in the present study.
The demographic characteristics are summarized in Table 1. Some form of 
narcolepsy medication was used by 62 patients (77.5%), including stimulants, 
anti-depressants for cataplexy, or sodium oxybate at night.
Q uestionnaires
Fatigue Severity
Fatigue severity was assessed using the Fatigue Severity Scale (8 items, score 
range 8- 56) of the validated Dutch version of the Checklist Individual Strength 
(CIS)-fatigue [11]. Each item was rated on a 7 point Likert scale, w ith higher scores 
representing a higher severity of fatigue. Healthy subjects do score fatigue 
symptoms as well. In other words: 'fatigue' should be regarded as a continuum. 
Previous studies showed a population mean of around 16 on the CIS-fatigue. The 
cut-off for 'severe fatigue' was defined as two standard deviations above this 
value, i.e. at 35 points [3]. The CIS is a validated measure with good internal 
consistency and international recognition [12]. This scale has been used in studies 
on chronic fatigue syndrome (CFS), but also on the presence of fatigue in several 
neurological disorders [7,13].
Depression and Psychological Distress
Depression was assessed using the Beck Depression Inventory for Primary Care 
(BDI-PC) [14]. The primary care version was used because the complete BDI 
contains somatic symptoms of depression which overlap with the physical aspects 
of fatigue. A score of 4 or higher indicates the presence of clinical depression. The 
Symptom Checklist-90 (SCL-90) was used to assess psychological distress [15].
Functional impairment and quality of life
Functional impairment was described and quantified with the Sickness Impact 
Profile (SIP) [16], containing the eight categories: sleep and rest, home 
management, mobility, social interaction, ambulation, alertness behavior, work, 
and recreation and pastimes. A higher score on the SIP indicates more impairment. 
The following subscales of the Short Form-36 (SF-36) were used to assess overall
quality of life: physical functioning, social functioning, role lim itations due to 
physical health problems, role lim itations due to emotional problems, mental 
health, bodily pain and general health perception [17]. The transformed scores 
for all SF-36 scales range from 0 -  100, with a higher score indicating better 
functioning or less pain.
Daytime sleepiness
The Epworth Sleepiness Scale (ESS) is a validated scale to measure the presence 
and severity of excessive daytime sleepiness [18]. Subjects rate the chance of 
falling asleep on eight 8 different circum stances often encountered in daily life.
Data analysis  and statistics
All data analyses were performed using SPSS for Windows (version 14) Overall 
data were analyzed using descriptive statistics. We divided our sample in patients 
with and w ithout severe experienced fatigue (cut-off value of > 35 on the 
CIS-fatigue, see above) Afterwards, d ifferences between groups were assessed 
using Student's T- or chi-square tests on continuous and categorical variables 
respectively. Levene's test was used to assess equality of variances and p-values 
adjusted when appropriate. In addition to the above analyses, correlations 
between CIS-fatigue scores and psychological distress, depression, functional 
impairment and quality of life, were calculated using Spearman's coefficients. All 
data are shown as mean ± standard deviation, unless otherwise indicated.
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RESULTS
Prevalence o f  s ev ere  fatigue
Severe fatigue was present in 50 patients (62.5%) (Table 1). There were no age or 
sex differences between patients with and w ithout severe fatigue. Patients with 
severe fatigue more often used stimulant medication (64% vs 40%, Table 1). This 
latter relation was stronger for patients using methylphenidate (8 out of 9 
patients severely fatigued; likelihood ratio 3.5, p = 0.028), than for patients using 
modafinil (21 out of 31 severely fatigued, LR 2.8, p=0.078). There were no other 
differences in medication use between the groups.
Fatigue and s leepiness
There was only a weak correlation between scores on the ESS and the CIS-fatigue 
subscale ( r = 0.274, p=0.014). ESS scores did not d iffer between the severely and 
not severely fatigued patients (see Table 2).
Fatigue and depression , psychological d istress, quality  o f  life and impairment
In Table 2, levels of psychological distress, depression, impairment in daily life as 
well as quality of life are compared between the patient subgroups. For the 
different scales, a direct correlation with CIS-fatigue scores was computed as 
well. Both the correlation analysis and the comparison between groups with 
different level of fatigue, showed converging results.
BDI-PC scores were higher in the severely fatigued patients compared to the not 
severely fatigued patients (p < 0.01, Table 2). Although the presence of clinical 
depression (i.e. a BDI-PC >4) was not significantly different between groups (Table 
2), depression was correlated to fatigue (r= 0.324, p= 0.002). Severely fatigued 
patients showed high levels of psychological distress, on almost all SCL-subscales 
(Table 2 and figure 1A). The SCL-sleep subscale which probes disturbed nocturnal 
sleep, was significantly higher in the severely fatigued patients as well.
Severe fatigue was significantly related to more functional impairment, as the 
total SIP score was almost doubled in the severely fatigued group (1051.2± 664.0 
vs 527.5 ± 449.1 , p < 0.001). However, even the not severely fatigued narcoleptics, 
had scores that were higher than reported in a reference group of 450 patients 
treated by general practitioners for mild somatic complaints (mean total score of 
211) [3]. SIP subscores on various categories of activities are shown in Table 2 and 
figure 1B. Severely fatigued patients were most impaired in the domains of 
mobility, ambulation, social interaction and recreation & pastimes. However, the 
SIP score 'work' was not significantly different between the two subgroups,
Table 1 Demographic variables and medication use
Total Severely fatigued  
(CIS-fatigue > 35)
Not severely fatigued 
(CIS-fatigue < 35)
P
N 80 50 (62.5 %) 30 (37.5 %)
Age 48.3 ± 14.7 47.3 ± 13.2 49.8 ± 17.2 0.47
M ales (%) 46 (57.5%) 28 (56%) 18 (60%) 0.73
Working 50 (62,5 %) 32 (64%) 18 (40%) 0.451
M edication total 62 (77.5%) 42 (84%) 20 (66.7%) 0.07
Stimulants 44 (55%) 32 (64%) 12 (40%) 0.02
Antidepressants 19 (23.8%) 10  (20%) 9 (30%) 0.37
Sodium oxybate 26 (32.5%) 16 (32%) 10 (33.3%) 0.98
Data as mean ± SD. Medication total: number of patients using any (combination of) narcolepsy 
medication; Stimulants: modafinil, methylphenidate and/or mazindol; Antidepressants: tricyclics 
or SSRI's.
suggesting that impairment of the severely fatigued subgroup was mostly felt in 
the private domain. There was a significant decrease in all dimensions of quality 
of life as measured in the SF-36 in the severely fatigued group (figure 1C).
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Table 2 Levels psychological distress, depression, quality of life and impairment in daily life, as possible determinants of fatigue
Subscale
Com parison betw een subgroups
Severely fatigued Not severely fatigued P
Correlation analysis  
Spearm an p
SCL anxiety 16.3 ±6.1 11.9 ±2.7 0.000 0.492 0.000
SCL agoraphobia 10.4 ± 4 .8 7.9 ± 1 .8 0.002 0.468 0.000
SCL depression 31.4 ± 13.5 21.4 ± 4 .6 0.000 0.525 0.000
SCL somatization 23.1 ±7.3 16.6 ± 3 .6 0.000 0.638 0.000
SCL insufficiency 21.9 ±7.2 15.0 ± 4 .8 0.000 0.638 0.000
SCL sensitivity 30.3 ± 13.2 21.8 ±4.7 0.000 0.436 0.000
SCL hostility 8.5 ± 2 .6 6.8 ± 1 .3 0.000 0.405 0.000
SCL sleep 8.6 ± 3 .2 6.3 ±2.7 0.001 0.370 0.001
BDI primary care 3.6 ±3.51 1.00 ±1.62 0.000 0.495 0.000
BDI total 13.7 ± 8 .4 5.8 ± 5 .3 0.000 0.588 0.000
BDI- PC >4 13 (26%) 3 (10%) 0.083 0.324 0.002
RAND physical functioning 65.5 ± 28.5 89.3 ± 13.6 0.000 0.673 0.000
RAND social functioning 54.5 ± 26.3 75.8 ±20.7 0.000 0.571 0.000
RAND role limitations -  physical 40.5 ± 40.1 60.0 ±39.1 0.037 0.431 0.000
RAND role limitations -  social 59.3 ± 46.3 87.8 ± 28.3 0.001 0.345 0.002
RAND mental health 64.8 ± 20.9 80.53 ±12.1 0.000 0.429 0.000
RAND vitality 36.1 ± 17.9 61.5 ±16.1 0.000 0.746 0.000
RAND bodily pain 69.8 ±29.7 84.5 ±20.1 0.010 0.405 0.000
RAND general health perception 49.3 ± 23.0 64.8 ± 20.6 0.003 0.459 0.000
RAND change in health (1 year) 41.5 ± 17.2 50.0 ± 13.1 0.015 0.236 0.035
Chapter
SIP sleep & rest 146.7 ± 92.8 87.6 ± 90.3 0.007 0.370 0.001
SIP home management 89.1 ±92.7 48.7 ±61.9 0.022 0.379 0.000
SIP mobility 60.9 ± 84.5 16.3 ± 34.4 0.001 0.489 0.000
SIP social interaction 235.1 ±213.1 102 ± 122.5 0.001 0.399 0.000
SIP ambulation 45.7 ± 83.6 3.9 ± 12.1 0.001 0.462 0.000
SIP alertness behavior 251.7 ±214.2 133.7 ± 166.5 0.008 0.430 0.000
SIP work 101.16 ± 132.3 75.4 ± 122.0 0.388 0.238 0.034
SIP recreation & pastimes 120.9 ± 80.2 60.0 ± 72.9 0.001 0.431 0.000
SIP total 1051.2 ± 664.2 527.5 ± 449.0 0.000 0.548 0.000
ESS total 14.3±4.2 13.1 ± 4 .4 0.215 0.274 0.014
O  Severe fatigue in narcolepsy  
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Figure 1 A) Group scores on the various items of the Symptom Checklist-90 ,
measuring general psychopathology. B) Functional impairment, reflected 
in changes of conduct in everyday activities due to sickness (Sickness 
Impact Profile).
10 6
Figure 1 C) Subscores on the Short Form-36 to assess quality of life
DISCUSSION
Here we show that severe fatigue is highly prevalent in narcolepsy with cataplexy. 
On average, ESS scores did not d iffer between patients with and w ithout severe 
fatigue, with only a weak correlation between individual fatigue and sleepiness 
scores. Severe fatigue was, however, associated with global psychological distress 
including depressive symptoms, functional impairment and a loss of quality of life.
Severe fatigue is more prevalent in narcolepsy than for example epilepsy, in 
which group 48% of the patients scored mild/moderate or severe on the Fatigue 
Severity Scale (FSS) [19]. The high prevalence of severe fatigue in narcolepsy 
(62%) is comparable to prevalence indicators in neuromuscular disorders such as
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facioscapulohumoral dystrophy (60% severely fatigued), myotonic dystrophy 
(74%), and HMSN-1 (64%) [8]. In a recent validation study of the FSS in a Swiss 
cohort of 429 sleep-wake disordered patients, Valko et al. showed that the small 
subgroup (n=22) of narcolepsy patients had the highest fatigue scores, together 
with insomnia group [20]. In contrast to our results, these authors did find a 
significant correlation in the narcoleptics between sleepiness as measured with 
the ESS, and the FSS (r=0.71).
Daytime s leep iness  and nocturnal s leep  disturbances
In this study, there was a clear separation between sleepiness and fatigue. This 
relative independency of fatigue and sleepiness has been described in other 
populations as well. In a recent study, daytime sleepiness and fatigue were 
measured in patients with chronic fatigue syndrome (CFS), sleep apnea and 
healthy controls [21]. Sleepiness was not only measured subjectively by the ESS, 
but also assessed with the Multiple Sleep Latency Test (MSLT). The distinction 
between fatigue and sleepiness was confirmed: CFS patients turned out to be less 
sleepy than both healthy controls and sleep apnea patients.
The positive relation between disturbed nocturnal sleep and fatigue has 
previously been described in healthy subjects [22] and in various neurological 
disorders [7]. In narcolepsy, fatigue could also be linked to disturbed nocturnal 
sleep, which is an im portant part of the narcolepsy phenotype. The direction of 
the association between nocturnal sleep disturbances and daytime fatigue 
remains unclear however: disturbed sleep may both be a cause or a consequence 
of fatigue, as was suggested by studies of sleep quality in patients with chronic 
fatigue syndrome [23].
The role o f  d epression  and physical activity
There was an association between severe fatigue and a high level of depressive 
symptoms. The question can thus be raised whether severe fatigue is just an 
equivalent of depression in the narcolepsy population. The association of fatigue 
with depressive symptoms is often found in studies of somatically ill patients [24] 
but alse in patients with chronic fatigue syndrome [25]. The direction of the 
association remains unclear however, as longitudinal studies have been 
inconclusive so far [24]. Interventional studies of fatigue using antidepressants 
show discouraging results, influencing depression and anxiety but not severe 
fatigue [25-27]. In the present study, antidepressant use was not associated with 
fatigue severity either. Several studies have shown an increase in depressive 
symptoms in narcolepsy, but w ithout an increase in major depression according 
to DSM-IV criteria [28]. Therefore, although there is a clear overlap of symptoms
of fatigue and symptoms of depression, severe fatigue is not adequately explained 
by the presence of major depression in narcolepsy.
In our sample, decreased physical activ ity correlated with severe fatigue. 
Decreased daytime physical activ ity has been reported in narcolepsy before [29]. 
In a predictive model of fatigue in neuromuscular disorder patients, both sleep 
disturbances and decreased physical activities were found to be perpetuating 
factors of experienced fatigue [7]. W hether a sim ilar mechanism is also present in 
narcolepsy requires further study.
Stimulant medication
A striking result was the association of severe fatigue and the use of stimulant 
medication. This seems paradoxical because stim ulants are frequently prescribed 
to treat fatigue in many patient categories [26], although e.g. modafinil showed 
only limited results for this indication [30]. Could stim ulants negatively affect 
nocturnal sleep quality, resulting in daytime fatigue? A study of modafinil in 
narcolepsy patients did not show adverse effects on sleep quality [31]. A recent 
study of methylphenidate in adult ADHD patients [32] reported initial insomnia 
and increased need for sleep as adverse events, more than half a year after the 
start of the study. In this view, methylphenidate-induced insomnia may be a 
factor leading to an increase in fatigue. However, another explanation could be 
that more severely affected patients need more stim ulants in order to stay 
awake, but remain fatigued nonetheless. A final explanation may be that fatigue 
represents a suboptimal adjustment to the burden of narcolepsy in daily life. The 
SIP results showed a considerable impairment in daytime functioning of 
narcolepsy patients, which was by far the most striking in the patients with severe 
fatigue. Interestingly, in a quality of life study, Daniels et al found lower scores on 
the physical and social subscales of the SF 36 as well as higher depression scores, 
in patients taking stim ulants combined with anticataplectic medication [33]. They 
commented that treatm ent apparently was not sufficiently effective to restore 
health status to normal.
Limitations o f  this study
Possible relations between objective measures of nocturnal sleep quality and 
severe fatigue could not be assessed in this study, as the mean interval between 
data collection and diagnostic sleep studies was more than six years. During this 
period, a variety of life style changes may have taken place, and -perhaps more 
importantly- treatm ent was initiated. We cannot exclude that a few patients 
developed comorbid sleep apnea between the diagnostic PSG and fatigue 
assessment, although there were no clear symptoms indicating this. To further
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our understanding of the mechanisms leading to severe fatigue in narcolepsy, 
future studies, preferably in a controlled design, should add objective sleep 
assessment in combination w ith fatigue m easurem ents.
Conclusions
There is a high prevalence of severe fatigue in patients with narcolepsy, which is 
associated with important psychological distress. These findings have 
consequences for the clinical care of narcolepsy patients. Doctors should actively 
inquire not only after the classical sleepiness, but also after the presence of 
fatigue. Just the recognition of severe fatigue by the physician will already be 
valuable for the patient, although the most effective treatm ent strategy still 
needs to be defined.
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CHAPTER 2
NARCOLEPSY AND PSYCHIATRY IN HISTORICAL PERSPECTIVE
Chapter 2 illustrates the fascinating and instructive historical relation between 
narcolepsy and psychiatry. Gélineau (1880) originally defined narcolepsy as a 
neurosis, which was in that period believed to be an organic disease. Soon 
thereafter he suggested the existence of a secondary type of narcolepsy as an 
expression of hysteria. Psychoanalysts later diagnosed narcolepsy as a conversion 
disorder and accordingly offered psychoanalysis as treatm ent. Another group of 
psychiatrists stayed however faithful to the more traditional 'organic' model of 
narcolepsy. The two directions in psychiatry hardly referred to each other, and 
during half a century made their progress in isolation, immunized to chances of 
correction. As a consequence of the rapid development of neuroscience in the 
second half of the 20th century the cellular and molecular base of narcolepsy was 
discovered. Narcolepsy was finally established as a brain disease, as originally 
suggested by Gélineau. At the same time, this also provided the basis for an open 
view towards the psychiatric phenotype of narcolepsy, and on this topic formal 
studies started to appear in the beginning of the 21st century studies. Soon it 
became clear that narcolepsy is not just a sleep disorder, but a highly complex 
behavior disorder as well.
The involvement of psychiatry with narcolepsy over the course of more than a 
century made a complete turn around: the original 'organic' model first shifted 
to a psychodynamic model of conversion hysteria and then again moved back 
to the 'organic' point of departure. Patients often have been passive watchers 
of these historical trends, and sometimes even victim s, not always being able 
to benefit from the change of scientific scenery.
CHAPTER 3
EATING DISORDERS >
Narcolepsy patients are known to have a high body mass index (BMI). In addition, E□
reports of so-called 'carbo-craving' are often provided by patients. These facts ^
sparked interest in the exact nature of eating habits and disorders in narcolepsy.
We compared our cohort of narcolepsy patients (n=60) with age- and sex-matched 117
population controls (n=120). Additional comparisons were made between a
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subgroup of patients (n=32) and a group of controls that were also matched for 
BMI (n=32). Eating disorders were assessed using the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN), as well as the Eating Disorder Examination- 
Questionnaire (EDE-Q). Criteria for a clinical eating disorder were fulfilled in 23% 
of patients, as opposed to none of the control subjects. Most of these were 
classified as Eating Disorder Not Otherwise Specified (EDNOS), with an incomplete 
form of binge eating disorder. Half of the patients reported a persistent craving 
for food as well as binge eating. A quarter of the patients reported binge eating 
tw ice a week or more often. Binge eating was not correlated with an increased 
BMI. When compared to BMI matched controls, the pattern of disordered eating 
behavior was again confirmed. Medication use did not influence the findings, 
except for a higher interference in daily activities due to eating disorders in 
patients using antidepressants.
In the narcolepsy group a quarter of patients have an eating disorder, classified 
as EDNOS, which is significantly more than population controls. Most patients 
had an incomplete form of binge eating disorder, with irresistible craving and 
binge eating as most prominent features. Disordered eating clearly interfered 
w ith daily activities.
CHAPTER 4
PSYCHOTIC SYMPTOMS OF NARCOLEPSY
Patients with narcolepsy often experience pervasive hypnagogic hallucinations 
that even can lead to diagnostic confusion with schizophrenia. This may result in 
mismanagement of narcoleptic patients, as treatm ent with antipsychotics is 
ineffective. We aimed to provide a detailed qualitative description of hypnagogic 
hallucinations and other 'psychotic' symptoms in patients with narcolepsy and 
contrast these with schizophrenia patients and healthy controls. We also 
compared the prevalence of formal psychotic disorders between narcolepsy 
patients and controls. We used the SCAN interview  to compare psychotic 
symptoms between patients with narcolepsy (n=60), w ith schizophrenia (n= 102) 
and matched population controls (n=120). In addition, qualitative data was 
collected to enable a detailed description of hypnagogic hallucinations in 
narcolepsy. We found clear differences in the pattern of hallucinatory experiences 
in narcolepsy versus schizophrenia. Narcoleptics reported m ultisensory 'holistic' 
hallucinations rather than the predominantly verbal auditory sensory mode of 
schizophrenia patients. Delusions were not more frequent in narcolepsy 
compared to population controls. Just a few patients reported delusional
memories or fantastic delusions. Memories of hallucinations or dreams were 
sometimes hard to separate from real life memories. This caused confusion in 
some patients. In spite of the 'psychotic symptoms', the prevalence of formal 
psychotic disorders was not increased in patients with narcolepsy, mainly because 
of preserved insight. Almost half of the narcoleptics reported moderate 
interference with functioning due to hypnagogic hallucinations, mostly due to 
related anxiety.
M ultisensory, 'holistic' hallucinations of narcolepsy patients can clearly be 
differentiated from predominantly 'verbal auditory' hallucinations in 
schizophrenia patients. Narcolepsy patients did not fulfill DSM-IV criteria for 
psychotic disorders more frequently than population controls. Reality testing 
was compromised in some patients by memories from vivid hallucinations and 
dreams that can be hard to separate from memories from real life experiences.
CHAPTER 5
ANXIETY AND MOOD DISORDERS
A high frequency of depression has since long been reported in narcolepsy 
patients. Usually this was measured with self-report scales such as the Beck 
Depression Inventory (BDI). However, the only controlled study with a diagnostic 
instrument (Present State Examination) did not show a higher prevalence of 
major depression or other mood disorder classification in the narcolepsy group.
We therefore aimed to answer this pending question of prevalence of mood and
anxiety disorder in narcolepsy. We performed a case control study in 60
narcolepsy patients and 120 age- and sex-matched controls from the Nijmegen
Health Area 2 population study, using the SCAN. We assessed symptom frequency
as well as DSM-IV diagnostic classification of mood and anxiety disorders. Up to a
third of patients had symptoms of a mood disorder. There was considerable
overlap between regular symptoms of narcolepsy and symptoms of depression,
complicating the diagnostic process. Importantly, major depression or any other
mood disorder was not overrepresented in the narcolepsy group. Interestingly,
we found that more than half of the patients had anxiety or panic attacks. A third
of the patients could be diagnosed with anxiety disorder. Social phobia was the ™
most im portant diagnosis. There was no influence of age, sex, duration of illness, E□
or medication use on the prevalence or mood or anxiety symptoms and disorders. ^
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Narcolepsy patients did not suffer from major depression or other mood 
disorders more frequently than controls. However, the frequency of depressive 
symptoms was significantly higher in the narcolepsy patient group. There was a 
considerable overlap between the symptom of narcolepsy and the somatic 
symptoms of depression, which complicated the diagnostic process. Although 
largely ignored in the past literature, anxiety symptoms and disorders, especially 
panic attacks and social phobias, were strikingly increased in narcolepsy.
CHAPTER 6
FATIGUE
Excessive daytime sleepiness is the predominant symptom of narcolepsy. 
However, patients often complain of fatigue as w ell. This symptom has been 
erroneously equated to sleepiness by doctors as well as patients. We examined 
the prevalence of severe fatigue in narcolepsy patients and its relation to 
excessive daytime sleepiness. Furtherm ore, we assessed the relation of fatigue to 
depression, psychological distress, functional impairment, and quality of life. 
Using the Checklist Individual Strength- Fatigue (CIS-F), fatigue was measured in 
80 narcolepsy-cataplexy patients. Sleepiness was assessed with the Epworth 
Sleepiness Scale (ESS). Psychological distress, depression, functional impairment 
and quality of life were assessed with appropriate and validated scales. We 
compared patients with severe fatigue (CIS-F score > 35) with patients without 
severe fatigue (CIS-F score < 35). Fifty patients (62.5%) reported severe fatigue. 
Both groups had the same level of daytime sleepiness, confirming the separation 
between sleepiness and fatigue. There were no sex or age diffences between 
patients with and w ithout severe fatigue. Interestingly, fatigued patients more 
often used stim ulant medication. Severe fatigue was associated with a significantly 
increased functional impairment, a lowered general quality of life, more 
depressive symptoms as well as psychological distress. The degree of fatigue was 
comparable to other chronic neurological disorders as M ultiple Sclerosis. We 
have the impression that fatigue reflects the way patients adjust to the disease 
rather than being a measure of disease severity.
1 2 0
A majority of narcolepsy-cataplexy patients suffered from severe fatigue 
which could be distinguished from daytime sleepiness. Severe fatigue was 
associated with significantly more functional impairment. Severe fatigue 
correlated with psychological distress and lower quality of life, and thus 
possibly reflected a poorer adjustment to the narcolepsy.
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DISCUSSION & PERSPECTIVES
The studies described in this thesis indicate that patients with narcolepsy present 
with a complex behavioral or psychiatric phenotype, in addition to the key 
defining characteristics of hypersomnia and cataplexy. This narcolepsy behavioral 
phenotype includes symptoms of eating disorders, psychotic signs and symptoms, 
anxiety and depressive symptoms and complaints about fatigue.
Two aspects of this behavioral phenotype merit attention. First, these symptoms 
span several domains of psychic functioning and are not confined to just one 
area. Second, though these symptoms can be categorized within more classic 
psychiatric categories as eating disorder, psychotic disorders and affective 
disorders, they do not wholly fit the full diagnostic criteria of these classic 
categories. For example, the eating problems are best described as an atypical 
eating disorder or eating disorder NOS, and the psychotic features do not reach 
the threshold of classification of a psychotic disorder. Although there is a high 
frequency of depressive symptoms in patients with narcolepsy, major depression 
is not overrepresented. Panic attacks are seldom accompanied by agoraphobia. 
How is it possible that psychopathology expresses itself systematically in such an 
atypical way? Further research is needed into whether this complex behavioral 
phenotype of narcolepy is replicated in other unselected groups of patients with 
narcolepsy, and whether these various symptoms of eating problems, psychosis, 
anxiety and fatigue co-occur more often than by chance in the same patient. The 
special and complex behavioral phenotype does suggest a particular etiology, 
pointing to an essential role for the hypothalamic hypocretin system.
NEUROBIOLOGICAL UNDERPINNINGS: THE HYPOCRETIN 
SYSTEM
i/iCD>
The hypocretin system S
Over the last decade, narcolepsy has firmly been established as a hypocretin psr
deficiency syndrome. The hypocretin (also known as orexin) peptides were Pe
discovered in 1998 [1-4]. ^a
There are two known hypocretin peptides, known as hypocretin 1 and hypocretin 
2 which are ligands for two receptors: the hypocretin receptor-1 and 2. |
Hypocretin-1 has a greater affinity for the hypocretin receptor-1, while both D
peptides have the same affinity for the hypocretin receptor-2.
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The hypocretin receptor-1 is expressed in the locus coeruleus (LC), dorsal raphe 
(DR), ventral tegmental area (VTA), the prefrontal and infralimbic cortex, 
hippocampus, amygdala, , laterodorsal tegmental nucleus (LDT) as well as the 
pediculopontine nucleus (PPT). The hypocretin receptor-2 is richly expressed in 
the arcuate nucleus (Arc), tuberomamillary nucleus (TMN), dorsomedial 
hypothalamic nucleus (DMH), paraventricular nucleus, hippocampus, and the 
medial septal nucleus.
The hypocretin system not only is crucial in sleep- wake control; the intense 
connections to the limbic system for example show a function in stress regulation, 
reward related behavior, eating behavior, as well as memory. Deficiency of 
hypocretin, as is the case in narcolepsy, not only influences sleep- wake behavior 
but also emotional balance, adjustment to stress, addiction and motivational 
behavior. The role of the hypocretin system in sleep/wake regulation has been 
extensively reviewed elsewhere. Below we describe some considerations on 
'psychiatry-related ' functions.
Hypocretin and stress: anim al studies
Arousal during fear and stress is accompanied by heightened sympathetic activity. 
An intracerebroventricular injection with hypocretin in rats resulted in an increase 
of sympathetic tone with an increase in corticosterone level [5]. This suggests 
that hypocretin has a role in enhancing wakefulness during emotional and 
stressful states. In a 'fight or flight' type experiment this response was 
demonstrated. Mice, tested in a resident- intruder paradigm, showed locomotor 
and cardiovascular responses to this stressor, while in prepro- hypocretin 
knockout mice these responses were attenuated [6]. Furthermore air-jet stress 
induced elevations in heart rate and blood pressure were diminished in hypocretin 
neurons ablated mice [7]. Sympathetic responses during emotional events seem 
to be conveyed by hypocretin activity. The stress axis has important connections 
with the hypocretin system. One of these links is the input of corticotrophin- 
releasing factor (CRF) neurons in the amygdala [8], where they directly innervate 
hypocretin neurons via the CRF-R1 receptor. Frequent signaling of hypocretin 
neurons during foot shock stress is severely impaired in CRF-R1 receptor deficient 
mice [9]. This suggests that the activation of hypocretin neurons is mediated 
by CRF. This is further demonstrated by the fact that production of pre- 
prohypocretin mRNA is enhanced by CRF administration [10]. The link between 
the CRH and the hypocretin system is functional in maintaining arousal during 
stressful events.
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Hypocretin and the rew ard system in addiction
Hypocretin neurons, located in the most lateral part of the hypothalamus (LH), 
are involved in the modulation of reward. Hypocretin neurons in the more 
medially located perifornical/ dorsomedial area of the hypothalamus (PFA- DMH) 
are functional in sleep- wake regulation and arousal [11]. In the reward circuit the 
mesolimbic dopamine pathways have an essential role. Central in this circuit is 
the ventral tegmental area (VTA). Neurons in the VTA send axons to the nucleus 
accumbens, striatum and frontal cortex, structures thought to be involved in 
motivation. The dopamine neurons in the VTA carry Hcrt-1-R's so as to make a 
direct influence of the Hcrt system on the VTA possible. Hypocretin knockout 
mice are less susceptible than wild type mice to develop morphine dependence 
as measured by the withdrawal response [12]. Furthermore animals were studied 
by Harris et al in a two- chamber conditioned place preference model, in which 
one chamber was associated with drug or food reward whereas the other chamber 
was associated with no reward [13]. The conditioned animals had greater place 
preference and dramatically higher Fos activation in hypocretin neurons in LH 
than non conditioned ones. Reinstatement of an extinguished preference for a 
drug- paired environment, a drug seeking model, was tested and demonstrated. 
This reinstatement was blocked by a hypocretin 1 antagonist. These experiments 
show how hypocretin neurons are involved in reward processing and drug seeking 
behavior. This processing is effectuated by the connections between hypocretin 
neurons and the reward circuit. These are reciprocal between hypocretin neurons 
and the VTA, while hypocretin neurons receive projections from the nucleus 
accumbens and the lateral septum [14]. In vivo administration of a hypocretin 1 
antagonist blocks locomotor sensitization to cocaine and stops cocaine- induced 
potentiation of VTA dopamine neurons [15]. Drug craving is suggested to be a 
consequence of the hyperarousal and excitement due to increased activity of 
hypocretin neurons [16].
A special role fo r the amygdala: opposed reactions to rew ard and aversive  
stim uli
The fact that narcolepsy patients react with cataplexy on strong positive emotions 
constitutes a clear change in emotional behavior. The change entails more than 
cataplexy alone: patients handle aversive and rewarding stimuli differently from 
controls. Ponz et al. [17] found a striking difference on aversive conditioning in an 
experimental study, using as stimulus a brief painful electrical stimulation, 
delivered on one finger. Subjects had to focus on a computer screen. A colored 
triangle signaled a possible upcoming unconditioned stimulus. In the acquisition 
phase this figure was learned to be the conditioned stimulus (CS+). Controls 
reacted to the conditioned stimulus with increased amygdala activation and
o2
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increase in functional coupling between the amygdala and the medial prefrontal 
cortex. Although narcolepsy patients showed the same reaction in the pain circuit 
as controls to the CS+ followed by an actual electrical stimulation, no reaction 
was seen after presentation of CS+ alone: there was no enhancement of the 
amygdala response and no functional coupling with the medial prefrontal cortex 
or any other area in the brain. This constituted an impaired aversive conditioning 
in human narcolepsy. In a previous experiment [18] amygdala dysfunction was 
demonstrated in a blunted startle eye blink response to unpleasant (aversive) 
stimuli in human narcolepsy but also in patients with amygdala lesions. The 
failure of aversive conditioning in patients is in stark contrast with exaggerated 
amygdala response to pleasant stimuli [19] and reward [20]. In an experiment, in 
which expectancy and the experience of winning money was measured in fMRI, 
patients showed abnormal activity increases in the amygdala and dorsal striatum. 
However at the same time patients did not, like controls, show increased 
activation of the dopaminergic VTA, during high reward expectancy and showed, 
unlike controls, reduced activation of the ventral striatum during actual winning. 
This indicates a functional unbalance of the reward circuit in narcolepsy, 
apparently due to hypocretin deficiency. The dysfunctional reward circuit offers 
an explanation for the fact that narcolepsy patients hardly ever abuse the 
stimulants that they are prescribed, contrary to for instance ADHD patients.
The atypical reactions to reward and positive stimuli with enhanced amygdala 
signal on one side and reduced amygdala signal to aversive stimuli on the other 
side reveal an emotional unbalance in narcolepsy. The absent reaction to the 
conditioned fear stimulus could be linked to a dysfunctional 'alarm system 'that 
is reported by family members of narcolepsy patients: reactions to impendent 
harm seem to be dampened. This way the terms that were used to describe 
personality traits in the older German literature 'dickfelligkeit ' and 'pommadigkeit 
' could fall into place.
THE HYPOCRETIN SYSTEM IN PSYCHIATRIC DISORDERS
A role for hypocretin in human psychopathology has been suggested in depression, 
schizophrenia treatment and addiction, although its contribution is relatively 
minor, and conclusive evidence is still scarce.
Depression
Brundin [21] studied a group of suicide attempters diagnosed with major depression, 
dysthymia and adjustment disorder. The patients with depression had a significantly
lower hypocretin level than the dysthymic and adjustment disordered suicide 
attempters. This finding has not been replicated yet, and the significance of this 
finding is unclear. In another study by Brundin [22] of suicide attempters with 
miscellaneous diagnoses, she found a negative correlation between hypocretin 
levels and slowness of movement and lassitude (difficulty to initiate activities). 
A low hypocretin level in CSF was related to inertia and reduced motor activity in 
suicidal patients. This finding has not been replicated either, and awaits further 
study.
Panic
Johnson et al. (2010) [23] found that patients with panic have elevated levels of 
hypocretin in CSF. Testing the panic model in animal studies, he found that rats 
with silenced hypocretin gene product, or treated with hypocretin antagonists 
showed a blocked panic response as opposed to wild type rats. He concluded that 
the hypocretin system has an important role in the pathophysiology of panic 
anxiety in the rat model. He suggested that hypocretin antagonists could be 
usesful as a novel treatment strategy for panic disorder in humans. Our findings 
of increased panic in narcolepsy patients seem to contradict these findings.
Schizophrenia treatm ent
Fadel (2002) [24], reported that antipsychotic drugs that have excessive weight 
gain as adverse event, activate hypocretin neurons in the lateral hypothalamus. 
The degree of activation correlated with the weight gain. This finding suggests 
that the metabolic syndrome as adverse event in antipsychotic drug treatment is 
possibly related to hypocretin. In a recent study of olanzapine in rats this 
hypothesis of drug induced metabolic syndrome due to increased hypo cretin 
signaling was not confirmed [25]. Dalal (2003) [26] found that patients with 
schizophrenia who were treated with haloperidol had lower hypocretine levels 
than unmedicated subjects. This could be explained by the changed inhibitory 
influence of dopamine on hypocretin neurons in the haloperidol treated group. 
Animal research revealed yet another association of an antipsychotic drug 
adverse event and the hypocretin system: a hypocretin-1 antagonist blocked 
catalepsy, caused by neuroleptics in rats. Catalepsy is thought to be a reliable 
predictor of extrapyramidal symptoms in humans [27]. This suggests that 
hypocretin antagonists could be used as drug for extrapyramidal adverse events 
in antipsychotic drug treatment.
Addiction
Addiction researchers foresee a possibility to use hypocretin antagonists as drug 
to cut craving or to prevent relapse [28], based on animal research of addiction
o2
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(see above). Of course the cure could be just as bad as the addiction itself, 
because of predictable adverse events of a hypocretin antagonist which could 
mimic narcolepsy.
IMPLICATIONS FOR THE DAILY CARE FOR NARCOLEPSY 
PATIENTS
Inform ing the patient
Therapeutic advice starts with assessment of the psychological burden. This first 
step has therapeutic implications by itself because it gives the patient an 
opportunity to communicate experiences that he hesitates to share. The doctor 
could start by taking time to ask about the content of hypnagogic hallucinations, 
eating habits, anxieties, phobia's, mood symptoms and fatigue. Alternatively a 
short list with psychiatric signs and symptoms that are frequently seen in 
narcolepsy could be filled out in advance of the appointment. This would facilitate 
discussion of the most disabling complaints and could spare time for both patient 
and doctor. In time it is not enough to just inform the patient: the family should 
be informed about narcolepsy and its main psychiatric features as well.
Consultation, psychopharm acology, and other treatm ent is team w ork
Therapeutic consultation is best performed by a joint effort of a neurologist or 
sleep specialist and a psychiatrist with experience in narcolepsy. Changes in 
psychotropic medication can have consequences for the treatment of narcolepsy 
per se. Standard evidence based treatments for psychiatric disorders according 
to protocol do not always apply to the narcolepsy patient. There have been no 
psychiatric treatment studies of the patient population. Treatment of hypnagogic 
hallucinations is atypical for a psychiatrist: neuroleptics are not effective while 
tricyclic antidepressants and SSRIs are. Interestingly, anxiety symptoms are also 
reported by patients that use antidepressant medication in a dose that is usually 
effective in anxiety and panic attacks (Chapter 5): this makes effectiveness of this 
medication doubtful. There is even an indication that venlafaxine might induce 
panic attacks as adverse event (Chapter 5). This raises the question if 
pathophysiology is different in narcolepsy patients due to differences in anxiety 
pathways. There are indications that narcolepsy patients do have different fear 
pathways from controls [29]. Antidepressant treatment for affective disorders in 
narcolepsy has not been studied. In my own experience regular treatment of 
depression with antidepressants can be effective. High dose stimulants are not 
indicated to cure depression in narcolepsy, because this strategy is not effective 
and can lead to serious adverse events as psychosis [30,31]. Mood swings can
occur as adverse event in methylphenidate or modafinil treatment, especially 
when used in 'pro re nata (PRN)' fashion.
Non pharm acological treatm ents
Cognitive behavioral treatment by a psychologist with enough experience in 
narcolepsy can be effective in overcoming social phobias and in treating depression.
Patients that are turning into recluse need stimulation in order to overcome the 
thresholds of social fear. A psychologist or specialized social worker can help to 
pave the way. In severe cases the patient does not dare to leave home any more, 
and patients have to be visited at home. Regular exercises, if needed accompanied 
by the therapist, can accomplish a breakthrough of this social fear so that the action 
radius can be extended. In extremely socially phobic patients a social dog can be a 
facilitating step in building up more interaction with the outside world. Exercises to 
fill in leisure time, perhaps a visit or a small holiday can be part of a behavioral 
program. Introduction of more physical movement by an adapted program (e.g.
'running therapy ' or regular fitness) as some patients have experienced, can be 
helpful too for alleviating depressive states. Special attention in counseling should 
be paid to regular topics as shame for being overweight or fat, about falling asleep 
in public and having cataplexy attacks. Guilt feelings about dependency, 
disappointing significant others, and failing to accomplish tasks are other important 
foci. Patients are valuable as experience specialists. Group sessions, combining 
'experienced' patients with patients that just recently acquired the disease, can be 
very valuable [32]. A big issue is accepting narcolepsy.
Accepting narcolepsy
A very difficult, but crucial step in treatment is the topic of accepting narcolepsy.
This does not just mean accepting to live with the burden of the disease per se, it 
also involves accepting the social consequences. The disease itself brings not only 
sleep- wake regulation disturbance, but also problems with weight, sexuality, 
memory and psychological functioning. The social consequences are numerous: 
reactions from others give rise to shame and trigger avoidant behavior.
Functioning at work as well as in intimate relations is often affected. Patients can 
have different reaction styles. One of these attitudes that we encountered is 
denial: 'narcolepsy is not an illness '. Another reaction can be severe anger at and O
resistance to the diagnosis itself. The anger can change into sadness when
diagnosis is slowly admitted. Coping with narcolepsy can refer to skills in handling |
symptoms and in capacity to deal with the emotional reactions that are raised by Q
the disease. Examples of skills developed by patients are self-pinching when
getting sleepy, countering cataplexy by emotional control, and tricks to assess 131
the reality of experiences in hypnagogic hallucinations (see Appendix for further
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details). In order to increase the capacity to deal with the emotional consequences 
patients can extend their social network, be active in the narcolepsy patient 
association, and can try to increase control over their life by changing their 
attitude, setting goals, investing in time management and preparing for stressful 
situations. Therapeutic work can include patient groups focusing on bottlenecks 
in daily situations and exchanging practical solutions.
In the process of accepting narcolepsy, the disease is at first often externalized, 
i.e. placed outside of the person. When acceptation starts to be successful, 
narcolepsy can become an integral part of the personality. Responsibility can be 
taken for the disease and finally a shift in identity can be reached. Next to the 
negative consequences some positive aspects can be seen: narcolepsy can bring 
about a deeper contact with the unconscious, psychic awareness and personal 
growth: narcolepsy patients hardly ever lead superficial lives.
Advice fo r the neurologist and sleep specialist: assess these psychological 
symptoms!
Psychiatric comorbidity, panic attacks, phobia's and fatigue are features that are 
frequently seen in narcolepsy patients, but patients may be reluctant to report 
impairment in their functioning due to these symptoms. Therefore psychiatric 
assessment is no luxury and should be a standard part of a comprehensive 
diagnostic work-up. This assessment could take the form of a self-report 
questionnaire, to be filled out in advance of the appointment with the doctor. A 
face-to-face interview is most informative. After consulting a psychiatrist or 
psychologist, a treatment plan can be proposed. This strategy would help 
overcome undue anxiety of the patient to report these 'notorious mental 
symptoms 'and open the way to consider psychotherapeutic treatment.
Advice fo r the psychiatrist
Psychiatrists, working in consultation and in psychosomatic psychiatry, should be 
informed of the psychiatric phenotype of narcolepsy and of the psycho- 
pharmacological pitfalls. Hypnagogic hallucinations should not be treated with 
antipsychotics. Psychiatric admission of narcoleptic patients should only be 
considered in crisis situations. More generally speaking, in the training of 
psychiatrists' implementation of education in sleep physiology and sleep 
disorders should be considered. Sleep disorders are in the majority of cases a 
psychological problem and if they persist for longer periods can act as a trigger 
for mood disorder, suicidal behavior, psychosis and substance abuse. Having a 
sleep specialist on the educational board who is able to diagnose and treat sleep 
disorders would benefit the training of psychiatrists.
SUGGESTIONS FOR FURTHER RESEARCH
Narcolepsy is a disease that can be described as a hypocretin deficiency syndrome. 
It demonstrates a functional impairment of a neurotransmitter system with many 
behavioral functions. The functions of hypocretin for motivational behavior, 
addiction, stress responses, emotional coordination, are being studied as shown 
above. Drugs are being tested that act as hypocretin agonists, possibly effective 
as (co)medication in depression, or as hypocretin antagonists, that can treat 
craving for drugs [33] or as functional in prevention of relapse into drug abuse. 
The role of narcolepsy in personality disorder is still unknown: emotional 
dysregulation, as presented in mood swings of borderline personality disorder, 
could be related to hypocretin abnormalities. A study of maternal deprivation in 
rats showed changes in the hypocretin system [34] that might also be relevant for 
personality development. Studying hypocretin and its role in the limbic system 
will enhance our understanding of the regulation of behavior in humans as well as 
animals and might one day result in a cure not just for narcolepsy but also for 
modulation of expression of different psychiatric disorders.
Our study of psychiatric morbidity in narcolepsy is far from complete: there are 
disorders that we did not assess but have been suggested to be overrepresented 
in narcolepsy. Among these there are disorders that are mentioned in the classic 
literature as being more frequent: personality disorders and disorders of sexual 
functioning. The changed reactions to stressors as measured in animals and the 
reactions to aversive as opposed to rewarding stimuli in humans would predict 
changed adjustment reactions in patients, which have not been studied so far. 
Another important topic that needs to be studied is the reality testing of patients: 
interference of reality testing by experiences of hallucinations and dreams that 
are recorded in memory. W ith the SCAN methodology we could not assess this in 
detail. Longitudinal studies are needed to answer questions about the course of 
the psychiatric expression of narcolepsy over time. An intriguing question is why 
positive emotions and anger lead to cataplexy, rather than anxiety and sadness. 
The answers to these questions will enrich not only the treatment of narcolepsy 
but also enhance insight in the functioning of the limbic system and related 
networks and as such the understanding of pathophysiology of psychiatric 
disorders in general.
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Appendix
Additional Clinical Notes

ADDITIONAL CLINICAL NOTES
In this appendix, some further notes on the clinical psychiatric presentation of 
narcolepsy patients are provided based on my clinical experience in the previous 
years. This information may complement the more empirical chapters in this 
thesis.
The SCAN 2.1 is a semi-structured interview, in which relevant data are quite 
strictly categorized. However, the original 'analogue' description as reported by 
patients is lost in this process. Here we describe a few of such 'lost' features, as 
reported by the patients in our studies. One must realize that, as narcolepsy has 
a highly heterogeneous expression, not all patients report all of these features.
COPING AND ADJUSTING TO STRESS: 'OBLOMOV STYLE'
W e have seen several patients who react in an atypical style to stress, and 
demonstrate a striking lack of urgency in reacting to stressors. Some typical 
examples are described in Box 1.
In these examples, the patients do not seem to 'hear the alarm bell' and do not 
take action to prevent unfavorable consequences. Their partners were surprised 
by this indifferent reaction style. The same indifferent style seems to be present 
in dealing with 'to do lists'. Patients are reported to be notoriously slow and 
inefficient in translating plans into actions. W e encountered this in our research, 
when getting slow and incomplete responses to questionnaires handed out by 
treating physicians. Although patients enthusiastically agreed to participate in 
the study, they had a lower response rate than expected compared to studies in 
other patient groups.
BOX 1 'O blom ov style' reactio n s
Patient A is a 45-year-old accounting officer in a nonprofit governmental 
organization. He had trouble meeting with his deadlines. His boss warned him 
repeatedly and finally told him that he would be laid off in case he would not 
meet the term for a next assignment. To the surprise of his wife, he reacted 
very relaxed to this warning, showing no distress whatsoever. He did not 
change his style of working and did not seem to be alarmed about the possible 
loss of his job at all.
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Patient B is a 43-year-old married painter who has a wife and 3 boys. Especially 
at the end of the day, he often had fits of anger. Not only did he shout and slam 
doors, but every now and then he hit his 7 year old son. The son talked about this 
at school and the school officials undertook an official investigation. They 
reported the case of child molestation to the authorities. The family was 
approached and a report was to be made up about the home situation. As the 
investigating organization has the authority to place children out of the home, 
the wife was very upset, but not the patient himself. When seeing his doctor, he 
grinned and stated that he never seriously touched the kid. He showed no 
concern about possible measures that could be taken. His wife described his 
typical reaction style as 'hard to come through', and 'as if covered by a grey veil'.
This coping style of narcolepsy patients reminds of the novel figure 'Oblomov', 
the gentleman described by the Russian author Gonsjarov. Oblomov passed his 
days in a semi slumber, dreaming about many actions, but systematically 
postponing them, insensitive to the consequences. Whether this 'Oblomov' style 
is just a paroxysmal coping problem or part of a more permanent narcolepsy 
personality profile, is still unclear and awaits further study. Patients have been 
shown to have impairments in executive function [1,2], which may play a role.
DID IT HAPPEN OR NOT? A DOUBLE REALITY
Because memories of hallucinations and dreams are remembered and stored into 
memory better in patients than in controls [3], patients can be left with the 
question whether an event really took place, or just happened in a hallucination 
or dream. We described this in Chapter 3. These difficulties in reality testing may 
have striking social consequences, as illustrated in Box 2.
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BOX 2 'D o u ble reality' exam ples
Patient C, a 28-year-old female doctor's assistant, had a crush on a man 
working in the same hospital. There had been no physical erotic exchange 
between the two. Probably after dreaming that they had kissed each other, 
she was not sure whether the occasion had occurred in reality or not. This 
created confusion and an uneasy feeling that could not easily be settled.
Patient D, a 26 year old female patient, living with her parents, frequently 
heard and saw family members entering her room at night. However the next 
day they denied having visited her. In order to stop this confusion she decided 
to lock her door before going to bed. This way she could be sure that the family 
members entering her room at night had been hallucinated.
Patient E, was a 46 year old woman who, on a journey abroad, took a massage. 
On the table she experienced sleep paralysis. She then felt as if the massage 
therapist started to touch her private parts, but she was unable to react. After 
the treatment she went to the police to complain and make a declaration of 
assault. She discarded the possibility that she had been experiencing haptic 
hallucinations during sleep paralysis, which not unusual in narcolepsy. 
Afterwards it remained unclear whether the assault really took place.
This type of confusion can have painful consequences because in some instances, 
patients are convinced of the fact that the event really happened although it can 
be proven that it did not [4]. As illustrated in Box 2, some patients use tricks in 
order to differentiate real events from hallucinated ones. Many patients report 
paranormal experiences in which contact with deceased persons played an 
important role. This type of experiences had a strong influence on reality 
perception and its 'story line'. Note, that many patients do not speak overtly 
about such extraordinary experiences, and these may represent a 'dark side' of 
patients.
SOME POSITIVELY LABELED FEATURES: PSYCHIC AWARENESS
Patients report paranormal experiences and contacts with the world of death, as 
discussed above. This is experienced by some patients as an extra dimension and 
a few patients do work as a professional medium. Patients sometimes claim to 
have enhanced insight into the character of others: 'I knew a lot about this person 
as soon as I first saw him'. These psychic features can have an additional, personal 
meaning for some patients, as they may be perceived as additional 'special 
qualities' that others do not possess. Other patients do not appreciate this faculty 
because of the great responsibility that accompanies this uninvited knowledge: 
the message that someone in the street is going to be killed by a car incident can 
make patients feel conscience-stricken.
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CHANGES AROUND THE LIFE CYCLE
The first years of having narcolepsy are notoriously difficult for patients. In many 
cases there is a long delay in diagnosis, leaving patients in limbo about what is 
happening to them. Next to the vigilance problems that influence the level of 
functioning, and the unexpected cataplexy attacks, hypnagogic hallucinations 
make patients fear that they are getting insane. Usually it takes some time before 
patients start to report this to parents or significant others. There are indications 
that disease duration has a positive influence on quality of life. The most 
influential independent factor predicting loss of quality of life over time is 
presence of depressive symptoms [5,6].
Childhood
Although adolescence is the modal age of disease onset, 30% of patients develop 
narcolepsy under the age of 15. Children with narcolepsy are more frequently 
introverted [7], and hesitant to discuss their dreams and hallucinations with their 
parents. Hallucinations may have a broad content in children, including monsters 
and dinosaurs, big spiders, 'seeing a screaming and bleeding eye', zombies and 
other strange figures. Depression scores are raised and general mental health 
scores are lowered [8]. Anxiety in general, and more specifically, social anxiety, is 
frequently underestimated in children. Emotional outbursts of patients can 
surprise parents and teachers [9].
Adolescence
In adolescence, peer group behavior is often impaired. Patients participate less in 
after school activities, and we witnessed how patients had to drop out of team 
sports such as soccer. Patients often have difficulty sustaining close friendships 
and meeting potential partners. When growing up, the first sexual experiences 
can be influenced by narcolepsy: cataplexy attacks just before the most exciting 
moments can spoil the date [10]. At school, patients report to function below 
their true level and do not reach their full potential. W e have seen several young 
patients who had to change to a lower level of education after disease onset.
Adulthood
Patients have difficulties in interpersonal relations, with women reporting this 
more frequently than men. Narcoleptics can have difficulty listening to their 
partners 'story of the day', when concentration diminishes and sleep takes over. 
Divorce rates are increased [11]. Women with narcolepsy are living alone more 
frequently than men [12], and living without a partner is associated with a 
decrease in quality of life. Patients complain about leisure activities even more
than about work activities: taking holidays, visiting movies or the theatre, a pub 
or nightclub, attending sport events and playing sports can pose serious problems 
[13]. Not just the fear of falling asleep in a passive situation, but also the tendency 
towards social phobia can play a key role here (see Chapter 5). Patients report 
more accidents at home, for example smoking accidents resulting in serious fires, 
falls, burns, cuts and fractures [14].
In work situations, patients may feel they are unable to use their qualifications 
fully and are more frequently unemployed. Furthermore motor vehicle accidents, 
accidental injuries, poor job performance, job loss, loss of promotion are 
reported, which is troublesome, as patients consider the possibility of having a 
job particularly desirable. One of our patients had to quit his career in a family 
business: his father had always seen him as his successor, and his academic 
success qualified him for the job as director of the firm. After disease onset he 
could not live up to the expectations any more due to his lack of concentration 
and vigilance.
Old age
As patients grow older, quality of life may get somewhat better, as some studies 
have shown [15]: patients report an increase in quality of life after retirement, 
although sleepiness is not clearly improved. As mentioned in Chapter 5, depressive 
symptoms tend to abate with older age.
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Summary in Dutch 
Nederlandse samenvatting

NEDERLANDSE SAMENVATTING
Narcolepsie is een slaapziekte met als kernsymptomen overmatige slaperigheid 
overdag en kataplexie, een plotselinge verslapping van de skeletspieren die na een 
emotionele prikkel (bijvoorbeeld zoals bij lachen, woede, opwinding) kan optreden. 
Verder is er vaak sprake van een verstoorde nachtelijke slaap, hypnagoge 
hallucinaties en van slaapparalyse. Na het begin van de klachten duurt het vaak 
lang totdat de diagnose narcolepsie wordt gesteld. In die "latente periode" stellen 
artsen vaak tal van psychiatrische diagnoses, zoals neurotische stoornis, depressie, 
persoonlijkheidsstoornis en aanpassingsstoornis. Dit proefschrift doet verslag van 
een inventarisatie van psychiatrische symptomen en stoornissen die gepaard gaan 
met deze aandoening: het psychiatrische phenotype van narcolepsie. Per hoofdstuk 
volgt nu een korte samenvatting van de inhoud.
HOOFDSTUK 2
NARCOLEPSIE EN PSYCHIATRIE IN HISTORISCH PERSPECTIEF
Hoofdstuk 2 bevat de fascinerende en instructieve geschiedenis van de relatie 
tussen de narcolepsie en de psychiatrie. Gélineau (1880), die de term narcolepsie 
heeft bedacht, noemde deze ziekte een "névrose". Indertijd werd een neurose 
gezien als een organische, neurologische aandoening. Niet lang daarna (1881) 
stelde hij voor dat "secundaire narcolepsie" ook een uitingsvorm van hysterie kon 
zijn. Psychoanalytici zagen vanaf het begin van de 20ste eeuw narcolepsie als een 
conversiestoornis, en boden de psychoanalyse aan als behandeling daarvoor. Een 
andere groep psychiaters en neurologen bleef trouw aan een meer traditioneel 
"organisch" model van narcolepsie. De twee stromingen hadden weinig wederzijds 
contact en negeerden elkaar, zoals blijkt uit de literatuurreferenties. Bijna een 
halve eeuw lang gingen deze twee stromingen hun eigen weg, min of meer 
immuun voor kritische geluiden van buitenaf. In het kader van de snelle 
ontwikkelingen van de neurowetenschappen in de tweede helft van de 20ste eeuw 
werd stapsgewijs de cellulaire en moleculaire achtergrond van narcolepsie 
ontdekt, met als uiteindelijke doorbraak de ontdekking van het ontbreken van 
hypocretine in het lumbale vocht van narcolepsie patiënten. Narcolepsie bleek 
toch een "organische" ziekte te zijn, zoals oorspronkelijk gesuggereerd door 
Gélineau. Nu kon met open vizier gekeken worden naar het psychiatrische 
phenotype van narcolepsie en over precies dit onderwerp begonnen studies te 
verschijnen na het begin van de 21ste eeuw. Het werd snel duidelijk dat narcolepsie 
niet alleen een slaapziekte is, maar eveneens een bijzonder complexe gedrags­
stoornis.
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De psychiatrische visie op narcolepsie heeft over het beloop van meer dan een 
eeuw een bijna volledige cyclus gemaakt: het oorspronkelijke "organische 
model" maakte plaats voor het psychodynamische model van de conversie 
hysterie en kwam uiteindelijk weer terug op het "organische" vertrekpunt. 
Patiënten zijn in die periode onderworpen geweest aan deze historische 
ontwikkelingen en werden hiervan soms zelfs het slachtoffer, zoals achteraf 
kan worden vastgesteld.
HOOFDSTUK 3
EETSTOORNISSEN
Het is bekend dat narcolepsie patiënten een verhoogde "body mass index (BM I)" 
hebben. Bovendien melden patiënten vaak dat ze buien hebben waarin ze 
behoefte hebben aan koolhydraten: het zogenaamde "carbo- craving". Hierdoor 
werd de nieuwsgierigheid gewekt naar de eetgewoontes of misschien zelfs 
eetstoornissen bij narcolepsie. W e hebben een groep narcolepsie patiënten 
(n=60) vergeleken met een groep personen uit de algemene bevolking met 
dezelfde leeftijd en hetzelfde geslacht (n-120). Deze controlegroep was 
gerekruteerd in het kader van de "Nijmegen Health Area-2 population study". Een 
tweede vergelijking maakten we tussen een subgroep van patiënten (n=32) en 
een controlegroep (n= 32) die niet alleen gematched was op leeftijd en geslacht, 
maar ook op BMI. Het voorkomen van eetstoornissen werd gemeten met behulp 
van een diagnostisch onderzoeksinstrument: "vragenschema's voor de klinische 
beoordeling in de neuropsychiatrie" (SCAN 2.1) en met een ander onderzoeksin­
strument dat alleen eetstoornissen meet: de EDE-Q. Van de patiënten voldeed 
23% aan de criteria voor een eetstoornis volgens DSM IV, terwijl geen van de 
personen in de controlegroep hieraan voldeed. De diagnose die het vaakst werd 
gesteld, was "eetstoornis niet anders omschreven (N.A.O.)" , vaak een onvolledige 
variant van een "vreetbuistoornis". De helft van de patiënten gaf aan vreetbuien 
te hebben en een onweerstaanbare en aanhoudende zucht naar voedsel. Een 
kwart van de patiënten rapporteerde tweemaal per week of vaker een vreetbui 
te hebben. Vreetbuien waren niet gecorreleerd aan een hoger BMI. Dit patroon 
werd bevestigd toen de patiënten werden vergeleken met een groep controle- 
personen met een gematched BMI. Het gebruik van antidepressiva was 
geassocieerd met een hogere belemmering van de activiteiten in de dagelijkse 
bezigheden ten gevolge van eetproblemen.
In de narcolepsie groep had een kwart van de patiënten een "eetstoornis niet 
anders omschreven", significant meer dan gevonden werd bij de controlegroep 
die geselecteerd werd uit de algemene bevolking. De meeste patiënten hadden 
een onvolledige variant van een "vreetbuistoornis", met vreetbuien en een on­
weerstaanbare, aanhoudende zucht naar voedsel als belangrijkste symptomen. 
De eetproblemen veroorzaakten een belemmering van activiteiten in de 
dagelijkse bezigheden.
HOOFSTUK 4
PSYCHOTISCHE SYMPTOMEN BIJ NARCOLEPSIE
Patiënten met narcolepsie ervaren vaak indringende hypnagoge hallucinaties 
waardoor diagnostisch verwarring kan ontstaan met psychiatrische stoornissen 
als schizofrenie. Dit kan leiden tot een behandeling van narcolepsie patiënten 
met antipsychotica. Deze behandeling is echter onjuist, want antipsychotica zijn 
ineffectief voor deze indicatie. Ons doel was om tot een gedetailleerde 
kwalitatieve beschrijving te komen van hypnagoge hallucinaties en andere 
"psychotische symptomen" bij narcolepsie patiënten en deze te vergelijken met 
die van een groep patiënten die lijdt aan schizofrenie en van een controlegroep 
met personen uit de algemene bevolking. W e wilden ook het vóórkomen van 
diagnoses van psychotische stoornissen vergelijken tussen narcolepsie patiënten 
en de controle personen. Ter vergelijking van psychotische symptomen bij 
narcolepsie patiënten (n=60), schizofrenie patiënten (n=102) en controleperso- 
nen uit de algemene bevolking (n= 120) gebruikten we de SCAN vragenschema's. 
Bovendien verzamelden we kwalitatieve gegevens om te komen tot een 
gedetailleerde beschrijving van hypnagoge hallucinaties bij de narcolepsie 
patiënten. W e hebben gevonden dat het patroon van hallucinatoire ervaringen 
bij narcolepsie patiënten duidelijk verschilde van het patroon dat aanwezig was 
bij patiënten die lijden aan schizofrenie. Narcolepsie patiënten bleken multisen­
sorische "holistische" hallucinaties te hebben, terwijl schizofrenie patiënten 
voornamelijk verbaal akoestische hallucinaties rapporteerden. Wanen kwamen 
niet vaker bij narcolepsie patiënten voor dan bij personen uit de algemene 
bevolking. Slechts enkele patiënten hadden waanherinneringen / fantastische 
wanen. Herinneringen van hallucinaties of dromen bleken soms moeilijk te 
onderscheiden van herinneringen van in werkelijkheid meegemaakte situaties. 
Hierdoor kon bij sommige patiënten onzekerheid of verwarring ontstaan. Ondanks 
de "psychotische symptomen" kwamen psychotische stoornissen niet vaker voor 
bij de patiënten met narcolepsie dan in de groep controlepersonen uit de 
algemene bevolking, mede dankzij het feit dat het inzicht met betrekking tot de
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hallucinatoire ervaringen behouden bleef. Bijna de helft van de narcoleptici 
rapporteerde een matige belemmering in de activiteiten ten gevolge van de 
hypnagoge hallucinaties, vooral door de angst waarmee dezen gepaard kon den 
gaan.
De multi sensorische "holistische" hallucinaties van narcolepsie patiënten 
kunnen goed gedifferentieerd worden van de voornamelijk verbaal akoestische 
hallucinaties van patiënten met schizofrenie. In de groep narcolepsie patiënten 
kwamen psychotische stoornissen, geclassificeerd volgens het DSM IV-TR 
systeem, niet vaker voor dan in de controlegroep uit de algemene bevolking. 
De werkelijkheids toetsing was bij een aantal patiënten gecompromitteerd 
vanwege het feit dat de herinneringen aan levendige hallucinaties en dromen 
soms moeilijk te onderscheiden bleken te zijn van werkelijk meegemaakte 
ervaringen.
HOOFDSTUK 5
ANGST- EN STEMMINGSSTOORNISSEN
Het in verhoogde mate voorkomen van symptomen van depressie is al sinds 
geruime tijd beschreven bij patiënten met narcolepsie. Dit bleek bijvoorbeeld uit 
metingen met instrumenten waarmee de ernst van depressie kan worden 
vastgesteld, zoals de Beck Depressie Schaal. De diagnose depressie of stemmings­
stoornis werd echter niet vaker bij narcolepsie patiënten gesteld dan bij gezonde 
controle personen in het enige onderzoek waarbij gebruik werd gemaakt van een 
gevalideerd en diagnostisch onderzoeksinstrument (Present State Examination). 
Vanwege deze nog prangende discrepantie stelden we ons ten doel angst- en 
stemmingsstoornissen in kaart te brengen bij narcolepsie patiënten. W e hebben 
met behulp van de vragenschema's voor de klinische beoordeling in de neuropsy­
chiatrie (SCAN 2.1) een "case- control" studie uitgevoerd bij 60 patiënten met 
narcolepsie en 120 controlepersonen uit de algemene bevolking. W e hebben 
zowel symptoomfrequenties als diagnostische classificaties volgens DSM IV 
gemeten en vergeleken. Symptomen van stemmingsstoornissen bleken bij 
maximaal een derde van de patiënten aanwezig te zijn. Een complicerende factor 
was de overlap die bestond tussen de gebruikelijke symptomen behorend bij 
narcolepsie en de symptomen van depressie, waardoor het diagnostisch proces 
werd bemoeilijkt. Hiermee rekening houdend, kon de diagnose "depressieve 
episode" of een andere diagnose uit de groep van stemmingsstoornissen niet 
vaker worden gesteld bij narcolepsie patiënten. Wel hebben we gevonden dat
angstsymptomen of paniekaanvallen bij meer dan de helft van de patiënten 
voorkwamen. Een derde van de narcolepsie patiënten kreeg de diagnose 
"angststoornis", hetgeen significant vaker dan in de controle groep het geval was. 
Sociale fobie was de meest voorkomende diagnose. Leeftijd, geslacht, ziekteduur, 
of medicatiegebruik hadden geen invloed op de prevalentie van stemmings- of 
angststoornissen.
Depressieve episodes of andere stemmingsstoornissen komen niet vaker bij 
narcolepsie patiënten voor dan in de algemene bevolking. De frequentie van 
depressieve symptomen is echter wel significant hoger in de patiëntengroep. 
De symptomen van narcolepsie en de "somatische" symptomen van depressie 
overlappen elkaar in aanzienlijke mate, waardoor het diagnostisch proces 
wordt bemoeilijkt. Angststoornissen en symptomen daarvan zijn echter wel 
duidelijk in verhoogde mate aanwezig bij narcolepsie patiënten: met name 
paniekaanvallen en sociale fobie komen vaker voor.
HOOFDSTUK 6
VERMOEIDHEID
Buitensporige slaperigheid overdag is het belangrijkste symptoom van 
narcolepsie. Patiënten klagen echter ook regelmatig over vermoeidheid. Dit 
symptoom is door behandelaars vaak ten onrechte gelijkgesteld aan de klassieke 
slaperigheid. W e hebben het vóórkomen van ernstige vermoeidheid onderzocht 
alsmede de relatie tussen vermoeidheid en slaperigheid. Daarnaast onderzochten 
we de relatie met depressie, psychologisch onwelbevinden, functionele beperking 
en kwaliteit van leven. Met de "Checklist Individual Strength- Fatigue (CIS-F)" 
hebben we vermoeidheid gemeten bij 80 narcolepsie patiënten. De slaperigheid 
werd gemeten met de "Epsworth Sleepiness Scale". Psychologisch onwelbevinden, 
depressie, functionele beperking en kwaliteit van leven hebben we gemeten met 
de daarvoor geschikte gevalideerde onderzoeksinstrumenten. W e hebben de 
subgroep patiënten met ernstige vermoeidheid (CIS-F score > 35) vergeleken met 
patiënten zonder ernstige vermoeidheid (CIS-F score < 35). Vijftig (62.5%) van de 
80 patiënten waren ernstig vermoeid. Patiënten in de beide subgroepen hadden 
dezelfde mate van slaperigheid, waardoor het onderscheid tussen vermoeidheid 
en slaperigheid werd bevestigd. Er waren geen verschillen in leeftijd of geslacht 
tussen de beide subgroepen. De patiënten in de "ernstig vermoeide" groep 
gebruikten vaker medicatie met stimulerende werking. Ernstige vermoeidheid 
was geassocieerd met een hogere mate van functionele beperking, een lagere
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kwaliteit van leven, een hoger psychologisch onwelbevinden en meer depressieve 
symptomen. De mate van vermoeidheid was vergelijkbaar met die bij andere 
chronische neurologische aandoeningen zoals Multiple Sclerose. Onze indruk was 
dat ernstige vermoeidheid eerder te maken had met de wijze waarop patiënten 
zich aan de ziekte aanpasten, dan dat het een uitdrukking was van de ernst van 
deze ziekte.
Een meerderheid van de narcolepsie patiënten lijdt aan ernstige vermoeidheid, 
die los gezien dient te worden van slaperigheid overdag. Terwijl narcolepsie al 
een aanzienlijke functionele beperking met zich meebrengt, is er bij de ernstig 
vermoeide groep sprake van een verdubbeling van deze beperking. Ernstige 
vermoeidheid is verder gerelateerd aan depressieve gevoelens, psychologisch 
onwelbevinden, het gebruik van stimulantia en een lagere kwaliteit van leven
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Dankwoord

DANKWOORD
Het schrijven van een proefschrift is geen bevlieging. Het is een project dat 
vergelijkbaar is met een wielerronde, in etappes. Dit kon alleen slagen door 
intensief teamwork. Ik ben veel mensen dankbaarheid en erkentelijkheid 
verschuldigd: het begeleiden van een oudere clinicus die betrekkelijk onervaren 
het onderzoeksterrein betreedt vraagt veel geduld. Ik zal in chronologische 
volgorde de personen noemen die mij op weg naar de voltooiing van het 
proefschrift hebben gestimuleerd en ter zijde hebben gestaan. De eerste persoon 
is anoniem: de eerste narcolepsie patiënt die mijn pad kruiste. De - naar later zou 
blijken - onjuiste interpretatie van zijn ziektebeeld waarmee deze patiënt te 
maken kreeg op onze afdeling psychiatrie hebben mij nieuwsgierig gemaakt en 
vormde de oorspronkelijke aanleiding voor het onderzoek. In zijn voetspoor 
volgden de vele patiënten met narcolepsie die participeerden in de verschillende 
onderzoeken. Ik dank hen voor hun vertrouwen en voor hun bereidheid klachten, 
dromen en nachtmerries met mij te delen. De diverse vragenlijsten, onderzoeken 
en de soms lange reizen moeten hen behoorlijk op de proef hebben gesteld. Door 
hen ben ik mij verbonden gaan voelen met de patiëntengroep en met het hun 
ziektebeeld. De volgende twee significante personen zijn van Belgische herkomst: 
Dr. Guus Declerck, neuroloog, Kempenhaeghe (Heeze) heeft mij toegang verschaft 
tot de patiëntengroep die in dit slaap-waakcentrum werd behandeld. Hij had al 
lang een scherp oog voor de psychologische lijdensdruk van zijn patiënten en 
juichte meer diepgaand onderzoek hiernaar toe. Zowel in zijn klinische benadering 
als in zijn wetenschappelijke visie was hij een voorbeeld: een echte dokter. De 
tweede Belg was promotor prof. Dr. W illy Renier, (kinder)neuroloog en epilepsie 
specialist. Hij heeft mij als eerste gestimuleerd om op dit onderwerp te gaan 
promoveren. Gesprekken hierover vonden aanvankelijk in de buitenlucht plaats, 
met de fiets in de hand. Hij heeft mij geleerd om niet terug te schrikken voor 
hindernissen en vasthoudend te zijn. Hij bleef over de jaren een zeer stimulerende 
kracht. De volgende persoon aan wie ik veel te danken heb is promotor Prof. Jan 
Buitelaar, destijds hoofd van de afdelingen Kinder- en Jeugd- en tevens van de 
Volwassen Psychiatrie. Hij zag het belang van dit onderzoek in en heeft de paden 
geëffend heeft om het doorgang te laten vinden hoewel het niet paste in een 
"speerpunt". Hij heeft mij op methodologisch en inhoudelijk terrein op bijzonder 
vruchtbare wijze bijgestaan, bijna altijd prompt reagerend op mails. Het time 
management dat hieraan ten grondslag lag was verbazend en onnavolgbaar. Hij 
heeft mij de diepgang van het gezegde "beter laat dan nooit" leren inzien. Hij 
heeft mijn vertrouwen nooit beschaamd. Het is de vraag of het onderzoek het 
stadium van data verzameling overstegen had als copromotor en narcolepsie 
specialist Dr. Sebastiaan Overeem zich niet met het onderzoek en de redactie van
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de artikelen was gaan bezig houden. Ik heb van deze jonge senior onderzoeker 
heel veel geleerd: hij heeft mij onder meer leren ordenen, tot aan het inrichten 
van niet allen mijn memory stick, maar ook van mijn rugzak aan toe. De ruimte in 
dit dankwoord is te beperkt om een volledige inventarisatie te geven van wat ik 
heb mee gekregen. Zijn stijl van coachen was onverbloemd en soms confronterend. 
Ook van zijn creatieve kanten ("Is this Sebastian?" vroeg een verbaasde 
Amerikaanse senior onderzoeker bij zijn popzang optreden in de wandelgangen 
van een internationaal congres) heb ik getuige kunnen zijn. Ik gun elke 
promovendus een dergelijke coach. Veel dank ben ik ook verschuldigd aan de 
Leidse specialist op het gebied van narcolepsie, dr. Gert Jan Lammers en zijn 
onderzoeksteam. Hij was onvermoeibaar in zijn bijdrage aan het vermoeidheids- 
onderzoek, dat vanuit Leiden werd uitgevoerd. Hij was actief co auteur van enkele 
artikelen. Zijn stijl van informeel en persoonlijk communiceren stelde ik bijzonder 
op prijs. Van de Leidse groep noem ik ook graag dr. Rolf Fronczek , Clair Donjacour, 
Mirjan Smitshoek en Mojca van Schie. Het samenwerken met hen was inspirerend 
en plezierig. Ik kwam hen op allerlei plaatsen in de wereld tegen als "flying 
dutchmen".
Van de samenwerking met prof. Dr. Paul Hodiamont en zijn onderzoeksgroep bij 
Sociale Geneeskunde heb ik veel profijt gehad. Uit de data van zijn REGIO-2 
project kon ik een controlegroep samenstellen. Jan Mulder hielp me met het 
vakkundig bouwen van de database. Dr. Cees Rijnders leerde mij de fijne kneepjes 
van de SCAN. Dr. Joop Furer was behulpzaam met de data verwerking.
Dr. Sophie Swinkels hielp mij vlot en met volle aandacht met de methodologie en 
statistiek van het eetstoornissen artikel. Martijn Lappenschaar, wiskundige en 
arts, stond me statistisch terzijde bij achtereenvolgens drie artikelen. Ik heb hem 
op ongebruikelijke tijden en soms tijdens zijn vakantie gebeld met prangende 
vragen; hij reageerde of het allemaal doodgewoon was.
Door de cursus van psycholoog Fokko Nienhuis (UMCG) kon ik gecertificeerd 
worden voor het afnemen van de SCAN. Wij werkten vervolgens vruchtbaar 
samen bij het "psychose project".
Prof. Dr. Gijs Bleijenberg ( Hoofd Kenniscentrum Chronische Vermoeidheid) hielp 
me op positieve wijze en zonder terughoudendheid met het instrumentarium, de 
methodologie en de formuleringen van het vermoeidheidsonderzoek. Uit zijn 
omgeving noem ik graag Carel Kruip, dr. Hans Knoop en - nadrukkelijk - dr. Joke 
Kalkman: ze wezen me de weg bij het duiden van de betekenis van de verschillende 
onderzoeksinstrumenten.
Gedurende het onderzoek heb ik met veel plezier samen mogen werken met 
collega's die inmiddels alweer geruime tijd hun specialisatie hebben voltooid: 
1 7 0  neuroloog Dr. Job Gilhuis hielp me bij het opstarten, vergezelde me op diverse
trips, en participeerde in beeldvormend onderzoek. Psychiater Anouk Raes en
Rachel Fraanje- Fikse deden bij mij hun student onderzoeksstages en hielpen met 
de data verzameling. Anouk's echtgenoot, dr. Paul Dechering, deed pionierswerk 
in de automatisering.
De publicaties die voortvloeiden uit het functie onderzoek bij narcolepsie 
patiënten, dat plaatsvond bij het Nijmegen Institute for Cognition and Information 
(NICI) onder leiding van Prof. Dr. A. Coenen, zijn niet meegenomen in dit 
proefschrift ter wille van de handhaving van de homogeniteit van het onderwerp. 
Ik bedank Dr. Annika Smit, Dr. Paul Eling en Prof. Ton Coenen voor de goede en 
royale samenwerking.
De Nederlandse Vereniging voor Narcolepsie, voorzitter Ab Lokkerbol, zijn mede­
bestuursleden en voorgangers, dank ik hartelijk voor de interesse in het onderzoek 
en voor de uitnodigingen om regelmatig lezingen te houden over de gevonden 
resultaten. Nico en Joke Witzenburg, onder meer actief in het NVNMagazine en 
de InfoLijn, dank ik voor het persoonlijk contact over de jaren heen.
Lieve Marijke, dochters Keetie, Lara, Sabine en Brigitte, schoonzoons Chris, Ricardo 
en Martijn, kleinkinderen Bowi en Marilu: als echtgenoot, vader, schoonvader en 
grootvader geniet ik van jullie en ben ik met jullie verbonden. Dat gaat veel verder 
dan dankbaarheid: onze uitwisselingen zijn van een geheel andere orde. W at niet 
wegneemt dat narcolepsie een dankbaar gespreksonderwerp is geworden.
171

Curriculum Vitae

CURRICULUM VITAE
Hal Droogleever Fortuyn werd op 14 november 1944 geboren in Amsterdam. In 1963 
behaalde hij zijn eindexamen Gymnasium bèta aan het Praediniusgymnasium te 
Groningen. Hierna studeerde hij geneeskunde bij de Universiteit van Amsterdam. 
Hij vervulde zijn coassistentschap gynaecologie/ obstetrie in Paramaribo, 
Suriname. Na het behalen van zijn artsexamen nam hij gedurende een jaar als 
huisarts waar in diverse praktijken. Van 1974-1977 verbleef hij in Californie, USA. 
Hij leerde daar "Primal Therapy" in het Center for Primal Therapy, geleid door 
David Rosen, psychiater. Hij werkte als arts in de "Height- Ashbury Free Clinic", 
San Francisco. In 1975 behaalde hij zijn Educational Commisschion for Foreighn 
Medical Graduates (ECFMG) diploma dat toegang gaf tot het instromen binnen 
internships en residency programma's in de Verenigde Staten. In 1977 keerde hij 
terug naar Nederland waar hij ging werken in dagkliniek "Welgelegen" te Velp, 
destijds onderdeel van psychiatrisch ziekenhuis Wolfheze. Hij vervulde zijn 
inrichtingsstage op het Socio Therapeutisch Centrum in Wolfheze onder 
supervisie van dr. H. van der Drift. Van 1978-1981 specialiseerde hij zich tot 
psychiater in het Universitair Medisch Centrum Groningen. Prof. Dr. W.K. van Dijk 
was zijn opleider. Van 1981 tot 1986 werkte hij als psychiater in Wolfheze. 
Hij zette samen met collega's een Hiërarchische Therapeutische Gemeenschap 
op, gecombineerd met een 'detox', ter behandeling van verslavingsproblematiek. 
Van 1986 tot 1995 werkte hij als psychiater op de PAAZ van het Zaans Medisch 
Centrum. Hij was daar B- opleider psychiatrie en eerste geneeskundige. 
Gedurende enige tijd was hij lid van het stafbestuur van dit ziekenhuis. In deze 
periode was hij tevens consulent voor de Reclassering Alkmaar. Van 1995 tot zijn 
pensioen in 2009 werkte hij in het UMC St. Radboud als universitair docent. 
Hij was hoofd van de consultatiedienst psychiatrie. Gedurende enkele jaren 
maakte hij deel uit van het bestuur van de sectie Consutatieve en Liaisonpsychiatrie 
van de Nederlandse Vereniging voor Psychiatrie. Hij fungeerde als opleider voor 
de assistenten in opleiding tot specialist (AIOS) in forensische rapportages. 
In 2009 kreeg hij van de AIOS "de Pluim", een onderscheiding voor zijn werk als 
supervisor. Hij huwde in 1978 Marijke Toes. Zij kregen vier dochters: Keetie, Lara, 
Sabine en Brigitte. Ze hebben bij het verschijnen van dit proefschrift twee 
kleinkinderen: Bowi en Marilu.
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